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ABSTRACT 
Atherosclerosis and post-angioplasty neointimal proliferation, which are leading causes 
of cardiovascular morbidity and mortality, develop as a result of chronic or acute 
vascular injury producing inflammatory and proliferative responses in the vessel wall. 
Glucocorticoids, the stress hormones produced by the adrenal cortex, have anti-
inflammatory and anti-proliferative characteristics and can also influence systemic 
cardiovascular risk factors. The systemic levels of these hormones are controlled by the 
hypothalamic pituitary adrenal axis. However, there is also a tissue-specific pre-receptor 
regulation of these hormones by the two isozymes of 11β-hydroxysteroid dehydrogenase 
(11β-HSD); type 1 regenerates active glucocorticoids within the cells and type 2 
inactivates glucocorticoids. Whilst it has been shown that the inhibition of 11β-HSD1 
has favourable effect on cardiovascular risk factors and the inhibition of 11β-HSD2 
results in hypertension; the effect of these enzymes on vascular lesion development is 
not known. The work described in this thesis tested the hypothesis that 11β-HSD1 
inhibition reduces vascular lesion development due to improvement in cardiovascular 
risk factors, whereas 11β-HSD2 inhibition leads to adverse vascular remodelling. 
Apolipoprotein-E deficient (ApoE
-/-
) mice fed on western diet were used to study 
atherosclerosis, whereas neointimal proliferation was investigated using a well-
established mouse model of wire-angioplasty. Vascular lesions were assessed using 
novel imaging and standard histological techniques. 
11β-HSD1 inhibition reduced the size of atherosclerotic lesions and improved markers 
of plaque stability with a reduction in lipid content and increase in collagen content of 
the plaques. This was associated with a reduction in weight gain and blood pressure but 
without any effect on lipid profile. 11β-HSD1 inhibition did not produce any significant 
effect on neointimal proliferation in C57Bl/6J mice. However in ApoE
-/- 
mice, 11β-
HSD1 inhibition reduced neointimal proliferation with corresponding increase in size of 
patent lumen and with an associated reduction in macrophage content of neointimal 
lesions. 11β-HSD2 deletion produced an outward remodelling in un-injured vessels but 
there was no effect on neointimal proliferation after wire-angioplasty. Administration of 
a selective mineralocorticoid antagonist, eplerenone, reduced neointimal lesions 
 XV 
significantly but to a similar degree in both C57Bl/6J and 11β-HSD2
-/-
 mice, associated 
with a significant reduction in macrophage content of lesions but without any effect on 
blood pressure. 
Data in this thesis highlight the potential therapeutic application of 11β-HSD1 inhibition 
in reducing the size and vulnerability of atherosclerotic plaques and also reduction in 
neointimal proliferation (and hence post-angioplasty restenosis) in high risk patients 
with „metabolic syndrome‟ phenotype. The results also indicate that 11β-HSD2 has a 
limited, if any, role to play in the development of neointimal lesions. 
 1 
1. Introduction 
 2 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality across the 
world. In the UK, more than one in three people (36%) die from CVD, accounting for 
over 200,000 deaths each year (British Heart Foundation, BHF, www.heartstats.org). 
Despite a decline in atherosclerosis-related deaths in the western world in recent years 
[Ford et al., 2007], the burden of CVD, both in terms of cost and human suffering, 
remains immense [Lim et al., 2007]. The overall financial cost for the National Health 
Service (NHS) in healthcare provision for these patients exceeds £25 billion a year 
(BHF, www.heartstats.org). The WHO estimates that CVD mortality will remain the 
number one killer worldwide in the next decades (12.2% deaths attributable to CVD in 
2004 vs. 14.3% projected in 2030) [Iqbal and Fox, 2010]. 
The major underlying cause of CVD is the formation of atherosclerotic lesions in the 
coronary circulation leading to limitation of blood flow. These lesions, if clinically 
significant, are usually treated with percutaneous angioplasty and stenting. In-stent 
restenosis, however, remains a significant problem, affecting up to 20% of patients 
[Welt and Rogers, 2002c]. This is perhaps not surprising, since the iatrogenic arterial 
injury during angioplasty creates an intense inflammatory response [Welt and Rogers, 
2002] and also induces migration and proliferation of vascular smooth muscle cells 
(VSMCs) [Edelman and Rogers, 1996] leading to an increase in neointimal lesion 
formation. 
Glucocorticoids, steroid hormones formed in the adrenal gland, can influence the 
development of atherosclerotic and neointimal lesions due to their interaction with 
systemic risk factors, inflammatory cells and VSMCs. The intracellular activity of 
glucocorticoids is regulated by the isozymes of 11beta-hydroxysteroid dehydrogenase 
(11β-HSD). The work described in this thesis was designed to determine whether 
activity of the isozymes of 11β-HSD influences the development of atherosclerotic and 
neointimal lesions. This chapter will summarise the current understanding of the 
pathogenesis of atherosclerosis and neointimal proliferation and describe how regulation 
of glucocorticoids by 11-HSD may influence these processes. 
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1.1 Atherosclerosis 
Atherosclerosis (from the Greek words athero (gruel or paste) and sclerosis (hardness)) 
is a chronic inflammatory disorder characterized by the formation of lesions in the large 
and medium sized arteries at the sites of injury-induced endothelial cell dysfunction 
[Benditt, 1977]. It begins with damage to the innermost layer of the artery (endothelium) 
which leads to accumulation of lipids, platelets, smooth muscle cells, inflammatory 
cells, connective tissue, calcium and cellular waste products in the arterial wall. The 
resultant lesion (plaque or atheroma) can grow large enough to significantly reduce the 
blood flow through an artery. However, most of the clinically-significant consequences 
of atherosclerosis occur when plaques become fragile and rupture leading to thrombosis 
and arterial occlusion. Occlusion of a coronary artery will result in a myocardial 
infarction (MI) [Shah and Forrester, 1991]. 
1.1.1 Structure of a healthy artery 
The healthy arterial wall (Figure 1.1) consists of three layers: the intima, media, and 
adventitia [Florey, 1969]. The intima is the innermost layer of the arterial wall and is 
defined as the region of the arterial wall from and including the endothelial surface at the 
lumen to the luminal margin of the media [Stary et al., 1992]. The internal elastic lamina 
(IEL), a fenestrated sheet of elastin fibres, is generally considered part of the media. The 
middle layer or media contains several layers of SMCs intermixed with elastic fibres and 
embedded in connective tissue rich in proteoglycans. The media is bound on the outside 
by the external elastic lamina (EEL) that separates it from the adventitia. The outermost 
layer or adventitia is formed of irregularly arranged collagen bundles, scattered 
fibroblasts, a few elastic fibres and small vessels that supply blood to the vessel wall 
itself and hence termed vasa-vasorum [Heistad et al., 1981]. 
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Figure 1.1: Structure of a healthy artery 
Lumen
Media
Adventitia
IEL
EEL
 
The cross-section of a healthy murine artery (stained with United States trichrome, UST) 
is shown here to illustrate the three layers of arterial wall. UST stains internal and 
external elastic lamina (IEL, EEL) in dark purple (indicated by arrow-head) and 
therefore defines intima (between lumen and IEL), media (between IEL and EEL) and 
adventitia (outside EEL). 
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1.1.2 Risk factors for atherosclerosis 
Large scale epidemiological studies, such as the Framingham Heart study [Wilson et al., 
1998] and the INTER-HEART study [Yusuf et al., 2004], have provided valuable data 
for identification of the major risk factors for CVD. Some of these risk factors, such as 
age, sex and ethnic origin, are non-modifiable but help in clinical diagnosis and risk 
stratification. On the other hand, the modifiable risk factors including hypertension, 
diabetes mellitus, obesity and dyslipidaemia serve as targets for prevention and 
treatment of atherosclerotic diseases.  A substantial body of evidence confirms that 
reducing risk factors reduces the morbidity and mortality associated with atherosclerotic 
diseases [Critchley and Capewell, 2003b;Ford et al., 2007]. 
However, it is notable that conventional risk factors predict less than 50% of 
cardiovascular events [Heller et al., 1984]. Consequently, a number of novel risk factors 
(Table 1.1) have emerged as potential predictors of atherosclerosis and its complications. 
Identification of these novel risk factors allows better insight into pathophysiology of the 
disease, and facilitates development of novel preventive and therapeutic interventions. 
1.1.3 Pathogenesis of atherosclerosis 
Whilst speculations about the pathogenesis of atherosclerosis date back to the 18
th
 
Century, the first scientific evidence was obtained from studies conducted in the second 
half of the 19
th
 century. This initial work was based mostly on the gross and microscopic 
appearance of lesions from human autopsy specimens. Temporal studies of 
atherogenesis could only be carried out from the early 20
th
 Century, following the 
introduction of suitable animal models. 
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Table 1.1: Risk factors for atherosclerosis 
Conventional 
risk 
factors 
Non-modifiable 
Age 
Gender 
Ethnic origin 
Family history 
Modifiable 
Smoking 
Obesity 
Hypertension 
Hypercholesterolemia 
Diabetes mellitus 
Insulin resistance 
Emerging 
risk 
factors/markers 
Inflammatory 
markers 
C-reactive protein (CRP) 
Interleukins (e.g. IL-1, IL-6) 
Inter-cellular adhesion molecule-1 
(ICAM-1) 
Serum amyloid A 
Soluble CD40 ligand 
Haemostasis 
factors 
Platelet activation 
Platelet aggregation 
Fibrinogen 
von Willebrand factor 
Plasminogen activator inhibitor-1 
(PAI-1) 
Tissue plasminogen activator 
Lipid related factors 
Low-density lipoprotein (LDL) 
Oxidized LDL 
Remnant lipoproteins 
Apolipoproteins A1 and B 
Lipoprotein a 
Other factors 
Homocysteine 
Angiotensin-converting enzyme 
Micro-albuminuria 
Viral infections 
Psychosocial stress 
Air pollution 
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There were various theories proposed in 19
th
 Century to explain pathogenesis of 
atherosclerosis: for example, the encrustation theory (Rokitansky, 1851) suggesting that 
atherosclerosis begins in the intima with deposition of thrombus and its subsequent 
organisation by the infiltration of fibroblasts and secondary lipid deposition; the 
insudation theory (Virchow, 1856) proposing that lipids insudate into the arterial wall, 
where they interact with cells of the vessel wall and extracellular matrix, leading to 
initiation and development of atherosclerosis; haemodynamic theories of atherogenesis; 
and the response to injury hypothesis (reviewed by [Tegos et al., 2001]). The currently 
accepted “response-to-injury hypothesis” was proposed by Russell Ross in the 1970s, 
suggesting that injury to the endothelium could lead to platelet aggregation and intimal 
thickening, resulting eventually in atherosclerosis [Ross and Glomset, 1976]. In the 
intervening years, observational and experimental data from a number of studies have 
further elaborated this response to injury theory, which now presents the generally 
accepted view on atherogenesis [Fuster et al., 1992]. A variety of local and systemic 
factors (such as disturbances of blood flow at branch points, hyperglycaemia, oxidised 
lipids, cigarette smoking and viruses) can result in vascular insult leading to initiation 
and progression of atherosclerosis [Fishman et al., 1998]. 
1.1.4 The stages of atherogenesis 
The American Heart Association‟s committee on vascular lesions has defined six 
different stages of development of atherosclerotic plaques [Stary et al., 1995]: 
 Type I (initial) lesion comprises isolated macrophages and foam cells in the 
intima 
 Type II (fatty streak) lesion is an accumulation of intra-cellular lipids and foam 
cells in the intima 
 Type III (intermediate) lesion includes type II changes and a small extra-cellular 
lipid pool 
 Type IV (atheroma) lesion has type II changes and a well defined core of extra-
cellular lipids 
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 Type V (fibro-atheroma) lesion is defined as a lesion in which prominent new 
fibrous connective tissue has formed. This type of lesion may be subdivided into 
the Va lesion (in which the fibrous tissue is part of a lesion with a lipid core), the 
Vb lesion (in which part of the lesion is calcified) and the Vc lesion (in which the 
lipid core is absent). 
 Type VI (complicated) lesion has features of plaque erosion/rupture, 
haemorrhage or thrombosis. It is subdivided by the superimposed features. Thus, 
disruption of the surface may be labelled as type VIa; haematoma or 
haemorrhage as type VIb; and thrombosis as type VIc. Type VIabc indicates the 
presence of all three features. 
1.1.5 Atherosclerosis - an inflammatory disorder 
Atherosclerosis was originally considered to be a lipid storage disease; but over the 
recent years, there has been a shift in thinking and it is now believed to represent a 
chronic inflammatory disorder [Ross, 1999]. 
Inflammation is considered to play a key role in plaque initiation, progression and 
disruption [Corrado et al., 2010]. Indeed, level of C-reactive protein (CRP), an acute 
phase protein released from liver in response to infection or inflammation, is a predictor 
of cardiovascular events [Danesh et al., 2000;Rutter et al., 2004]. The various forms of 
vascular injury, including elevated levels of modified low-density lipoproteins (LDL), 
incite pro-inflammatory effects leading to the recruitment of monocytes and T-
lymphocytes which is the earliest feature of lesion formation [Munro and Cotran, 1988]. 
This infiltration by inflammatory cells is mediated by various chemokines including 
monocyte chemo-attractant protein type 1 (MCP-1) and interleukins [Gerszten et al., 
1999]. These monocytes then differentiate into macrophages and up-regulate their 
scavenger receptor expression, allowing them to accumulate lipid and, thus, leading to 
the formation of foam cells and fatty streaks. These activated macrophages release 
numerous cytokines and growth factors including interleukins (IL, especially IL-1β, IL-6 
and IL-8), tumour necrosis factor- (TNF-) and MCP-1. These factors, which can 
induce adhesion molecule expression, vascular permeability, leukocyte migration, 
macrophage activation and VSMC proliferation, are normally expressed in the vessel 
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wall but their concentrations are significantly higher in atherosclerotic plaques 
[Dewberry et al., 2000]. Inhibiting these inflammatory cytokines, for example IL-1, has 
been shown to reduce atherosclerosis in experimental models [Kirii et al., 2003] and 
their clinical potential is being investigated [Crossman et al., 2008]. 
1.1.6 Plaque stability 
There are robust data to suggest that the major cause of mortality in atherosclerotic 
diseases is the disruption of atherosclerotic plaques leading to an athero-thrombotic 
occlusion of vessels, and not merely the size of plaques or degree of luminal obstruction 
[Zaman et al., 2000]. This growing evidence over the last decade has shifted the focus 
from just reduction in lesion size to reduction in both the size and vulnerability of 
lesions [Weissberg, 2000]. The significance of plaque stability has been emphasised, for 
example, by the demonstration that the clinical benefit provided by 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMGR) inhibitors (statins) is greater than is predicted from the 
modest improvements in lumen diameter [Brown et al., 1993;Libby and Aikawa, 2003]. 
A number of factors can influence plaque stability as discussed here. 
1.1.6.1 Systemic risk factors 
Although the conventional cardiovascular risk factors (Section 1.1.2) robustly correlate 
with the extent of plaque formation, they are not strong predictors of plaque disruption 
and development of acute cardiac events [Body et al., 2008]. There is a suggestion of 
gender-related changes in plaque composition and a difference in type of plaque 
disruption [Farb et al., 1996]. Whilst deep plaque rupture reaching into the lipid core is 
more common in men, women tend to have plaques rich in smooth muscle cells and 
matrix proteins rather than lipids and macrophages and plaque rupture usually results in 
superficial erosions only [Farb et al., 1996]. Smoking tends to increase the oxidised LDL 
content and thrombogenic potential of plaques [Wissler, 1994]. The clinical data also 
highlight the effect of dyslipidaemia and statin treatment on stability of plaques [Takano 
et al., 2003]. However, the therapeutic benefit of statins may not only be via reduction in 
systemic cholesterol [Libby and Aikawa, 2003]. Diabetic patients are also more prone to 
plaque erosions and rupture, independent of severity or extent of lesions [Schwartz and 
Bornfeldt, 2003]. 
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1.1.6.2 Haemodynamic factors 
Haemodynamic factors such as local disturbances in flow velocity and alterations in 
shear stress can also affect plaque stability. Circumferential tensile stress on the fibrous 
cap is recognised as an important mechanical factor involved in plaque rupture [Cheng 
et al., 1993].  However, these mechanical effects can also modulate plaque composition 
by affecting endothelial cell function and consequently recruitment of inflammatory 
cells, expression of adhesion molecules and production of growth factors [Walpola et al., 
1995]. It has been shown that upstream parts of plaques have more macrophages 
whereas the downstream margin (distal shoulders) has more smooth muscle cells 
[Dirksen et al., 1998]. 
1.1.6.3 Plaque composition 
A typical atheromatous plaque has a fibrous cap and a central core which contains 
extracellular lipids, inflammatory cells, necrotic tissue and fibrous components. Plaques 
rich in fibrous tissue are stable whereas vulnerable plaques are characterized by large 
lipid pools [Davies, 1996]. Post-mortem studies have revealed that lipid-rich plaques are 
frequently found beneath coronary thrombosis [Falk, 1989]. Furthermore, atherectomy 
samples obtained from patients with unstable coronary artery disease frequently contain 
more extracellular debris than those of patients with stable angina [Rosenschein et al., 
1994]. Lipid-rich plaques are, therefore, considered “rupture prone”. 
The thickness or strength of the cap is another important predictor of plaque stability [Li 
et al., 2006]. Similarly the composition of cap is important: collagen provides the 
biomechanical strength to the cap [Libby, 2000], whereas infiltration by inflammatory 
cells makes it prone to rupture [Lendon et al., 1991]. 
Plaques contain variable amounts of inflammatory cells which have an inverse 
correlation with plaque stability. Macrophages are a major cellular source of matrix 
metalloproteinases (MMPs) within the atherosclerotic lesion. MMPs can contribute to 
degradation of the stabilizing matrix and digestion of the fibrous cap [Galis et al., 1994]. 
Macrophages within a vulnerable plaque also express tissue factor on their surface. 
Tissue factor is an essential component for activation of the coagulation cascade when 
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plaque components are exposed to the blood following rupture and, therefore, increases 
athero-thrombotic potential leading to vascular occlusion [Hatakeyama et al., 1997]. 
Smooth muscle cells also form an important component of atherosclerotic plaque. They 
produce extracellular matrix and fibrous components and thereby serve to encapsulate 
the soft atheroma and, thus, stabilise plaque. Various inflammatory cytokines, growth 
factors (such as transforming growth factor beta, TGF-β) and thrombin (generated 
during episodes of local thrombosis) act as stimulants for smooth muscle cell 
proliferation/migration and connective tissue production [Newby, 1997]. 
1.1.7 Treatment and prevention of atherosclerosis 
1.1.7.1 Primary prevention 
Atherosclerosis is a chronic progressive disease that starts in childhood and adolescence, 
but usually remains asymptomatic until middle age. This has led to a growing emphasis 
on primary prevention. The American Heart Association has issued guidelines for 
primary prevention of atherosclerotic disease in childhood [Kavey et al., 2003]. Primary 
prevention is generally targeted towards risk factor modification by adopting a healthy 
life style (healthy eating, exercise, smoking cessation etc), controlling glycaemic and 
lipid profile by pharmacological and non-pharmacological measures and blood pressure 
control [Pearson et al., 2002]. 
1.1.7.2 Secondary prevention 
Although there is no definite role for anti-platelet drugs (such as aspirin or clopidogrel) 
in primary prevention, there are robust data to suggest that these drugs reduce recurrent 
ischemic events in patients with established atherosclerotic disease [Budaj et al., 
2002;Baigent et al., 2009]. Based on the guidelines from the expert panel of the National 
Cholesterol Education Programme, patients with established atherosclerosis should also 
be treated with lipid-lowering drugs [ATP III, 2001]. Although niacin therapy may be 
used for patients with low levels of high-density lipoproteins (HDL) and fibrates for 
those with high triglycerides, the mainstay of lipid lowering is treatment with 
statins[Maron et al., 2000]. The patients with established atherosclerotic disease also 
need an aggressive management of other risk factors which may require use of anti-
 12 
diabetic and anti-hypertensive drugs. Most of these patients with cardiovascular disease 
require a combination of drugs, including treatment with beta-blockers and inhibitors of 
angiotensin converting enzyme (ACE), for symptomatic and prognostic reasons 
[Hippisley-Cox and Coupland, 2005]. Finally, advanced or symptomatic lesions can be 
treated with percutaneous (angioplasty and stenting) or surgical (coronary artery bypass 
grafting, CABG) revascularisation procedures [Schofield, 2003]. 
1.1.7.3 Need for novel therapeutic targets 
Recent epidemiological data have shown a decline in mortality from atherosclerotic 
diseases in the developed countries as a consequence of better prevention and treatment 
[Fox et al., 2007]. However, despite recent advances in pharmacological and non-
pharmacological interventions, there are warning signs that the decline in cardiovascular 
mortality may be attenuated or even reversed, as a late consequence of the rising 
prevalence of obesity and diabetes. Evidence that the decline in mortality has attenuated 
is already apparent in the younger (35-44 years) age group [Critchley and Capewell, 
2003]. Hence, there is a growing need to identify and develop novel therapeutic targets 
for treatment of metabolic syndromes and atherosclerosis. 
1.1.8 The ApoE-/- mouse as an experimental model of atherosclerosis 
Animal models are necessary for pre-clinical research to study the mechanism of 
atherogenesis and the effects of anti-atherosclerotic interventions. Ideally, a model 
should exhibit similar plaque morphology and biology to humans, and a similar response 
to various therapies. Since the first use of fat-fed rabbits in the early 20
th
 Century, 
numerous animal species have been used to study atherosclerosis [Bocan, 1998]. 
Although rabbits do not develop spontaneous atherosclerosis, they are sensitive to fat 
feeding and promptly develop fatty streaks. However, there is a striking (~ 40x) 
difference in cholesterol levels between humans and fat-fed rabbits [PRIOR et al., 1961]. 
Rats and dogs are not good models because they do not develop spontaneous lesions and 
require profound dietary modifications to produce vascular lesions [THOMAS et al., 
1960]. The cholesterol fed pig is a reasonably good model and develops lesions similar 
to those seen in humans. However, diet induced atherosclerosis (without surgical/genetic 
interventions) can take months to develop and, therefore, there are cost, maintenance and 
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handling issues. Non-human primates may develop lesions similar to humans with 
modest dietary interventions. These lesions can be assessed with techniques used in 
clinical practice and, therefore, they are better suited to model human atherosclerotic 
lesions [Bush and Verlangieri, 1989;Takai et al., 2005]. However, they are not widely 
used due to cost and ethical concerns. 
The use of mice is desirable in research because they are economical to maintain, well-
characterized and ideal for genetic modifications. However, rodents are generally 
resistant to atherogenesis, which usually has to be induced by genetic manipulation 
and/or mechanical injury; often combined with feeding a high fat diet [Kashyap et al., 
1995;Russell and Proctor, 2006]. In 1992, apolipoprotein E deficient (ApoE
-/-
) mice were 
generated by inactivating the ApoE gene in mouse embryonic stem cells by homologous 
recombination [Piedrahita et al., 1992]. Apolipoprotein E is present on the surface of 
several lipoproteins, including chylomicrons, very-low-density lipoprotein (VLDL) and 
HDL particles. It is an important modulator of lipoprotein interactions with several 
receptors, including LDL receptors and LDL-related receptors [Mahley, 1988]. ApoE
-/-
 
mice have, therefore, defective hepatic clearance of cholesterol resulting in a five-fold 
increase in total plasma cholesterol levels, 68% higher triglyceride levels but only 45% 
higher HDL levels [Plump et al., 1992]. This model has been studied extensively for the 
effects of genetic and pharmacological interventions on the development of lesions. 
However, this model has its own limitations; the response to different pharmacological 
interventions may not always mirror the response seen in humans (reviewed by 
[Zadelaar et al., 2007]) and the small size of mice may pose some technical challenges, 
such as the imaging of atherosclerotic plaques and acquisition of sufficient blood to 
characterise biochemical events [Daugherty, 2002]. 
The lesion formation in ApoE
-/-
 mice has been characterized during feeding of both 
standard chow and high-fat diet and resembles atherogenesis in humans [Zhang et al., 
1992;Nakashima et al., 1994]. Monocyte adhesion to intact endothelium, one of the 
earliest cellular events in atherogenesis, can be detected in 2-month old ApoE
-/-
 mice fed 
on chow. Lesions predominantly containing foam cells can be seen from 3-months 
onwards and fibro-fatty lesions became apparent from 4-months onwards [van Ree et al., 
1994]. ApoE
-/-
 mice fed on high-fat diet show accelerated progression of atherogenesis 
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and can also develop complex lesions in many vascular areas, including the aortic sinus, 
aortic arch, brachiocephalic trunk (BCT), renal arteries and coronary arteries [van Ree et 
al., 1994;Rosenfeld et al., 2000]. Although intra-plaque haemorrhage has been 
demonstrated in advanced lesions in the BCT, there is no convincing evidence that these 
mice develop spontaneous plaque rupture [Rosenfeld et al., 2000]. 
The advanced, complicated or symptomatic atherosclerotic lesions are often treated with 
percutaneous revascularisation (angioplasty and stenting) procedures [Keeley et al., 
2003;Smith, Jr. et al., 2001]. However, the long term outcome of these revascularisation 
procedures is hampered by development of restenosis due to neointimal proliferation 
[Bennett, 2003]. 
1.2 Neointimal proliferation 
Although neointimal proliferation shares many pathophysiological components with 
atherogenesis, it is a distinct pathological and clinical entity [Wang and Paigen, 2002]. 
Whilst atherosclerosis represents a chronic response to a systemic vascular insult, 
neointimal proliferation in response to acute and focal (usually iatrogenic) vascular 
injury comprises an acute inflammatory response followed by a substantial fibro-
proliferative response. This results in lesions rich in fibro-cellular elements rather than 
the lipid rich plaques seen in atherosclerosis. Atherosclerosis and neointimal 
proliferation may also have different genetic determinants [Kuhel et al., 2002]. 
1.2.1 Pathogenesis of neointimal proliferation 
Angioplasty (± stenting) results in an iatrogenic injury to intimal and medial layers with 
activation of haemostatic, inflammatory and fibro-proliferative processes leading to the 
formation of neointimal lesions [Bennett, 2003]. 
1.2.1.1 Platelet activation 
Angioplasty-induced endothelial cells denudation and medial tearing exposes circulating 
blood cells to the sub-endothelial matrix containing numerous platelet-activating factors 
including thrombin, thromboxane, platelet-activating factor and collagen. This leads to 
platelet activation, aggregation and release of their contents into the injured arterial wall 
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[Chandrasekar and Tanguay, 2000]. Anti-platelet therapy has been shown to not only 
reduce acute thrombosis following angioplasty [Barnathan et al., 1987;Mishkel et al., 
1999] but also to reduce neointimal proliferation [Akbulut et al., 2004] and, therefore,  
strongly recommended in all patients undergoing angioplasty [King, III et al., 2008]. 
1.2.1.2 Inflammatory cell infiltration 
Inflammatory cells are involved in the acute response to arterial injury. After balloon 
injury, monocyte-derived macrophages are seen within the neointimal lesions [Ferns et 
al., 1991c]. In the cholesterol-fed rabbit these macrophages are transformed into 
macrophage-derived foam cells, and constitute a substantial part of the neointima [Ferns 
et al., 1992]. The importance of inflammatory cytokines in the vascular response to 
injury has been further highlighted in experiments where blocking various cytokines, 
such as CD11b/CD18 [Rogers et al., 1998], IL-1 [Morton et al., 2005], or IL-10 
[Feldman et al., 2000], produced a reduction in neointimal proliferation. IL-1, an 
extensively studied pleotropic cytokine, has been shown to stimulate VSMC 
proliferation [Raines et al., 1989] and expression of cell adhesion molecules on 
endothelial and smooth muscle cells [Wang et al., 1995]. It has been shown that a 
genetic polymorphism in the IL-1 receptor antagonist (IL-1ra) gene correlates with post-
angioplasty remodelling in humans [Francis et al., 2001]. SMC-derived TNF-α serves as 
a marker for an altered VSMC phenotype and may contribute to local cellular activation 
and proliferation of VSMCs at sites of arterial injury [Tanaka et al., 1996]. Increased 
MCP-1 expression following angioplasty has also been linked to restenosis and it has 
been reported that patients with raised plasma levels of MCP-1 have higher incidence of 
restenosis [Oshima et al., 2001]. Glucocorticoids can interact with inflammatory process 
(section 1.3.5) and therefore modulate neointimal lesion formation. 
1.2.1.3 VSMC migration and proliferation 
Neointimal lesions that develop after angioplasty are characterised by smooth muscle 
cell accumulation within the neointima [Waller et al., 1991]. Balloon injury is initially 
associated with medial smooth muscle cell death [Clowes et al., 1983]. This is followed 
by a phase of coordinated proliferation of medial smooth muscle cells and subsequent 
migration of medial smooth muscle cells into the intima in response to the release of 
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chemo-attractants such as platelet-derived growth factor (PDGF) [Ferns et al., 1991]. 
About 80% of the migrating cells are reported to be in the G1 and S phases of the cell 
cycle resulting in further proliferation of these intimal smooth muscle cells [Yoshida et 
al., 1997]. Data are also accumulating to suggest that the circulating bone marrow-
derived progenitor cells serve as a complementary source of intimal smooth muscle (and 
smooth-muscle like) cells during vascular remodelling [Han et al., 2001;Kumar et al., 
2010]. 
Among the various growth factors involved in post-angioplasty vascular remodelling, 
PDGF, TGFβ1 and fibroblast growth factor (FGF) are considered to play the main role. 
The importance of PDGF as a VSMC chemo-attractant has been demonstrated in several 
species including rats, rabbits and non-human primates [Ferns et al., 1991a;Levitzki, 
2005]. TGFβ1 plays a central role in vascular lesion development and tissue repair 
owing to its effects on cell growth and extracellular matrix synthesis [McCaffrey, 2009]. 
It also stimulates adventitial fibroblast differentiation into myofibroblasts after injury, a 
process that may affect arterial remodelling [Shi et al., 1996]. The binding of cytokines 
and growth factors to their respective receptors stimulates mitogen-activated protein 
(MAP) kinases. MAP kinases are involved in nuclear signalling and their expression 
increases after angioplasty [Hu et al., 1997] with resultant increase in cellular 
proliferation. 
Inhibition of VSMC proliferation is, therefore, an attractive mechanism for preventing 
neointimal lesion formation and, indeed, the pharmacological agents (sirolimus or 
paclitaxel) in currently used drug eluting stents (DES) have anti-proliferative 
characteristics. 
1.2.1.4 Re-endothelialisation 
Endothelial injury during angioplasty initiates a vascular response to injury and re-
endothelialisation helps to curtail this response. Whilst, small/superficial injuries may 
heal without neointimal proliferation, deep/wide injuries are usually associated with 
substantial neointimal thickening [Reidy and Silver, 1985]. Arteries that have sustained 
extensive endothelial damage may not become fully re-endothelialised but instead 
become lined by phenotypically-modified smooth muscle cells [Reidy and Silver, 1985]. 
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It has also been reported that endothelium dependent vascular wall reactivity may be 
affected after balloon angioplasty, and that the duration of impaired responses are related 
to the extent of injury [Weidinger et al., 1990]. 
Delayed re-endothelialisation after angioplasty increases the risk of late thrombosis 
[Ertas et al., 2009]. Currently used DES (containing sirolimus and paclitaxel) may have 
unfavourable effects on re-endothelialisation due to the non-specific action of these 
drugs on cell proliferation [Bavry et al., 2006] and, therefore, can increase the risk of 
late thrombosis [McFadden et al., 2004]. Endothelial progenitor cells, stem cells derived 
from various sources, and other promoters of endothelial regeneration are being 
evaluated to improve re-endothelialisation [Wu et al., 2008;Barsotti et al., 2009]. 
1.2.2 Prevention and treatment of neointimal proliferation (restenosis) 
1.2.2.1 Stents 
Stents were first introduced in 1986 and their use has increased exponentially over the 
last decade, as they are the most effective mechanical means for reducing post 
angioplasty restenosis [Erbel et al., 1998]. Stents are thin cylindrical wire meshes 
(diameter 3-5mm; length 1.5-3.0cm) and are commonly made of stainless steel (bare 
metal stent, BMS). Coating stainless-steel stents with gold, carbide, phosphorylcholine 
or heparin does not appear to confer any additional benefit compared with BMS 
[Birkenhauer et al., 2004]. In contrast, randomised clinical trials have shown that coating 
stents with various anti-proliferative drugs reduces restenosis rates compared with BMS 
[Weisz et al., 2009;Ellis et al., 2009]. 
1.2.2.2 Anti-proliferative drugs 
In the era of stents, restenosis is mainly due to neointimal proliferation, rather than 
elastic recoil and constrictive remodelling [Bennett, 2003]. The recent research has, 
therefore, mainly focused on reducing neointimal proliferation. 
Sirolimus and paclitaxel are the two most commonly used drugs for stent coating in 
clinical practice. Sirolimus acts by receptor inhibition of the mammalian target of 
rapamycin (mTOR), resulting in the cessation of cell-cycle progression in the late G1 to 
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S phases and, consequently, inhibiting VSMC proliferation [Poon et al., 1996]. 
Paclitaxel inhibits cell proliferation and migration by disrupting cellular microtubule 
organisation [Axel et al., 1997]. There are robust data from multi-centre trials to suggest 
that stents coated with these drugs prevent restenosis [Stone et al., 2004;Ellis et al., 
2009;Moses et al., 2003;Weisz et al., 2009]. Various other agents, for example inhibitors 
of growth factors or transcriptional factors, are being evaluated [Bilder et al., 2003]. 
1.2.2.3 Anti-inflammatory agents 
Inflammation is a key mediator of the vascular response to injury and, therefore, anti-
inflammatory agents have been tested to limit neointimal proliferation [Welt and Rogers, 
2002]. There has been some success with IL-1 inhibition in a porcine coronary 
angioplasty model [Morton et al., 2005] and cyclo-oxygenase 2 inhibition in humans 
[Koo et al., 2007]. It has also been suggested that part of the benefit seen from sirolimus 
or paclitaxel eluting stents is also derived through an anti-inflammatory mechanism 
[Suzuki et al., 2001]. However, the use of anti-inflammatory steroids (discussed in 
section 1.3) has produced conflicting results. 
1.2.2.4 Anti-thrombotic agents 
As the steel matrix used in BMSs offers a highly thrombogenic surface, anti-platelet 
drug therapy is necessary to prevent thrombotic events. Dual anti-platelet treatment 
(aspirin and clopidogrel) is currently recommended for 6-12 months after stent 
deployment, followed by indefinite use of low dose aspirin [King, III et al., 2008]. 
Anti-platelet treatment with abciximab (a glycoprotein IIb/IIIa inhibitor) has been shown 
to be effective in a porcine model of neointimal proliferation [Hong et al., 2007] and 
anti-thrombotic recombinant pegylated-hirudin and the prostacyclin analogue iloprost 
have also been shown to reduce neointimal proliferation in pigs and sheep (Alt et al 
2000). Heparin, although it inhibits VSMC proliferation in-vitro (Au et al 1993; Chajara 
& Capron 1993; Yang et al 1999), did not prevent restenosis when administered 
systemically (Brack et al., 1995) or from DESs (Semiz et al 2003). 
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1.2.2.5 Hormonal agents 
Oestrogen reduces VSMC proliferation and stimulates endothelial regeneration after 
angioplasty [Geraldes et al., 2002]. In a porcine model, oestrogen eluting stents were 
associated with reduced neointimal proliferation without affecting endothelial 
regeneration [New et al., 2002]. Although the first study in humans (EASTER trial) 
suggested that oestrogen-eluting stents may reduce restenosis [Abizaid et al., 2004], 
subsequent multicentre trials (ETHOS-1 and ISAR-PEACE) failed to show any benefit 
[Ryu et al., 2009]. The effect of glucocorticoids on neointimal proliferation is complex. 
Experimental studies in general have suggested that glucocorticoids (administered 
systemically or locally) can reduce neointimal proliferation [Villa et al., 1994c;Guzman 
et al., 1996;Poon et al., 2001;Ribichini et al., 2007;Strecker et al., 1998;Van Put et al., 
1995]. However, clinical trials have shown variable and often contradictory results. Oral 
prednisone reduced restenosis after stenting (the IMPRESS trial) [Versaci et al., 
2002;Ferrero et al., 2007] and low dose dexamethasone was associated with low 
restenosis rate in the STRIDE trial [Liu et al., 2003]. On the other hand, 
methylprednisolone did not inhibit restenosis after coronary angioplasty [Pepine et al., 
1990] or stenting [Reimers et al., 1998] and dexamethasone-drug eluting stents (D-DES) 
did not reduce the incidence of restenosis [Hoffmann et al., 2004;Ribichini et al., 2007]. 
The role of glucocorticoids in neointimal lesion formation is discussed further in section 
1.3.9. 
1.2.2.6 Need for novel therapeutic targets 
The currently used DESs containing sirolimus and paclitaxel have greatly reduced the 
prevalence of post angioplasty restenosis [Ellis et al., 2009;Weisz et al., 2009]. 
However, these anti-proliferative drugs lack selectivity with respect to the targeted cell 
types. Therefore, they not only inhibit VSMC proliferation underlying neointima 
formation, but also compromise endothelial repair and, hence, increase the risk for late 
thrombosis [Bavry et al., 2006]. Accordingly, there is a need for novel agents capable of 
inhibiting restenosis without clinically-relevant, adverse effects. In the recent years, a 
number of drug types have been tested and reported as therapeutic targets to prevent 
restenosis. Such agents target inflammation [Morton et al., 2005], VSMC proliferation 
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[Selvendiran et al., 2009] and ion channels [Kohler et al., 2010]. However, randomised 
clinical trials and long-term outcome data are yet to support use of such agents. 
1.2.3 Experimental models of neointimal proliferation 
Experimental models are needed to develop and test novel therapeutic agents for 
neointimal proliferation. Carotid artery injury in rabbits/rats was one of the earliest 
models used to study the mechanisms of restenosis [Groves et al., 1979;Clowes et al., 
1983]. A variety of animal models are currently available; however, there are 
anatomical/procedural and pathophysiological/biochemical differences between these 
models and humans [Lafont and Faxon, 1998]. Whilst coronary angioplasty in humans is 
used to dilate arteries with advanced atherosclerotic disease, animal models usually 
employ angioplasty of arteries with no pre-existing stenosis. The force applied to the 
vessel wall also differs in magnitude and nature. The compliance of human arteries 
containing advanced atherosclerotic and calcified lesions is usually poor, and 
angioplasty can cause considerable tissue damage, including intimal tears and splitting 
of the tunica media (Waller 1989; Brady & Warren 1991). Finally, experimental animals 
usually lack the variety of risk factors seen in patients undergoing angioplasty (e.g. 
diabetes, hypertension, obesity). Attempts have been made to improve the study of the 
pathogenesis and treatment of restenosis by combining models of atherosclerosis and 
acute injury [Leidenfrost et al., 2003;Weingartner et al., 2005;Abela et al., 1995;Skinner 
et al., 1995;Aikawa et al., 1998], in which angioplasty is performed in arteries with 
existing lesions. However, these models are complex, require a longer time period and 
are technically challenging [Lardenoye et al., 2000;Ivan et al., 2002]. The animal 
models, despite their limitations, have been useful for understanding restenosis in 
humans, and for testing novel therapies. However, care must be exercised when 
interpreting these results and extrapolating them to humans. 
The models of neointimal lesion formation can be categorised into large animal (such as 
pigs, dogs and non-human primates) and small animal (including rabbits , rats and mice) 
models [Mehta et al., 1996;Narayanaswamy et al., 2000]. 
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1.2.3.1 Large animal models 
The obvious advantage of large animals is their anatomical and physiological 
resemblance to humans. The response to vascular injury in pigs [Schwartz et al., 1990], 
dogs [Lafont and Faxon, 1998] and primates [Geary et al., 1996] resembles that in 
humans. The clinical relevance of large animal models is demonstrated by their ability to 
predict the effect of therapeutic interventions in humans (not without exceptions [Lafont 
and Faxon, 1998]). Moreover, it is possible to use the same catheters and devices that 
are used for angioplasty in humans. However, the use of large animals imposes issues 
such as higher purchase and maintenance costs, difficulties associated with husbandry 
and handling, and slower development of lesions. 
1.2.3.2 Small animal models 
Small animal models are useful in mechanistic experiments, for example, to study 
inflammation or VSMC proliferation in response to vascular injury [Johnson et al., 
1999]. These animals are readily available, cost less to purchase and house, are easy to 
handle and their small size reduces the amount of drug needed for interventional studies. 
The rapid growth of lesions allows a quick assessment of therapeutic agents, and it is 
possible to include large numbers in each group for reliable statistical analysis. 
However, the small size of arteries studied, the need to assess lesion formation in 
arteries that are not relevant to the clinical situation (e.g. femoral, iliac), and poor 
replication of the condition in humans are obvious disadvantages [Lafont and Faxon, 
1998;Johnson et al., 1999]. 
1.2.3.3 Mouse models of neointimal proliferation 
Mouse is a useful animal to investigate neointimal proliferation due to the availability of 
genetically modified strains [Allayee et al., 2003], making it possible to assess lesion 
development in animals deficient in, or over-expressing, key factors involved in the 
vascular response to injury. Although various interventions (such as application of a 
peri-vascular cuff, arterial ligation, and chemical or electrical injury) have been used to 
induce neointimal lesion formation, these models are poor representative of post-
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angioplasty neointimal proliferation. Intra-luminal injury models have, therefore, been 
developed over recent years [Lindner et al., 1993;Sata et al., 2000;Dover et al., 2007]. 
Intra-luminal mechanical injury in mice using a flexible guide-wire introduced into the 
common carotid artery was first described by Linder et al. [Lindner et al., 1993]. 
However, the lesions produced in mouse carotid arteries are small, have a high inter-
animal variability and may produce intra-cerebral complications, including stroke 
[Lindner et al., 1993]. Therefore, the same technique has been applied to the femoral 
arteries [Roque et al., 2000;Sata et al., 2000] producing large, often occlusive, lesions 
and fewer procedural complications. Intra-luminal injury causes endothelial denudation, 
and stretches the arterial wall, inducing disruption of the IEL and damage to VSMCs in 
the media. Early responses to injury include the adherence of platelets and neutrophils to 
the endothelial surface [Lindner et al., 1993;Roque et al., 2000;Petrov et al., 2005], and 
medial cell apoptosis [Sata et al., 2000;Petrov et al., 2005]. Neointimal lesions, rich in 
macrophages and VSMCs, are first evident one week after the injury and continue to 
grow in size until 3-4 weeks [Lindner et al., 1993;Sata et al., 2000]. More recently, a 
method of balloon injury to the mouse aorta [Petrov et al., 2005] and a stent model 
[Chamberlain et al., 2010] have also been developed. 
1.3 Glucocorticoids and the cardiovascular system 
Glucocorticoids are stress hormones with a key role in the regulation of metabolic and 
immune responses. The name glucocorticoid (glucose + cortex + steroid) derives from 
their role in the regulation of the metabolism of glucose, their synthesis in the adrenal 
cortex, and their steroidal structure. 
1.3.1 Synthesis and metabolism 
Glucocorticoid synthesis from cholesterol (Figure 1.2) occurs in the zona fasciculata of 
the adrenal cortex and is tightly regulated by the hypothalamic-pituitary-adrenal (HPA) 
axis. Cortisol is the major glucocorticoid in man, whereas corticosterone predominates 
in rodents due to lack of the enzyme 17-hydroxylase.  
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Figure 1.2: Synthesis of glucocorticoids 
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Glucocorticoids are synthesised de novo from cholesterol in the zona fasciculata of the 
adrenal cortex. In humans, cortisol is the principal glucocorticoid hormone; however, 
rodents lack the enzyme 17-hydroxylase (required to convert pregnenolone or 
progesterone to their hydroxy metabolites), and, therefore, corticosterone is their 
predominant glucocorticoid. 
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Glucocorticoids are produced de novo and released into the blood as required, exhibiting 
a diurnal variation with concentrations reaching peak levels in the early morning and 
diminishing in the evening [Dallman et al., 1993]. On secretion into the blood, 
approximately 90% of glucocorticoids are bound to corticosteroid-binding globulin and 
albumin, and only the unbound fraction is available to interact with receptors [Hammond 
et al., 1990]. Metabolic inactivation of glucocorticoids (Figure 1.3) occurs 
predominantly in the liver with inactive metabolites excreted in the urine. 
1.3.2 Molecular actions of glucocorticoids 
The classic glucocorticoid actions are mediated by the ubiquitously expressed 
glucocorticoid receptors (GR). GR are members of the nuclear receptor super family of 
ligand activated transcription factors and form multi-protein complexes with numerous 
proteins (such as heat-shock proteins). Glucocorticoids enter a cell probably via passive 
diffusion and bind to their receptors, prompting dissociation of heat shock proteins, 
receptor dimerisation and translocation to the nucleus. The ligand-receptor complex then 
binds to glucocorticoid response elements in the promoter region of target genes, and 
activates transcription (trans-activation) or inhibits the function of transcription factors 
(trans-repression) [Gower, Jr., 1993;Schaaf and Cidlowski, 2002]. In addition to these 
transcriptional or „genomic‟ effects, glucocorticoids can also induce rapid, so-called 
non-genomic effects, by affecting the physicochemical properties of cell membranes, or 
through membrane-bound GR or by initiation of signal transduction within the cytosol 
[Hafezi-Moghadam et al., 2002]. 
The main actions of glucocorticoids mediated by GR stimulation are: regulation of 
carbohydrate and protein metabolism, negative feedback on the HPA axis, regulation of 
cell proliferation and differentiation, and anti-inflammatory and immunosuppressive 
effects [Munck et al., 1984]. Glucocorticoids are also required for blood pressure 
maintenance [Ullian, 1999] although the mechanisms involved are complex and 
incompletely understood [Raff, 1987;Shields et al., 1988;Montrella-Waybill et al., 
1991;Ullian, 1999]. 
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Figure 1.3: Metabolism of glucocorticoids 
 
Metabolic inactivation of glucocorticoids occurs predominantly in the liver, and also in 
the kidney, with inactive metabolites excreted in the urine. This involves a complex 
modification process in which glucocorticoids and their 11-keto-metabolites (cortisone, 
11-dehydrocorticosterone)] are reduced in a pathway involving 5- and 5-reductases, 
3-hydroxysteroid dehydrogenase (HSD), 20- and 20-hydroxysteroid 
dehydrogenases followed by conjugation with glucuronic acid or sulphates. Metabolism 
by 11-HSD enzymes is discussed in detail in next section. 
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1.3.3 Systemic glucocorticoid regulation by HPA axis 
Glucocorticoid concentration in systemic circulation is regulated by hypothalamic-
pituitary-adrenal (HPA) axis which provides a feedback loop. The main hormones that 
activate the HPA axis are corticotropin-releasing hormone (CRH) and 
adrenocorticotropin hormone (ACTH). The loop is completed by the negative feedback 
of cortisol on the hypothalamus and pituitary [Dallman et al., 1994]. The HPA axis 
exhibits a well-characterized circadian rhythm that is under the control of the 
suprachiasmatic nuclei of the hypothalamus, whose activation, in turn, is regulated by 
light [Moore and Eichler, 1972]. Cortisol is released by the adrenal cortex in a pulsatile 
manner, driven by the pulsatile release of CRH by the hypothalamus, which then leads 
to the release of ACTH by the pituitary. Increased glucocorticoid secretion at the 
circadian peak depends on increased hypothalamic-pituitary activity and on increased 
sensitivity of the adrenal cortex to ACTH [Jacobson, 2005]. 
Activation of the HPA axis, with increased cortisol secretion
 
rate and elevated morning 
plasma cortisol levels, has been associated
 
with central obesity, insulin resistance, 
hyperglycaemia, dyslipidaemia
 
and hypertension [Walker, 2007]. Relationships
 
of 
plasma cortisol with obesity, however, are more complex,
 
since obesity is associated 
with increased metabolic clearance
 
rate of cortisol, which tends to lower plasma cortisol 
levels
 
despite enhanced cortisol production rate [Walker, 2007]. Given the similarities 
between Cushing's syndrome
 
and the metabolic syndrome, subtle abnormalities of HPA 
have been sought and found in subjects with cardiovascular risk factors [Rosmond and 
Bjorntorp, 2000]. 
Although systemic circulatory levels of glucocorticoids are regulated by the HPA axis, 
there is another level of regulating glucocorticoid activity which is regulated at intra-
cellular level and is the main theme of this thesis. 
1.3.4 Intra-cellular glucocorticoid regulation by 11β-HSD enzymes 
The intra-cellular, pre-receptor regulation is catalysed by the 11β-hydroxysteroid 
dehydrogenase (11β-HSD) isozymes, originally described more than 50 years ago 
[Amelung et al., 1953;Hubener et al., 1956]. Two isozymes of 11β-HSD, type 1 and type 
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2, have been identified, both of which are microsomal enzymes of the short-chain 
alcohol dehydrogenase super family [Stewart and Krozowski, 1999] and catalyse the 
inter-conversion of active glucocorticoids and their inert 11-keto forms [Amelung et al., 
1953]. These isozymes can also catalyse the inter-conversion of the oxysterols, 7-
ketocholesterol and 7β-hydroxycholesterol [Hult et al., 2004]. 
1.3.4.1 11β-HSD1 
11β-HSD1 is a low affinity (Km in the μM range for both cortisol and corticosterone 
[Lakshmi and Monder, 1988]) nicotinamide adenine dinucleotide phosphate (NADPH)-
dependent enzyme. 11β-HSD1 is widely expressed in many glucocorticoid-target tissues 
(including, liver, lung, adipose tissue, brain, vascular smooth muscle, skeletal muscle, 
anterior pituitary, gonads and adrenal cortex) [Stewart and Krozowski, 1999], where it 
amplifies local glucocorticoid concentrations [Seckl and Walker, 2001]. 11β-HSD1 
synthesis and activity are regulated by a complex interaction of many factors, including: 
glucocorticoids [Hammami and Siiteri, 1991;Takeda et al., 1994;Low et al., 1994], stress 
[Jamieson et al., 1997;Walker et al., 1994], sex steroids [Low et al., 1994], growth 
hormone [Painson et al., 1992], cytokines [Cai et al., 2001] and peroxisome proliferator 
activated receptor agonists [Tomlinson et al., 2001]. 
11β-HSD1, although originally described as bi-directional enzyme, acts predominantly 
as an oxo-reductase in vivo. Intact cells or organs, including liver [Ricketts et al., 
1998;Jamieson et al., 1995;Jamieson et al., 2000], adipose tissue [Bujalska et al., 1997], 
neurones [Rajan et al., 1996] and vascular smooth muscle [Hatakeyama et al., 1999], do 
not generally exhibit dehydrogenase activity of this isozyme. NADPH is the co-factor 
required for oxo-reductase activity and is generated by an enzyme hexose-6-phospate 
dehydrogenase (H6PDH). 11β-HSD1 and H6PDH are co-expressed in the inner 
microsomal compartment of cells and H6PDH confers oxo-reductase activity upon 11β-
HSD1 [Hewitt et al., 2005]. It has been shown that a direct relationship exists between 
11β-HSD1 reducatse activity and H6PDH expression [Bujalska et al., 2005]. 
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1.3.4.2 11β-HSD2 
11β-HSD2, in contrast to 11-HSD type 1, is a high affinity (Km for cortisol and 
corticosterone in the nM range) nicotinamide adenine dinucleotide (NAD)-dependent, 
exclusive dehydrogenase and converts active glucocorticoids into inactive 11-
ketosteroids. It is expressed mainly in mineralocorticoid target tissues (for example, 
kidney, sweat glands, salivary glands and colon [Stewart and Krozowski, 1999]), where 
it protects MR from illicit occupation by glucocorticoids [Edwards et al., 1988;Funder et 
al., 1988]. 11β-HSD2 is also expressed in the heart and blood vessels, although the 
specific cellular localization and in-vivo activity in vascular tissues remains debatable. 
There are reports suggesting the presence of 11β-HSD2 in VSMC (Hatakeyama et al., 
1999; Cai et al., 2001) and also in ECs (Brem et al., 1998) but a comprehensive analysis 
showed that in rodents 11β-HSD2 is predominantly localized to ECs [Walker et al., 
1991;Christy et al., 2003] where it can influence vascular function by modulating 
endothelium-derived nitric oxide activity [Hadoke et al., 2001]. In these sites 11β-HSD2 
is constitutive; its synthesis and activity are not highly regulated. It has also been noted 
that 11β-HSD2 is expressed in tissues (such as lung, lymph nodes, heart, blood vessel 
wall and placenta) which are not classic MR targets [Stewart et al., 1995;Waddell et al., 
1998;Slight et al., 1996]. In the placenta 11β-HSD2 protects the foetus from exposure to 
maternal glucocorticoids [Murphy et al., 1974;Brown et al., 1996]. 
Inactivation of cortisol by 11β-HSD2 explains why MR, which have similar affinities for 
aldosterone and cortisol [Funder et al., 1988], preferentially bind aldosterone despite the 
presence of glucocorticoids at 100 fold higher circulating concentrations [Sheppard and 
Funder, 1987]. Thus, a key physiological role of 11β-HSD2 is to protect MR from 
inappropriate activation by glucocorticoids. Therefore, 11β-HSD2 inhibition (using 
liquorice or its derivatives), transgenic disruption in mice [Kotelevtsev et al., 1999], or 
congenital deficiency in man [Walker et al., 1992], produces the glucocorticoid-
mediated „syndrome of apparent mineralocorticoid excess‟ (SAME) with its 
characteristic hypertension [Walker and Edwards, 1994]. Excess MR activation is 
associated with hypertension and other cardiovascular risk factors (reviewed by [Connell 
et al., 2008]). 
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1.3.5 GR expression and activity in the cardiovascular system 
GR (and also MR) have been demonstrated in cultured VSMC [Meyer and Nicholls, 
1981;Scott et al., 1987], in endothelial cells (EC) [Inoue et al., 1999;Jun et al., 
1999;Golestaneh et al., 2001;Newton et al., 2002] and in intact arteries [Kornel et al., 
1982;Christy et al., 2003]. Vascular GR have been shown to be active as demonstrated 
by dexamethasone (a potent synthetic glucocorticoid) -mediated induction of ACE 
activity in rat aortic ECs [Sugiyama et al., 2005], cortisol-mediated inhibition of 
prostacyclin synthesis in rat aorta [Jeremy and Dandona, 1986] and both dexamethasone 
and cortisol -mediated increase in protein kinase C in porcine coronary arteries. All 
these responses are sensitive to GR antagonism [Maddali et al., 2005]. Whether 
membrane binding sites for corticosteroids are present, or have a role, in the vascular 
wall has not been established [Fernandez-Perez et al., 2008]. The nature of the 
interaction between glucocorticoids and vascular cells is complex and can also be 
affected by the duration of exposure; prolonged exposure can inhibit proliferation of 
cultured VSMCs whereas short exposures (2min-6 hours) can stimulate proliferation 
[Kawai et al., 1998]. 
Both GR and MR are also expressed in the murine and human myocardium [Lombes et 
al., 1995;Pujols et al., 2002]. Their relationship to cardiac function has been 
demonstrated by conditional GR over-expression in the murine heart which induces 
atrio-ventricular block [Sainte-Marie et al., 2007]. Similarly, MR knockdown in mice 
induces severe heart failure and fibrosis [Beggah et al., 2002], whilst mice over-
expressing cardiac MR develop ventricular arrhythmias [Ouvrard-Pascaud et al., 2005]. 
1.3.6 Glucocorticoids and cardiovascular risk factors 
It was suggested by Adlersberg and colleagues (more than half a century ago) that 
cortisone administration can cause dyslipidaemia [Adlersberg et al., 1950a;Adlersberg et 
al., 1950]. Glucocorticoids have the potential to regulate the cardiovascular system by 
modulation of systemic risk factors [Walker et al., 1998]. Glucocorticoid excess can 
affect virtually all classical cardiovascular risk factors, including obesity [Dallman et al., 
2004], insulin resistance [Andrews and Walker, 1999], hyperglycaemia [Clore and 
Thurby-Hay, 2009], hypertension [Whitworth et al., 1997] and dyslipidaemia [Walker, 
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2007] and, therefore, it is not surprising to see higher cardiovascular mortality in patients 
with Cushing‟s syndrome [Etxabe and Vazquez, 1994]. 
The association between excess glucocorticoids and hypertension has been known for 
many years but the underlying mechanisms remain poorly understood [Krakoff and 
Elijovich, 1981]. Glucocorticoid induced hypertension may involve multiple complex 
pathways influencing renal homeostasis, cardiac, vascular and central nervous systems 
[Simmons et al., 1996;Whitworth et al., 1997;Brem, 2001]. Glucocorticoid exposure 
during intra-uterine life has also been linked to the development of hypertension (and 
other cardiovascular risk factors) in adult life [Benediktsson et al., 1993]. The 
cardiovascular effects of glucocorticoids have been reviewed by Whitworth et al 
[Whitworth et al., 2005]. 
1.3.7 Glucocorticoids and vascular inflammation 
Since inflammation is a key mediator of cardiovascular pathologies, inhibition of 
inflammation would be expected to reduce the development of fibro-fatty lesions in 
atherosclerosis, remove the stimulus for smooth muscle cell migration/proliferation in 
restenosis and also attenuate myocardial scarring and fibrosis [Wainwright et al., 
2001;Miller et al., 2001]. 
Although glucocorticoids are generally considered to be anti-inflammatory hormones 
this is a rather simplistic notion. There are considerable data to suggest that 
glucocorticoids can also have pro-inflammatory / immuno-stimulatory actions [Dhabhar 
and McEwen, 1997;Yeager et al., 2004]. Indeed, it appears that glucocorticoids have 
dynamic interactions with inflammatory cells which may result in diametrically opposite 
effects on several components of the inflammatory and immune response [Meagher et 
al., 1996;Dhabhar and McEwen, 1999]. These opposing effects of glucocorticoids 
probably stem from their marked pleiotropy, pharmacokinetic properties, physiological 
versus pharmacological effects, systemic vs. tissue type-specific actions, and the timing 
and duration of the exposure. Glucocorticoids can influence both the innate and the 
adaptive immune responses as outlined below. 
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1.3.7.1 Effects of glucocorticoids on innate immunity 
Glucocorticoids play a major role in leukocyte trafficking during local or systemic 
inflammation, by promoting the survival / proliferation of neutrophils and inducing 
apoptosis of eosinophils and basophils [Meagher et al., 1996]. Glucocorticoid-induced 
neutrophilia is enhanced by the increased release of bone-marrow polymorphonuclear 
cells and inhibition of neutrophil transmigration to inflammatory sites. This occurs 
through down-regulation of leukocyte adhesion molecules, such as leukocyte factor 
adhesion-1 (LFA-1) and L-selectin, and endothelial adhesion molecules, such as 
intercellular adhesion molecule-1 (ICAM-1), as well as through inhibition of chemokine 
release (for example IL-8) at inflamed sites [Cronstein et al., 1992;Jilma et al., 
2000;Nakagawa et al., 1999]. However, the influence of glucocorticoids on adhesion 
molecules is complex; for example, glucocorticoids inhibit NF-kappaB induced vascular 
cell adhesion molecule-1 (VCAM-1) expression, but they also stabilise VCAM-1 mRNA 
[Simoncini et al., 2000]. 
Glucocorticoids suppress inflammation by enhancing the clearance of foreign antigens, 
toxins, micro-organisms and dead cells by improving opsonisation and the activity of 
scavenger systems and by stimulating macrophage phagocytotic ability and antigen 
uptake [Liu et al., 1999]. They also suppress the synthesis of many inflammatory 
mediators, such as several cytokines and chemokines, prostaglandins, leukotrienes, 
proteolytic enzymes, nitric oxide (NO) and free oxygen radicals [Franchimont et al., 
2002].  
1.3.7.2 Effect of glucocorticoids on adaptive immunity 
Glucocorticoids can impair maturation of dendritic cells resulting in a decreased ability 
to present antigens to T-lymphocytes and to elicit an immune response [Piemonti et al., 
1999]. However, once an immune response has developed, glucocorticoids may 
modulate the type of immune response by regulating the differentiation of CD4
+
 T-cells 
into Th1 lymphocytes, which drive cellular immunity, or into Th2 lymphocytes, which 
drive humoral immunity [Cousins et al., 2002]. Glucocorticoids have been shown to 
block IL-12 secretion from monocyte/macrophages and dendritic cells, which is an early 
crucial step in the development of the Th1-directed cellular immune response and, 
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hence, is a key link between innate and cellular immunity [Blotta et al., 1997]. 
Glucocorticoids may promote Th2 development by enhancing IL-10 secretion by 
macrophages or Th2 cells [Ramirez et al., 1996]. On the other hand, glucocorticoids may 
also promote the development of T-regulatory cells to suppress immune responses, 
prevent self-reactivity and encourage immune tolerance [Barrat et al., 2002]. Thus, by 
acting directly either on leukocytes or on dendritic cells, endogenous glucocorticoid 
hyper-secretion or chronic, excessive administration causes a progressive shift from a 
Th1-directed cellular immune response to a Th2-driven humoral immune response. 
1.3.7.3 Effect of glucocorticoids on T-cell apoptosis and survival 
Glucocorticoids can influence inflammation in either direction by inducing T-
lymphocyte apoptosis or survival, depending on the cell sub-type and differentiation 
stage [Zacharchuk et al., 1990]. Also, both the degree of activation and the timing of 
glucocorticoid exposure (before, during or after activation) can make T-cells either 
sensitive or resistant to glucocorticoid-induced apoptosis [Ashwell et al., 2000]. Several 
studies have shown that concomitant T-cell receptor (TCR) and glucocorticoid 
signalling promotes T-cell survival, whereas either TCR signalling alone or GR 
signalling alone induces T-cell apoptosis.[Ashwell et al., 2000] Glucocorticoids might 
also attenuate TCR signalling through non-genomic actions [Van et al., 2001]. There is 
growing evidence that endogenous glucocorticoids play a role in T-cell development and 
selection in the thymus [Ashwell et al., 2000]. Glucocorticoids can also influence 
peripheral T-cell development and selection in the extra-thymic immune system, where 
glucocorticoids might be essential in shaping the immune response and maintaining 
peripheral T-cell pool homeostasis by preventing TCR-induced T-cell deletion and 
enhancing T-cell survival simultaneously [Gonzalo et al., 1993]. 
1.3.8 Glucocorticoids and haemostasis 
Glucocorticoids can directly affect haemostasis. Dexamethasone has been shown to 
increase production of von Willebrand Factor (vWF), endothelin and PAI-1 in human 
umbilical vein endothelial cells (HUVEC) [Huang et al., 1995] and of PAI-1 in cultured 
human adipose tissue [Halleux et al., 1999]. Patients with Cushing‟s syndrome (excess 
of endogenous glucocorticoids) have elevated levels of vWF, PAI-1, thrombin-
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antithrombin and plasmin-antiplasmin complexes and factor VIII. These haemostatic 
problems may resolve after curative surgical treatment [Patrassi et al., 1985;Fatti et al., 
2000]. Patients with Cushing‟s syndrome also have increased platelet count, fibrinogen, 
PAI-1, and decreased tissue factor pathway inhibitor levels which represents a potential 
hypercoagulable and hypofibrinolytic state and may increase the risk for atherosclerotic 
and athero-thrombotic complications [Erem et al., 2009]. 
1.3.9 Direct effects of glucocorticoids on the cardiovascular system 
Whilst much of the impact of glucocorticoids on the cardiovascular system is due to 
exacerbation of the cardiovascular risk factors and interaction with renal homeostasis, 
[Bjorntorp, 1991], there is evidence for additional, direct effects on the cells of the 
cardiovascular system. 
1.3.9.1 Effects of glucocorticoids on the vessel wall 
Glucocorticoids can increase peripheral vascular resistance in animals devoid of renal 
mass [Langford and Snavely, 1959] suggesting a direct interaction with the cells of the 
heart and vascular wall. In man, topical administration of glucocorticoids induces dermal 
vasoconstriction [Walker et al., 1991] possibly due to glucocorticoid-mediated 
enhancement of contractile responses to noradrenaline and angiotensin-II [Ullian, 
1999;Hadoke et al., 2006]. In VSMCs, glucocorticoids have been shown to up-regulate 
contractile receptors, alter intracellular second messenger activation and modulate the 
activity and synthesis of vasoactive substances leading to an augmentation of 
contraction. Increased contractility may be due to increased release of endothelium-
derived vasoconstrictors (such as angiotensin II, endothelin-1) [Mendelsohn et al., 
1982;Morin et al., 1998] and/or impaired endothelium-dependent relaxation [Mangos et 
al., 2000] due to impaired vasodilators (e.g. prostaglandins, nitric oxide) activity 
[Gerritsen and Rosenbaum, 1985;Wallerath et al., 1999;Simmons et al., 1996]. 
Glucocorticoids can also inhibit migration and proliferation of VSMCs [Longenecker et 
al., 1982;Longenecker et al., 1984] and tube formation by endothelial cells [Nicosia and 
Ottinetti, 1990]. Glucocorticoids have also been shown to inhibit angiogenesis [Folkman 
et al., 1983;Crum et al., 1985;Folkman and Ingber, 1987] which can be abolished by GR 
receptor antagonism [Small et al., 2005]. 
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1.3.9.2 Effect of glucocorticoids on the heart 
Glucocorticoids may help in maintaining normal cardiac contractile function. 
Dexamethasone treatment enhances the development of contractile tension and increases 
contraction and relaxation velocities in cardiac muscles [Penefsky and Kahn, 1971]. The 
decrease in contractile force of rat papillary muscles following adrenalectomy can be 
prevented by dexamethasone administration [Lefer, 1968] which can modulates Ca
2+
 
transport in cardiac myocytes [Whitehurst, Jr. et al., 1999;Narayanan et al., 2004] and 
activity of K
+
 channels [Lefer, 1968;Wang et al., 1999;Penefsky and Kahn, 1971]. 
Therefore, glucocorticoids may also influence cardiac electrical activity. Over-
expression of cardiac GR in mice leads to reduced heart rate and depressed cardiac 
conduction with atrio-ventricular blocks despite no major changes in cardiac structure 
[Sainte-Marie et al., 2007]. Short-term dexamethasone treatment has also been shown to 
decrease resting heart rate in healthy human volunteers [Brotman et al., 2006]. 
Several experimental and human studies have also revealed harmful effects (e.g. 
cardiomyopathy) of glucocorticoids on the myocardium [Zecca et al., 2001;Mitsuya et 
al., 2004]. Glucocorticoid-induced cardiomyopathy is characterized by accumulation of 
lipid droplets in myocardium, cardiomyocyte hypertrophy, and dissolution of myofibrils 
[Clark et al., 1982;de Vries et al., 2002]. Dexamethasone treatment in adulthood leads to 
hypertrophy and precocious degeneration of cardiomyocytes [de Vries et al., 2002]. 
Glucocorticoid treatment in the neonatal period can also induce hypertrophy of the 
myocardium with changes in the protein-to-DNA ratio and in the actin content of the 
heart [Werner et al., 1992;La Mear et al., 1997]. The role of glucocorticoid signalling in 
the development of cardiomyopathy is not entirely understood. Some studies, however, 
suggest that cardiomyocyte hypertrophy is probably related to cross-talk between 
glucocorticoid signalling and hypertrophic signalling pathways [Lister et al., 2006]. In 
this model the enhanced glucocorticoid signal up-regulates kinase-1, which may 
augment α-adrenoceptors-mediated hypertrophy [Lister et al., 2006]. Dexamethasone 
treatment also significantly increases ACE activity [Barreto-Chaves et al., 2000] which 
has direct and indirect effects on the myocardium, resulting in myocardial fibrosis and 
heart failure. 
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1.3.10 Glucocorticoids and atherosclerosis 
Chronic glucocorticoid excess is associated with increased cardiovascular mortality in 
humans. Retrospective analysis of the association between plasma cortisol 
concentrations and atherosclerosis shows a correlation of elevated morning plasma 
cortisol levels with moderate to severe coronary atherosclerosis [Troxler et al., 
1977;Alevizaki et al., 2007]. These results are consistent with epidemiological studies as 
patients with untreated or non-remitting Cushing‟s disease exhibit a four-fold increase in 
mortality, compared with the general population, mainly as a result of vascular disease 
[Etxabe and Vazquez, 1994]. This is further supported by the demonstration that 
normalization of glucocorticoid levels in patients with Cushing‟s disease improves the 
distensibility-coefficient and intima-media thickness (IMT) [Faggiano et al., 2003]. 
However, whilst these patients show improvement in atherosclerosis and cardiovascular 
outcome, the incidence of these conditions remains higher than in the general population 
[Colao et al., 1999]. In addition, glucocorticoids have been shown to promote foam cell 
formation by increasing the accumulation of cholesterol esters, by enhancing acyl 
coenzyme A cholesterol acyltransferase 1 (ACAT-1) expression [Yang et al., 2004]. It 
has also been proposed that the beneficial effects of lipid lowering drugs on 
atherosclerosis may partially be due to their effect on synthesis of steroid hormones from 
cholesterol [Kanat et al., 2007]. 
Chronic therapeutic administration of glucocorticoids is also linked to increased 
cardiovascular events, including fatal and non-fatal myocardial infarctions [Wei et al., 
2004;Davis et al., 2007]. This increased risk is cumulative and dose-dependent, and is 
reduced if treatment is discontinued [Souverein et al., 2004;Varas-Lorenzo et al., 2007]. 
Daily administration of prednisolone in dose equivalents exceeding 10mg, for example, 
is associated with a two-fold increased risk of acute myocardial infarction [Varas-
Lorenzo et al., 2007]. The relationship between chronic glucocorticoid therapy and 
cardiovascular disease has been addressed most consistently in patients with chronic 
inflammatory conditions, such as rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE). In RA, the risk of mortality (predominantly from cardiovascular 
disease) increases by 14% after 1 year, rising to 69% after 10 years, in patients treated 
with low-dose, oral glucocorticoids [Sihvonen et al., 2006]. However, when interpreting 
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these studies, it must be kept in mind that it is difficult to differentiate the effect of 
glucocorticoid treatment from that of the underlying inflammatory condition [Hadoke et 
al., 2009]. 
Experimental studies of the link between glucocorticoids and atherosclerosis, using 
various animal models, have produced conflicting results. Glucocorticoids prevent or 
arrest atherosclerosis in fat-fed rabbits, despite increasing hyperlipidaemia [Bailey and 
Butler, 1985;Asai et al., 1993;Naito et al., 1992;Jain et al., 1965]. This effect was first 
demonstrated over 50 years ago [Oppenheim and Bruger, 1952;Gordon et al., 
1954;Stumpf and Wilens, 1954;Constantinides et al., 1962] and has subsequently proved 
to be reproducible in this model [Asai et al., 1993;Naito et al., 1992;Cavallero et al., 
1976;Bailey and Butler, 1985] and in rabbits with inherited hypercholesterolaemia 
(Watanabe heritable hyperlipidaemia, WHHL) [Makheja et al., 1989]. The 
mechanism(s) underlying the apparent anti-atherosclerotic effect of glucocorticoids is 
(are) incompletely understood. The possible mechanisms include inhibition of DNA 
synthesis in the cellular component of lesions [Cavallero et al., 1976], inhibition of 
inflammatory cell proliferation [Asai et al., 1993;Sakai et al., 1999], inhibition of intimal 
VSMC proliferation [Voisard et al., 1994] and migration [Van Put et al., 1995], and 
reduced chemotaxis of circulating monocytes / macrophages into the sub-endothelial 
space [Yamada et al., 1993;Prescott et al., 1989;Dhawan et al., 2007]. However, there 
are several studies suggesting an atherogenic effect of glucocorticoids. In cockerels, 
cortisone feeding has been shown to increase atherogenesis [Stamler et al., 1954]. There 
is also an indication that social stress, which increases cortisol and corticosterone 
secretion [Szeto et al., 2004], increases atherogenesis in WHHL rabbits [Mccabe et al., 
2002]. Furthermore, GR antagonism with RU38486 has been shown to reduce lesion 
formation by 45% in atherosclerotic mice [Santanam et al., 2004] suggesting a pro-
atherogenic effect of GR stimulation. 
1.3.11 Glucocorticoids and neointimal proliferation 
Several properties of glucocorticoids suggest that they may prevent the intense fibro-
proliferative vascular remodelling that occurs following percutaneous revascularisation 
(angioplasty ± stenting), prompting a number of experimental and clinical studies. 
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Studies in animals have largely supported the hypothesis that glucocorticoid 
administration reduces neointimal proliferation. Systemic dexamethasone administration 
inhibited neointimal lesion formation in rats [Villa et al., 1994;Guzman et al., 1996], 
rabbits [Van Put et al., 1995;Poon et al., 2001] and dogs [Strecker et al., 1998] with 
inhibition of macrophage accumulation proposed as a possible mechanism of action 
[Poon et al., 2001]. Similar results were obtained with either oral or local prednisone in 
rabbit iliac artery [Ribichini et al., 2007]. Not all studies in animals have yielded positive 
results, however, as dexamethasone treatment did not reduce neointimal hyperplasia 
after angioplasty in the rabbit [Karim et al., 1997] or in the pig [Lincoff et al., 1997]. 
Moreover, early clinical trials were disappointing: methylprednisolone did not inhibit 
restenosis after coronary angioplasty [Pepine et al., 1990] or stenting [Reimers et al., 
1998] whilst dexamethasone-eluting stents (D-DES) have not reduced the incidence of 
restenosis [Hoffmann et al., 2004;Ribichini et al., 2007]. More recently, interest in the 
potential of glucocorticoids in prevention of restenosis has been re-awakened [Radke et 
al., 2004;Liu et al., 2004;Ferrero et al., 2007] with several trials suggesting a beneficial 
effect of glucocorticoids: oral prednisone produced a dose-dependent reduction in 
clinical events and angiographic restenosis rate after stenting (the IMPRESS trial) 
[Versaci et al., 2002;Ferrero et al., 2007]; low-dose dexamethasone was associated with 
low restenosis rate (the STRIDE trial) [Liu et al., 2003]), D-DES produced a low rate of 
clinical events (death, myocardial infarction and ischemia driven target vessel 
revascularization) at 6 months (despite no inhibition of restenosis; the DESIRE trial) 
[Ribichini et al., 2007]. There are on-going multi-centre trials to further evaluate the 
effects of local and systemic administration of glucocorticoids [Ribichini et al., 2009]. 
1.4 11β-HSD isozymes and the cardiovascular system 
The ability to regulate glucocorticoid activity within the target tissues has highlighted 
the possibility of tissue-specific glucocorticoid excess (or deficiency) in the presence of 
normal circulating concentrations of the enzyme [Wamil and Seckl, 2007]. Altered 
activity of 11β-HSD isozymes in the adipose tissue, liver, skeletal muscle and brain have 
been linked to diabetes mellitus, metabolic syndrome and cognitive dysfunction. The 
association of some of these conditions with hypertension and atherosclerosis has 
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suggested a role for 11β-HSD activity in the development of cardiovascular disease 
[Walker, 2007]. The physiology of both isozymes has been explored in greater detail in 
the recent years, particularly since the generation of mice with targeted disruption of the 
genes encoding each isozyme [Kotelevtsev et al., 1997;Kotelevtsev et al., 1999]. 
1.4.1 Non-selective 11β-HSD inhibitors 
Inhibition of 11β-HSD activity in experimental and clinical studies depended, until 
relatively recently, upon the use of several naturally-occurring compounds. Principal 
among these were compounds derived from glycyrrhizic acid, the principal active 
component of the liquorice plant, Glycyrrhiza glabra. In addition to these plant-derived 
compounds, endogenous bile acids, such as lithocholic acid and chenodeoxycholic acid 
are also non-selective inhibitors of 11β-HSD [Perschel et al., 1991;Latif et al., 1994]. 
Excessive liquorice ingestion causes a characteristic syndrome, with clinical and 
biochemical features of pseudo-hyperaldosteronism, which is the result of 11β-HSD2 
inhibition [Conn et al., 1968]. Glycyrrhetinic acid [Adamson and Tillman, 1955], the 
hydrolytic product of glycyrrhizic acid, and its hemi-succinate derivative, carbenoxolone 
[Csonka and Murray, 1971], have anti-inflammatory properties in the skin and have also 
been used extensively for pharmacological inhibition of 11β-HSD activity. The 
usefulness of these compounds is limited, however, as they inhibit both isozymes of 
11β-HSD [Schleimer, 1991;Li et al., 1997] although it has been suggested that 
carbenoxolone is more active against the dehydrogenase activity of 11β-HSD [Morris et 
al., 2003;Brem et al., 1997]. 
1.4.2 11β-HSD1 inhibition and the metabolic syndrome 
It has been shown that over-expression of 11β-HSD1 in the adipose tissue [Masuzaki et 
al., 2001;Masuzaki et al., 2003] or liver [Paterson et al., 2004] results in central obesity, 
hypertension and dyslipidaemia. Conversely, 11β-HSD1 knockout mice have an 
atheroprotective phenotype, including lower cholesterol and triglyceride levels and 
improved glucose tolerance [Morton et al., 2005]. Transgenic deletion of 11β-HSD1 has 
no effect on blood pressure [Kotelevtsev et al., 1997] or vascular contractility [Hadoke 
et al., 2001d], and this enzyme does not seem to influence vascular reactivity in-vivo. 
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The identification of 11β-HSD1 as a potential target for the treatment of diabetes 
mellitus and metabolic syndrome has prompted considerable interest in the 
pharmaceutical industry; leading to the discovery and development of a multitude of 
novel selective 11β-HSD1 inhibitors. There have been nearly 100 patents filed by ~29 
different pharmaceutical companies and research organisations since 2002. These 
embrace a wide variety of compounds, based predominantly around: triazoles, aryl 
sulphonamide thiazoles, sulphonamides and adamantyl carboxamides [Hughes et al., 
2008]. 
Initial results from in-vivo studies in mouse and rat models have produced promising 
evidence that selective 11β-HSD1 inhibitors provide an effective treatment for systemic 
cardiovascular risk factors, including: obesity, type II diabetes and dyslipidaemia. 11β-
HSD1 inhibition with BVT 2733 (a thiazole type inhibitor, 200mg/kg twice daily) 
improved insulin sensitivity and dyslipidaemia [Alberts et al., 2003] and decreased 
blood glucose (7 days administration by mini-pump) [Alberts et al., 2002] in 
hyperglycaemic mice. Compound 544 (a triazole type inhibitor, 30mg/kg twice daily for 
11 days) reduced body weight, fasting glucose and serum lipids in mice with diet-
induced obesity and streptozotocin/high-fat-diet -induced diabetes mellitus 
[Hermanowski-Vosatka et al., 2005]. Improvements in cardiovascular risk factors are 
not restricted to these compounds or to mouse models as low dose (3mg/kg/day)  of 
another triazole type 11β-HSD1 inhibitor also improved fasting triglyceride levels and 
prevented lipid accumulation in tissues of rats with diet-induced obesity [Berthiaume et 
al., 2007a;Berthiaume et al., 2007]. 
Selective 11β-HSD1 inhibitors potentially have a variety of clinical applications (for 
example, in the treatment of wound healing and age-related cognitive impairment 
(Alzheimer‟s disease)). Their application in the cardiovascular arena could include 
treatment of the metabolic syndrome, obesity, type II diabetes and prevention and 
treatment of atherosclerosis [Hadoke et al., 2009]. The demonstration that these 
compounds also inhibit 11β-HSD1 in the brain raised a concern of possible side-effects 
caused by disruption of the HPA axis but no such complications have been identified in 
animal studies. Several companies have now produced orally-active compounds that 
achieve inhibition in these tissues in rodents [Hughes et al., 2008], with tissue inhibition 
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in human adipose also recently demonstrated in a Phase IIa clinical trial where 
compound INCB13739 reduces fasting plasma glucose, cholesterol and LDL levels in 
patients with type II diabetes [Rosenstock et al., 2010]. Other selective 11β-HSD1 
inhibitors produced by Amgen and Biovitrum (AMG221) are also currently being 
evaluated in clinical trials [Hughes et al., 2008]. 
1.4.3 11β-HSD1 inhibition and inflammation 
There is evidence to suggest that glucocorticoid metabolism through the 11β-HSD 
enzymes provides an additional level of regulation of inflammatory response [Chapman 
et al., 2006]. 11β-HSD1 is expressed in monocytes, macrophages and lymphocytes and 
can regulate innate and adaptive immune responses. 
Circulating monocytes express low levels of 11β-HSD1; however, on differentiation to 
macrophages or dendritic cells, there is substantial increase in expression [Thieringer et 
al., 2001]. Expression in macrophages is stimulated further by IL-4 and IL-13 
[Thieringer et al., 2001]. Expression of 11β-HSD1 in resident macrophages is detectable 
in-vivo in the mouse, and the activity increases very rapidly during acute inflammation 
(e.g. peritonitis [Gilmour et al., 2006]) The expression of 11β-HSD1 in macrophages has 
been shown to be important in the early induction of the capacity of these cells to 
phagocytose apoptotic neutrophils [Gilmour et al., 2006]. This suggests that 
glucocorticoid production via 11β-HSD1 can have a very active role in enhancing anti-
inflammatory responses and is not solely due to effects on expression of pro-
inflammatory cytokines. 
11β-HSD1 expression has also been demonstrated in various lymphocyte populations 
[Zhang et al., 2005]. Resting CD4
+
 or CD8
+
 T-cells and B-cells isolated from mice 
express 11β-HSD1. This activity increases further when naive CD4
+
 cells are activated 
by T-cell receptor stimulation or when the cells are differentiated in-vitro into Th1 or 
Th2 subtypes [Zhang et al., 2005;Hu et al., 2009]. Intracellular generation of active 
glucocorticoids from inactive precursors was associated with a reduction in cytokine 
production, an effect that did not occur in cells obtained from 11β-HSD1 knockout mice. 
The expression of 11-HSD1 is also seen in the thymus. Thymocytes express low levels 
of 11β-HSD1, but this increases substantially in an experimental burn injury model in 
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mice, an effect that is associated with an increased rate of thymocyte apoptosis [D'Elia et 
al., 2009]. 
Inflammation can also up-regulate expression of 11β-HSD1 in a variety of cells and 
tissues including VSMCs, adipocytes, osteoblasts, myoblasts, fibroblasts, synovial and 
colonic tissue [Tomlinson et al., 2001;Cai et al., 2001;Hardy et al., 2006;Bryndova et al., 
2004]. This is largely mediated by IL-1 and TNF-α and to a lesser extent by the Th2 
cytokines (IL-13 and IL-4). The induction of 11β-HSD1 activity has been shown to have 
functional effects on the cells (an intracrine effect) but is likely to also increase 
glucocorticoid levels within the tissue (a paracrine effect). This has been shown in the 
synovium in which the increased expression in response to inflammation was proposed 
to reflect an attempt to reduce inflammation within the joint [Hardy et al., 2008]. In such 
tissues it is likely that the high local glucocorticoid levels could impair the function of 
immune cells that migrate into the joint, even if they themselves do not express 11β-
HSD1. These findings suggest that 11β-HSD1 may play a dynamic role in the regulation 
of the inflammatory responses in both innate and adaptive immunity. 
1.4.4 11β-HSD1 inhibition and atherosclerosis 
A striking example of the benefit of selective 11β-HSD1 inhibition in mouse models of 
disease is provided by a study with an inhibitor (Compound 544, 10mg/kg/day, 8 
weeks), that produced a dramatic (~85%) reduction in aortic cholesterol content in 
ApoE
-/-
 mice on a high fat diet [Hermanowski-Vosatka et al., 2005]. Non-selective 11β-
HSD1 inhibition with carbenoxolone (4 weeks) significantly reduced atherosclerosis in 
obese LDLR
-/-
 mice [Nuotio-Antar et al., 2007]. In addition, it is possible that some anti-
atherosclerotic interventions owe part of their effectiveness to regulation of 11β-HSD1 
as PPAR-α agonists, such as fibrates, which are important agents for treating 
dyslipidaemia, reduce 11β-HSD1 expression and activity in murine liver [Hermanowski-
Vosatka et al., 2005]. However, another selective 11β-HSD1 (compound 2922, 
100mg/kg/day for 12 weeks) did not reduce atherosclerosis, despite improvement in 
glycaemic profile [Lloyd et al., 2009]. Finally, one slight concern is raised, however, by 
the ability of 11β-HSD1 to metabolise 7-oxysterols, as this may be pro-atherogenic 
[Schroepfer, 2000]. 7-Ketocholesterol which is present in very small quantities in the 
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plasma is highly concentrated in human atherosclerotic lesions [Brown et al., 2000] and 
is linked with an increased risk of developing atherosclerotic plaques at an early age, as 
demonstrated in patients with cerebrotendinous xanthomatosis [Fujiyama et al., 1991]. 
11β-HSD1 inhibition in-vivo results in increased 7-ketocholesterol levels in the liver and 
plasma in rats [Schweizer et al., 2004b;Schweizer et al., 2004]. 
The mechanisms through which selective 11β-HSD1 inhibitors reduce atherosclerosis 
have yet to be demonstrated unequivocally. It was notable that the dramatic reduction in 
lesion formation produced by Compound 544 in atherosclerotic mice was greater than 
predicted by the more modest improvements in systemic metabolic risk factors 
[Hermanowski-Vosatka et al., 2005]. It was proposed, therefore, that 11β-HSD1 
inhibition may have a direct protective effect on the vascular wall [Hermanowski-
Vosatka et al., 2005]. If this is the case, the mechanism has not been established 
although data were provided to suggest that 11-HSD1 inhibition reduces concentrations 
of MCP-1 in the circulation and aortic wall (MCP-1 is not normally found in the arterial 
media or intima but has been found in human and rodent atherosclerotic plaques 
[Ylaherttuala et al., 1991]). This is not consistent with the reported GR-dependent 
inhibition of MCP-1 from arterial SMC by glucocorticoids [Dhawan et al., 2007]. 
1.4.5 11β-HSD1 inhibition and neointimal proliferation 
Glucocorticoids can decrease neointimal proliferation due to anti-inflammatory and anti-
proliferative actions or increase neointimal proliferation via a detrimental effect on 
systemic cardiovascular risk factors. Therefore, the effect of 11β-HSD1 inhibition on 
neointimal proliferation will depend on the balance between these two factors. However, 
the role of 11β-HSD1 in regulating neointimal proliferation has not been described in the 
literature. 
1.4.6 11β-HSD1 inhibition and heart function post myocardial infarction 
There are emerging data to suggest that 11-HSD1 inhibition may reduce the size of 
infarct after acute myocardial infarction and may, therefore, improve left ventricular 
function and ejection fraction [McSweeney et al., 2010]. The possible mechanisms for 
this beneficial effect on myocardium are enhanced inflammatory cell recruitment and 
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angiogenesis [Small et al., 2005;McSweeney et al., 2010]. The impact of 11-HSD1 
inhibition in the context of chronic heart failure, however, has not been studied. 
1.4.7 11β-HSD2 inhibition and the cardiovascular system 
Mice with transgenic deletion of 11β-HSD2 are hypertensive [Kotelevtsev et al., 1999], 
and have enhanced vasoconstrictor responses to noradrenaline with impaired NO-
mediated, endothelium-dependent vasodilatation [Hadoke et al., 2001]. The cause for the 
changes in vascular reactivity and endothelial dysfunction are unknown, but are unlikely 
to be due to renal sodium retention and increased blood pressure since chronic renal 
mineralocorticoid excess does not replicate the changes in vascular function [Hadoke et 
al., 2001]. Data from 11β-HSD2 knockout mice suggested that the observed changes in 
vascular reactivity are due to a loss in 11-HSD2-mediated protection of GR within 
endothelial cells and, hence, to glucocorticoid-mediated endothelial cell dysfunction 
[Hadoke et al., 2001]. However, studies in isolated vessels from these mice failed to 
confirm this [Christy et al., 2003], suggesting that some other indirect mechanism causes 
the vascular abnormality in-vivo. 
Another possible, but controversial, explanation of the effect of 11β-HSD2 on the 
cardiovascular system may be modulation of the immune response. There are some data 
suggesting expression of 11β-HSD2 in circulating and tissue monocytes/macrophages in 
patients with rheumatoid arthritis [Olsen et al., 2004]. Expression of 11β-HSD2 has also 
been described in synovial tissue from patients with RA [Hardy et al., 2008]. Although, 
this issue needs further in-depth investigation, it highlights how 11β-HSD2 (and 11β-
HSD1) expression can change in pathological conditions and modify immune responses. 
11β-HSD2 may also help prevent myocardial fibrosis by protecting MR from 
glucocorticoids [Konishi et al., 2003]. Mice with transgenic deletion of 11β-HSD2 on 
ApoE
-/-
 background tend to develop extensive atherosclerotic changes without the need 
for dietary interventions (Deuchar et al., unpublished data). However, the role of 11β-
HSD2 in regulating the inflammatory and proliferative responses in a model of 
intravascular injury has not been studied yet. 
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1.5 Hypotheses and Aims 
1.5.1 Hypotheses 
Vascular lesion development (atherosclerosis and neointimal proliferation) represents an 
inflammatory and proliferative response to chronic or acute vascular injury. 
Glucocorticoids can modulate inflammation and cellular proliferation within the vessel 
wall and may contribute to the development of systemic risk factors associated with 
cardiovascular disease. 11β-HSD1 inhibition improves cardiovascular risk factors and 
loss of 11β-HSD2 activity results in hypertension. Therefore, the work described in this 
thesis addressed the hypotheses that 11β-HSD1 inhibition reduces the size and alter the 
composition of vascular lesions (atherosclerotic and neointimal) by modulating systemic 
risk factors and vascular inflammation, whereas, 11β-HSD2 deletion results in 
glucocorticoid-mediated activation of vascular MR leading to an increase in neointimal 
proliferation which can be blocked with MR antagonism. 
1.5.2 Aims 
The primary objectives of this project were: 
 To establish whether 11β-HSD1 inhibition reduces lesion size and alters plaque 
composition in a murine model of atherosclerosis 
 To determine whether 11β-HSD1 inhibition/deletion reduces neointimal 
proliferation in a mouse model of wire-angioplasty 
 To determine whether 11β-HSD2 deletion results in enhanced neointimal 
proliferation in a mouse model of wire-angioplasty 
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2. Materials and Methods 
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2.1 Animals 
All animal work was carried out under UK Home Office licence in accordance with the 
Animal (Scientific Procedures) Act (UK), 1986 and conforms with the “Guide for the 
Care and Use of Laboratory Animals” published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996). 
All non-genetically modified mice used were the C57Bl/6J strain and were either bred 
in-house or purchased from Harlan Laboratories (Bicester, UK). Apolipoprotein E 
knockout (ApoE
-/-
) mice were either bred in-house or purchased from Charles River 
Laboratories (Kent, UK). 11β-HSD1
-/-
 mice, 11β-HSD2
-/-
 mice and 11β-HSD1
-/-
, ApoE
-/-
 
double knockout mice, all congenic on a C57Bl/6J background, were bred in-house. 
All animals were housed at the Biomedical Research Facility, University of Edinburgh. 
Mice were maintained under standard conditions of light (lights on 8am-8pm), humidity 
(50%) and temperature (21-22ºC). 
2.2 Materials 
2.2.1 Chemicals and reagents 
Unless stated otherwise, all chemicals and solutions were from Sigma-Aldrich 
(Gillingham, UK) and all solvents were from Fisher Scientific (Loughborough, UK). 
Harris‟ haematoxylin was obtained from Thermo Shandon (Runcorn, UK), Weigert‟s 
iron haematoxylin A and B solutions from Bios Europe (Skelmersdale, UK), DPX 
mounting medium from VWR International (Lutterworth, UK), monoclonal rat anti-
mouse primary antibody against Mac-2 from Cedarlane (Burlington, Canada) and [
3
H]4 
corticosterone from GE Healthcare (Amersham, UK). 
2.2.2 Diets and drugs 
Animals were fed standard chow (RM1; Special Diet Services, UK) unless specified 
otherwise. Western diet (OpenSource
TM
 D12079B), containing 21% fat, 20% protein 
and 50% carbohydrate, was obtained from Research Diets (Brunswick, USA). Animals 
were allowed to feed ad libitum in all studies. 
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Compound 544 (3-adamantan-1-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-α]azepine), 
a selective 11β-HSD1 inhibitor [Hermanowski-Vosatka et al., 2005], was obtained (as 
compound T5293658) from Enamine Ltd. (Kiev, Ukraine). This compound is a 
competitive inhibitor for cortisone, but not NADPH, suggesting that it interacts with the 
steroid binding site (unpublished data). It has poor water solubility and does cross blood-
brain barrier [Hermanowski-Vosatka et al., 2005]. The advantages of this particular 
compound include published data and good bioavailability with oral administration 
[Hermanowski-Vosatka et al., 2005]. The molecular weight of compound 544 is 
271.4nM; IC50 for human 11β-HSD1 is 7.5±0.5nM and IC50 for mouse 11β-HSD1: 
97±5.1nM. The biochemical structure of compound 544 is shown in Figure 2.1. 
Eplerenone, a selective mineralocorticoid receptor antagonist [Rabasseda et al., 1999], 
was obtained from Pfizer Inc. (New York, USA). The molecular weight of eplerenone is 
414.5 nM and IC50 for minerelocortcioid receptors is 360nM. The biochemical structure 
of eplerenone is shown in Figure 2.1. 
2.2.3 Surgical material 
Surgical instruments were purchased from Fine Science Tools (Interfocus Ltd, UK). 
Angioplasty guide-wires (0.015”) were obtained from Cook Inc. (Bloomington, USA), 
Mersilk 6-0 sutures were from Ethicon Ltd. (Livingston, UK), isoflurane was from 
Merial Animal Health Ltd. (Harlow, UK), buprenorphine 0.3mg/ml as vetergesic from 
Alstoe Animal Health (York, UK) and 1% lignocaine from Hameln Pharmaceuticals 
Ltd. (Gloucester, UK). 
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Figure 2.1: Biochemical structure of compound 544 and Eplerenone 
 
 
EplerenoneCompound 544
 
Compound 544 “3-adamantan-1-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-α]azepine” 
was used as a selective inhibitor of 11β-HSD1. 
Eplerenone “Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,γ-
lactone, methyl ester, (7α,11α,17α)-” was used as a selective inhibitor of 
mineralocorticoid receptors. 
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2.3 Preparation of solutions and drugs 
2.3.1 Solutions for histology 
Alkaline tap water: 2 drops of ammonia were added to 300ml tap water. 
Gomori’s aldehyde fuchsin: 5g pararosaniline base was dissolved in 500ml of 60% 
ethanol and then 1ml hydrochloric acid (HCl) and 2ml paraldehyde were added and 
mixture was allowed to blue at room temperature for 2 days. 
Gomori’s trichrome: 3g phosphotungstic acid was dissolved in 500ml distilled water 
and then 3g chromotrope 2R and 1.5g fast green FCF were added and mixed well. 
Finally 5ml acetic acid was added and the mixture was filtered. 
Phosphate buffer saline (PBS): 1 tablet was dissolved in 200ml of distilled water. 
PBS/1%BSA: Bovine serum albumin (BSA) was dissolved in PBS to make 1% w/v 
solution. 
Weigert’s iron haematoxylin: Equal volumes of Weigert‟s haematoxylin solutions A 
and B were mixed just before use. 
0.2% acetic acid: 1ml of glacial acetic acid was diluted in 499ml distilled water. 
0.3% potassium permanganate in 0.3% sulphuric acid: Prepared from stock solutions 
of 1% potassium permanganate (5g in 500ml distilled water) and 3% sulphuric acid 
(15ml concentrated sulphuric acid + 485ml distilled water). 1% potassium permanganate 
(90ml) was mixed with 3% sulphuric acid (30ml) and 180ml distilled water to make 
300ml solution. 
2% oxalic acid: 100% oxalic acid (10ml) was mixed with distilled water (490ml). 
3% hydrogen peroxide (H2O2): Commercially-available 30% H2O2 solution was diluted 
10 fold in PBS. 
5% phosphotungstic acid: Commercially-available 10% phosphotungstic acid was 
diluted with an equal volume of distilled water. 
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20% goat serum: Commercially available normal goat serum (Vector Labs, UK) was 
diluted 1:4 with PBS/1%BSA solution. 
74 OP: A solution of 99.5% ethanol and 0.5% methanol 
2.3.2 Solutions for 11β-HSD1 activity assay 
Sucrose buffer: Sucrose (42.79g) was dissolved in distilled water (500ml) to produce a 
0.25M solution and the pH adjusted to 7.5 with concentrated NaOH. 
Krebs-Henseleit buffer: NaCl (118mM), KCl (3.8mM), KH2PO4 (1.19mM), CaCl2 
(2.54mM), MgSO4 (1.19mM), NaHCO3 (25mM) were dissolved in water and the pH 
was adjusted to 7.4 with concentrated NaOH. 
HPLC mobile phase: High performance liquid chromatography (HPLC)-grade water 
(60%, Fisher Scientific, UK) was mixed with methanol (25%) and acetonitrile (15%). 
2.3.3 Drugs 
11β-HSD1 inhibitor: Compound 544, a triazole compound selectively inhibiting 11β-
HSD1 activity, was administered by oral gavage (30mg/kg dissolved in 5% solution of 
2-Hydroxypropyl-β-cyclodextrin) for assessing its effect on hepatic 11β-HSD1 reductase 
activity. The inhibitor was administered by admixture with food to study its effects on 
atherosclerosis (10mg/kg/day for 8 weeks) or neointimal proliferation (30mg/kg/day for 
4 weeks). 
Eplerenone: To assess the effects of MR antagonism on neointimal proliferation, a 
selective MR antagonist, eplerenone, was administered by admixture with food 
(200mg/kg/day, for 4 weeks). 
2.4 Blood pressure measurement 
Systolic blood pressure (BP) was measured in conscious, warmed, restrained mice by 
tail-cuff photo-plethysmography as described [Evans et al., 1994]. 
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2.4.1 Principle 
In photo-plethysmography, a progressively inflating/deflating pressurised cuff is applied 
to the proximal part of the mouse‟s tail and blood flow through the tail is monitored by 
light transmittance (inversely proportional to the tail volume) at a point distal to the cuff. 
The cyclical changes in tail volume (indicating blood flow) cease when cuff pressure 
exceeds systolic blood pressure. 
2.4.2 Protocol 
Mice were habituated to the restraining device and heated chamber for one week before 
starting the studies. In rodents, increasing tail blood flow is one of the methods to 
dissipate excess body heat. To ensure adequate tail blood flow for photo-
plethysmography, mice were put in a heated chamber (37ºC) for 3-5min immediately 
prior to the experiment. Mice were then transferred to a Perspex tubular restraint device 
mounted above a heated pad. A tail-cuff (Harvard Apparatus, Kent, UK) with integrated 
pressure cuff and photo-sensor sleeve was placed around the proximal part of the tail 
and connected to a computer for data acquisition. Animal restraint force and the position 
of the tail cuff were adjusted to ensure animal comfort and a good baseline pulse trace of 
cyclical tail volume changes. The tail cuff was inflated to beyond the point at which the 
distal pulse stopped, deflated, and the pressure at which the pulse trace reappeared (i.e. 
systolic blood pressure) was noted. For each mouse, 8-12 cycles of inflation/deflation 
were performed and the mode value (or the mean value if no mode value) was recorded 
as systolic blood pressure. 
2.5 Biochemical tests 
2.5.1 Glucose tolerance test 
For glucose tolerance tests (GTT), mice were housed individually and fasted for 6hr. 
After this period, baseline (time 0min) blood samples were collected by tail tipping, and 
then glucose (2mg/g) was administered by intra-peritoneal injection. Further blood 
samples were taken 15, 30, 60 and 90 min after glucose administration. Blood samples 
 52 
were initially kept in wet ice and then spun at 10,000rpm for 5min to separate plasma. 
Plasma was collected into Eppendorf tubes and stored below -20°C until assayed. 
2.5.2 Glucose assay 
Serum glucose levels were determined spectrophotometrically using the glucose 
hexokinase reagent (Infinity
TM
, Thermo Electron Corporation, Middletown, USA). 
Standard solutions were prepared following manufacturer‟s instructions. Standards (2μl) 
or samples (2μl), each in duplicates, were added to a clean 96 well plate and then 200μl 
of reagent added to each well. Plates were incubated at room temperature for 3-5min and 
then absorbance was read on a plate reader (OPTImax turnable microplate reader, 
Molecular Devices, USA) at 340nm and the sample values were then interpolated from 
the standard curve (Figure 2.1). 
2.5.3 Cholesterol assay 
Serum cholesterol levels were measured spectrophotometrically using cholesterol liquid 
stable reagent (Infinity 
TM
, Thermo Electron Corporation, Middletown, USA). 
Standard solutions were prepared following the manufacturer‟s instructions. Standards 
(2μl) or samples (2μl), each in duplicates, were added to a clean 96 well plate and then 
200μl of reagent added to each well. Plates were incubated at 37ºC for 5mins and 
absorbance was read on a plate reader (primary wavelength 500nm, secondary 
wavelength 660nm). A standard curve was generated using standard solutions and was 
used to calculate unknown sample values. 
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Figure 2.2: A standard curve from spectrophotometric analysis to calculate 
unknown sample values 
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Known concentrations of glucose (x-axis) were used as standards for spectrophotometric 
analysis using Infinity™ regents. Absorbance was read at 340nm and a standard curve 
was generated. Absorbance values were also obtained for samples and glucose 
concentration in samples were interpolated from the standard curve. 
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2.5.4 Triglyceride assay 
Serum triglyceride levels were measured spectrophotometrically using Infinity
TM
 
triglyceride reagent (Thermo Electron Corporation, Middletown, USA). 
Standard solutions were prepared following the manufacturer‟s instructions. Standards 
(2μl) or samples (2μl), each in duplicates, were added to a clean 96 well plate and then 
200μl of reagent added to each well. Plates were incubated at 37ºC for 5mins and 
absorbance was read on a plate reader (primary wavelength 500nm, secondary 
wavelength 660nm). A standard curve was generated using standard solutions and the 
sample values were then interpolated from the standard curve. 
2.5.5 Serum insulin 
Serum insulin levels were measured by ultra-sensitive mouse insulin ELISA kit (Crystal 
Chem., USA). All reagents were prepared from the kit provided, as per manufacturer‟s 
instructions. The assay kit includes a microplate with columns of clip-on wells coated 
with guinea pig anti-insulin antibodies. Diluent (95μl) and sample (5μl) or standard (5μl) 
were added to the wells and the plate was incubated at 4˚C for 2hr. Plates were then 
rinsed and washed with a wash-buffer (5 x 300μl). Anti-insulin enzyme conjugant 
(100μl) was added to each well and the plate was incubated (room temperature, 30min) 
and then washed with the wash-buffer (7 x 300μl). Enzyme-Substrate solution (100μl) 
was added to each well and the plate covered with tin foil and incubated at room 
temperature for 40min. The reaction was stopped by adding Enzyme Stop solution 
(100μl) to each well. The optical density of each well was calculated using a microplate 
reader set to 450nm and the sample values then interpolated from the standard curve. 
The limits of detection from these biochemical tests, correlation coefficients and p-
values from standard curves are given in Table 2.1. 
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Table 2.1: Sensitivity and correlation coefficients of biochemical assays 
 
Assay Sensitivity range Correlation coefficient p 
Glucose 40-240 mg/dl 0.99 <0.001 
Cholesterol 0.1-12 mmol/L 0.96 <0.001 
Triglyceride 1.1-4.1 mmol/L 0.98 <0.001 
Insulin 0.1-6.4 ng/ml 0.99 <0.001 
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2.6 Measurement of 11-HSD1 activity 
11-HSD1 activity was quantified by measuring dehydrogenase activity in liver 
homogenates (by centrifugation, 1000g, 4°C, 15min). The protein concentration of 
samples was determined by Bradford method using a calorimetric protein assay kit (Bio-
Rad, UK). Hepatic homogenates were then diluted in Krebs-Ringer buffer to obtain a 
protein concentration of 20µg/ml. Aliquots of collected supernatant (180µl) were then 
mixed with 50µl cofactor mix (0.2% glucose, 2 mM NADP, dissolved in Krebs-Ringer 
buffer) and 20µl substrate mix (5nM [
3
H]4-corticosterone, 15nM unlabeled 
corticosterone, dissolved in 25% ethanol: 75% Krebs-Ringer buffer). Reactions were 
prepared in duplicate with a final volume of 250µl. Reaction mixtures were incubated 
(1hr, 37
o
C) and then stopped by adding 10 volumes of ethyl acetate. The tubes were then 
vortexed and the upper organic phase containing steroids was collected in fresh tubes 
and dried down under nitrogen (60
o
C). Steroids were then reconstituted in 800µl mobile 
phase and analysed by using reverse phase High Performance Liquid Chromatography 
(HPLC). 
The HPLC system consisted of an auto-sampler and a mobile phase pump (Waters, UK) 
equipped with C18 Sunfire Symmetry column (length 15 cm, internal diameter 4.6 mm, 
pore size 5 µm; Waters, UK), and a radioflow detector (LB509, Berthold, UK). 
Steroid samples suspended in mobile phase (60-100µl) were injected into the HPLC 
system. The flow rate of mobile phase was maintained at 1.0ml/min and of the scintillant 
(ProFlow, Meridian, UK) at 2.0ml/min. The column temperature was kept at 35
o
C to 
stabilise retention times and peak shapes. The elution times of [
3
H]4 11-
dehydrocorticosterone and [
3
H]4 corticosterone were typically 12.4 and 17.5 min, 
respectively. Peaks were more than 2 minutes in width and more than 50 times higher 
than background. 
The area under each peak was integrated using Chromeloen v6.7 (Dionex, UK) software 
and used to calculate the percentage conversion of corticosterone to 11-
dehydrocorticosterone. Enzyme activity was calculated from the amount of product 
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([
3
H]4 11-dehydrocorticosterone) formed from unit hepatic proteins in a unit time and 
was expressed as reaction velocity (pmol/mg/min). 
2.7 Wire angioplasty 
Neointimal proliferation was induced by insertion of an angioplasty guide-wire into the 
femoral artery, as described by Sata et al. (2000) and subsequently used by Dover et al. 
(2007) and others. 
2.7.1 Surgical preparation 
All surgical instruments were sterilized by autoclaving prior to each session, and a bead 
sterilizer was used to re-sterilise between consecutive operations. 
Mice were weighed and anaesthetised by inhaled isoflurane. Animals were first placed 
in an induction chamber containing 4-5% isoflurane. Upon loss of consciousness, mice 
were transferred to a heated pad where anaesthesia was maintained with ~2% isoflurane, 
administered via a nasal cone. Adequate anaesthesia was indicated by loss of pedal 
withdrawal reflex. To provide post-operative analgesia, 0.05mg/kg buprenorphine was 
injected subcutaneously. Mice were then placed in a supine position, both hind limbs 
were secured with adhesive tape and hairs were removed from left groin and upper thigh 
with an electric shaver. 
2.7.2 Operative procedure 
A 5mm longitudinal skin incision was made at the proximal thigh. The subcutaneous 
space was opened by blunt dissection revealing the femoral bundle (containing femoral 
artery, vein and nerve). The vessels were carefully isolated from the nerve both 
proximally and distally to the branch point of the popliteal artery (which is located 
between the rectus femoris and vastus medialis muscles) by blunt dissection. Blood flow 
in the femoral artery and vein was interrupted with temporary ligatures (6-0 silk suture) 
proximal and distal to this branch point, and the popliteal artery was isolated and ligated 
distally with 6-0 suture (Figure 2.2). The surgical field was irrigated with 1% lignocaine 
(lidocaine hydrochloride) to prevent arterial vasospasm. A fixed core straight 0.015” 
diameter guide-wire was introduced into the popliteal artery via an arteriotomy. 
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After loosening the proximal temporary ligature, the guide-wire was advanced 5-10 mm 
into the common femoral artery towards the iliac artery, left in place for 1 minute and 
then removed. The popliteal artery was then ligated with a 6-0 suture proximal to the 
arteriotomy site, and blood flow restored in the common femoral artery by removing the 
two temporary ligatures. This procedure induced endothelial denudation and stretching 
of the artery wall, followed by reperfusion of blood over the injured area. The wound 
was closed using 6-0 sutures and the animal was allowed to recover. 
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Figure 2.3: Surgical steps of wire angioplasty of mouse femoral arteries 
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Temporary ligatures (tLig) were placed on the isolated femoral artery (FA) for vascular 
control during the procedure, and the popliteal artery (PA) was permanently ligated 
(pLig) distally (a). An arteriotomy (arrow-head) was performed proximal to pLig. A 
fixed core straight guide-wire was inserted into the PA via this arteriotomy and 
advanced into the FA, causing endothelial denudation and stretching of the vessel wall 
(b). After removal of the wire, the PA was ligated proximal to the arteriotomy site (c). 
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2.8 Ex-vivo 3-dimensional assessment of lesion volume using OPT 
Optical Projection Tomography (OPT) is a relatively new technique that allows 3-
dimensional imaging and reconstruction of whole tissue samples [Sharpe et al., 2002]. It 
has superior resolution than other imaging techniques and is non-destructive, allowing 
subsequent histological analysis. 
2.8.1 Principles of OPT imaging 
OPT is based on using a light source and an image focusing lens system (optical) to 
capture raw data and then mathematical transformation to create a 3-dimensional image 
of original object (projection tomography). OPT is equipped with an apparatus that 
rotates specimen through 360º around a single axis whilst holding it in position for 
imaging [Alanentalo et al., 2007]. 
The optical projection tomograph (Bioptonics 3001, Bioptonics, UK) consists of a 
diffuse light source, an apparatus for holding and rotating biological samples, adjustable 
optical lenses to focus light and a charged couple device (CCD) to capture intensity data. 
The Bioptonics 3001 is equipped with three different light sources, to provide a visible 
white light, an infrared light and an ultraviolet (UV) light. This device can work in two 
different modes, transmission mode (tOPT) using visible or infrared light to capture 
shadows of transmitted light (as in CT scanning) or emission mode (eOPT) using UV 
light to illuminate the specimen following which photons emitted by excited 
flourophores within the specimen are focused on to the CCD (as in SPECT scanning). 
2.8.2 Trans-cardiac perfusion fixation 
To obtain good tissue fixation and to maintain vascular dimensions and lumen size for 
OPT analysis, trans-cardiac perfusion fixation of whole animals was performed. 
Animals were terminally-anaesthetised by intra-peritoneal injection of sodium 
pentobarbital (80mg/kg, Ceva Animal Health Ltd., UK). Following the onset of deep 
anaesthesia, indicated by loss of pedal withdrawal reflex, a midline sternotomy and left 
thoracotomy were performed. The heart was exposed and a 23G needle (Microlane
TM
, 
BD Ltd., UK) was introduced into the cavity of the left ventricle. A further incision was 
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made in the wall of the right atrium to allow the perfusate to escape. PBS containing 
heparin (10 units/ml) was infused into the left ventricle at a constant rate (7.5 ml/min) 
using a peristaltic pump (Gilson Inc, USA). Adequate perfusion was indicated by 
blanching of the liver and other organs and was usually achieved in 3-4 minutes. 
Afterwards, animals were perfused with 10% neutral formalin to provide internal 
fixation and tissue preservation. Adequate fixation was indicated by characteristic 
muscular contractions and subsequent rigidity. The vessels of interest (aortic arch, BCT, 
femoral arteries etc) were then excised from mice, post-fixed in 10% formalin for 24 
hours and then stored in 70% ethanol. 
2.8.3 Sample preparation 
Samples were embedded in 1.35% w/v low melting point agarose (Invitrogen, UK). 
Agarose was mixed in distilled water, heated to 90ºC and filtered through Whatman 
113V paper to eliminate any particulate matter. The agarose was poured into petri dishes 
and placed on a cold plate (-5ºC) in order to accelerate solidification whilst keeping the 
vessels in the correct alignment. The gelled agarose blocks were then glued with 
cyanoacrylate adhesive (Henkel, UK) onto specialized OPT mounts, with the 
longitudinal axis of the sample in an upright position, and the agarose was then trimmed 
to a conical shape to reduce back-reflection of light in the scanning plane. The mounted 
blocks were dehydrated in methanol for 24 hours and then cleared in Murray‟s clear or 
BABB (34% v/v benzyl alcohol and 66% v/v benzyl benzoate). 
2.8.4 Scanning and image reconstruction protocol 
At the beginning of each session, the tomograph was calibrated using a metal pin to 
calculate and correct any axial or rotational misalignment. 
Tissue samples (attached to OPT mounts and immersed in BABB) were placed in the 
scanning chamber of the tomograph. Sample positioning, focus and appropriate 
magnification were set under white light (bright-field condition) and then samples were 
illuminated by a UV light (dark-field condition). The excitation filter was set at 
425/40nm band-pass, the emission filter at 475nm low-pass and the CCD exposure time 
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as appropriate (typically 200-800ms). Raw data were acquired by capturing images of 
rotating objects at increments of 0.9º so that a 360º rotation provided 400 images. 
Raw images were digitally evaluated and corrected for focus and rotational 
misalignment and then image reconstruction was performed by filtered back-projection 
of raw data using NRecon (Skyscan, Belgium) software. 
2.8.5 3-dimensional quantification of lesion volume 
Volumetric measurements were achieved using CT data analysis (CTan; Skyscan, 
Belgium) software. A vertical region of interest was defined for each sample and then 
the position of internal elastic lamina was located (identified by difference in fluorescent 
signals emitted by media and neointimal) for every 25th scan line by manual tracing and 
by automated interpolation for the interleaved scan lines. This 3-D volume was further 
segregated into lumen and neointimal volumes by manually defining intensity threshold 
for both vascular compartments and automated calculation of volumes (Kirkby et al, 
unpublished data). 
2.9 Cross-sectional analysis of lesion size by histology 
2.9.1 Preparation of vessels 
Samples fixed in 10% neutral buffered formalin and stored in 70% ethanol were 
dehydrated through a graded alcohol series and embedded in paraffin using an automatic 
tissue processing machine (Shandon, U.K.) and embedding station (Shandon, U.K.). 
Paraffin blocks were then cut into 4µm thick serial sections using a Leitz microtome 
(Leica Microsystem, Germany) and MB35 premier low profile disposable blades 
(Thermo-Shandon, UK). Ribbons of sections were floated on the surface of a water bath 
(45ºC) to remove creases and then mounted onto electrostatically coated microscope 
slides (Superfrost plus; VWR International, UK). Slides were baked (37ºC) overnight to 
allow good adherence of sections. 
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2.9.2 Unites States trichrome staining 
United States trichrome (UST) staining [Hadoke et al., 1995] was carried out either 
manually or using an automated staining system (Varistain Gemini; Thermo Shandon, 
U.K.). The stepwise protocol used for this staining is described in Table 2.1. 
Briefly; sections were dewaxed in xylene and rehydrated through graded alcohols to 
water. Freshly-prepared potassium permanganate was applied and, after rinsing in water, 
sections were decolourised in aqueous oxalic acid. Sections were washed in tap water, 
rinsed in 70% alcohol and then immersed in filtered Gomori‟s aldehyde fuchsin, which 
stains elastic fibres deep purple. After differentiating in 70% alcohol and washing well 
in water, the staining of elastin was checked microscopically (if slides were being 
stained by hand), before filtered Weigert‟s iron haematoxylin was applied for 5 minutes 
to stain cell nuclei. The slides were then left to blue in running tap water, before 5% 
aqueous phosphotungstic acid was applied, which prepares the tissue for the trichrome 
stain. After rinsing in water, sections were immersed in filtered Gomori‟s trichrome 
stain (which stains platelets mauve, collagen fibres green and muscle red). Finally, the 
slides were rinsed in aqueous acetic acid, dehydrated, cleared in xylene and cover-
slipped using Di-N-Butyle Phthalate in Xylene (DPX). The result is staining of elastic 
fibres in deep purple, collagen in green, SMC in red, Nuclei in dark blue, RBCs in green 
and platelets in mauve (Figure 2.3). 
2.9.3 Morphometric analysis of lesion size 
Images of stained sections were digitised using a Photometric CoolSnap camera 
(Tucson, U.S.A.) coupled to a light microscope (Zeiss Axioskop) via a microcolour 
liquid crystal turnable RGB filter (Cambridge Research and Instrumentation Inc., 
Woburn, U.S.A.). Microcomputer Imaging Device software (MCID Basic 7.0; Imaging 
Research Inc., St. Catharines, Canada) was used to integrate the microscope and camera, 
and to carry out image analysis of the digitised images. Analysis was performed on 
sections every 60m along the length of artery, and the parameters measured were: 
mean area (µm
2
) inside the external elastic lamina (EEL), internal elastic lamina (IEL) 
and lumen. These measurements could then be used to calculate the area of the media 
(area inside EEL - area inside IEL) and the area of plaque or neointima (area inside IEL 
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- area inside lumen). The section with the largest area of plaque or neointima was chosen 
to represent each artery when calculating the mean lesion size in a group. All analyses 
were carried out under blinded conditions; slide labels were covered to ensure that there 
was no bias in the image analysis. 
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Table 2.2: Protocol for United States trichrome staining 
Step Procedure Time 
1 Deparaffinise in Xylene 2 x 5 min 
2 Place in 100% ethanol 1 min 
3 Place in 90% ethanol 1 min 
4 Place in 70% ethanol 1 min 
5 Wash in running tap water 5 min 
6 Place in fresh 0.3% KMnO4 in 0.3%H2SO4 1 min 
7 Rinse in distilled water 1 min 
8 Decolourise using 2% oxalic acid 5 sec 
9 Wash in running tap water 5 min 
10 Rinse in 70% alcohol 1 min 
11 Apply filtered Gomori‟s aldehyde fuchsin 5-10 min 
12 Rinse in 70% alcohol 1 min 
13 Wash in running tap water 5 min 
14 Check under microscope for elastin staining  
15 Apply filtered Weigert‟s iron haematoxylin 5 min 
16 Blue in running tap water 5 min 
17 Place in 5% aqueous phosphotungstic acid 5 min 
18 Rinse in distilled water 1 min 
19 Apply filtered Gomori's trichrome 20 min 
20 Rinse in 0.2% acetic acid 30 sec 
21 Place in 70% ethanol 1 min 
22 Place in 90% ethanol 1 min 
23 Place in 100% ethanol 1 min 
24 Place in xylene 2 x 2 min 
25 Mount cover-slips with DPX  
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Figure 2.4: Section of a vessel (after wire-angioplasty) stained with UST 
 
 
United States trichrome (UST) stains internal and external elastic lamina (IEL, EEL) in 
deep purple which allows differentiation of vascular layers and measurement of luminal, 
neointimal (between lumen and IEL) and medial (between IEL and EEL) areas. 
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2.10 Analysis of lesion composition by histology 
Lesion composition was determining by staining serial sections at the point of maximum 
lesion cross-sectional area. 
2.10.1 Picrosirius red staining for collagen 
Picrosirius red is a sensitive and specific stain for collagen fibres [Dolber and Spach, 
1993]. Slides were dewaxed in xylene (2 x 5 min), rehydrated through graded alcohols 
(100%, 90% and 70%, 1 min each) and rinsed in running tap water (5min). Slides were 
then immersed in staining solution, 0.1% w/v Direct Red 80 and 0.1% w/v Fast Green 
FCF in saturated aqueous picric acid, for 2hr. Slides were then briefly rinsed in running 
tap water, dehydrated through graded alcohols (70%, 90% and 1005, 1 min each) and 
xylene (2 x 2 min) and cover-slipped using DPX medium. 
2.10.2 Immunohistochemistry for smooth muscle cells 
Smooth muscle content in atherosclerotic and neointimal lesions was determined by 
immunohistochemistry. The protocol is in Table 2.2. Slides were deparaffinised and 
rehydrated, then mounted in sequenza cassettes (Thermo Shandon, U.K.). 20% goat 
serum in PBS was applied to sections which were then incubated with a 1:400 dilution 
of mouse anti-mouse monoclonal primary antibody against α-smooth muscle actin 
(Sigma A2547) made up in PBS/1% BSA. Goat anti-mouse IgG (Vector Labs BA-9200) 
diluted 1:400 in PBS/1% BSA was then used as secondary antibody. To visualise sites of 
antibody binding, sections were treated with Extravidin-Peroxidase LSAB reagent and 
developed with DAB substrate. Sections were then washed, counterstained with 
haematoxylin, blued in tap water, dehydrated, cleared and mounted in DPX. 
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Table 2.3: Protocol for immunohistochemical staining for smooth muscle cells 
Step Procedure Duration 
1 Bake sections at 55ºC 30 min 
2 Deparaffinise in Xylene 2 x 5 min 
3 Place in 100% ethanol 1 min 
4 Place in 90% ethanol 1 min 
5 Place in 70% ethanol 1 min 
6 Wash in running tap water 5 min 
7 Mount slides onto sequenza  
8 Wash with PBS 2 x 5 min 
9 Apply 200µl 3% H2O2 10 min 
10 Wash with PBS 2 x 5 min 
11 Apply 200µl 2.5% BSA, 2.5% milk powder in PBS 1 hour 
12 Apply 200µl 20% goat serum 30 min 
13 Apply 200µl of 1:400 mouse anti-mouse α-SMA antibody 30 min 
14 Wash with PBS 3 x 5 min 
15 Apply 200µl of 1:400 goat anti-mouse IgG (2º antibody) 30 min 
16 Wash with PBS 3 x 5 min 
17 Apply 200µl of 1:200 Extravidin-Peroxidase LSAB reagent 30 min 
18 Wash with PBS 3 x 5 min 
19 Apply prepared DAB solution (Vector Labs SK-4100) ~ 3 min 
20 Quench reaction with tap water  
21 Remove from sequenza and rinse in distilled water 5 min 
22 Counter-stain nuclei with haematoxylin 10 sec 
23 Blue in running tap water 5 min 
24 Place in 70% ethanol 1 min 
25 Place in 90% ethanol 1 min 
26 Place in 100% ethanol 1 min 
27 Place in xylene  2 x 2 min 
28 Mount cover-slips with DPX  
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2.10.3 Immunohistochemistry for macrophages 
Macrophage content was assessed by immunohistochemistry for which sections were 
deparaffinised, blocked with normal goat serum, incubated with purified monoclonal rat 
anti-mouse Mac-2 antibodies (1:6000; Cedarlane, UK), followed by goat anti-rat IgG 
secondary antibody and Extravidin-Peroxidase LSAB reagent, developed with DAB 
substrate and counterstained with haematoxylin (Table 2.3). 
All immunohistochemistry examinations had a positive control using tissues with 
definitive expression of antigen being tested and a negative control by omitting primary 
antibody in staining steps. The vessels wall (tunica media) was used as positive control 
for smooth muscle cells and spleen was used as positive control for macrophages (Figure 
2.4).
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Table 2.4: Protocol for immunohistochemical staining for macrophages 
Step Procedure Duration 
1 Bake sections at 55ºC 30 min 
2 Deparaffinise in Xylene 2 x 5 min 
3 Place in 100% ethanol 1 min 
4 Place in 90% ethanol 1 min 
5 Place in 70% ethanol 1 min 
6 Wash in running tap water 5 min 
7 Mount slides onto sequenza  
8 Wash with PBS 2 x 5 min 
9 Apply 200µl 3% H2O2 10 min 
10 Wash with PBS 2 x 5 min 
11 Apply 200µl 20% goat serum 30 min 
12 Apply 200µl of 1:6000 rat anti-mouse Mac-2 antibody  
13 Store slides at 4ºC Overnight 
14 Wash with PBS 3 x 10 min 
15 Apply 200µl of 1:200 goat anti-rat IgG (2º antibody) 30 min 
16 Wash with PBS 3 x 5 min 
17 Apply 200µl of 1:200 Extravidin-Peroxidase LSAB reagent 30 min 
18 Wash with PBS 3 x 5 min 
19 Apply prepared DAB solution (Vector Labs SK-4100) ~ 3 min 
20 Quench reaction with tap water  
21 Remove from sequenza and rinse in distilled water 5 min 
22 Counter-stain nuclei with haematoxylin 10 sec 
23 Blue in running tap water 5 min 
24 Place in 70% ethanol 1 min 
25 Place in 90% ethanol 1 min 
26 Place in 100% ethanol 1 min 
27 Place in xylene 2 x 2 min 
28 Mount cover-slips with DPX  
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Figure 2.5: Illustration of positive and negative controls for immuno-
histochemsitry 
+ve control (Spleen) -ve control (vessel without Ab) Vessel sample
a) b) c)
 
 
Vascular lesion composition was determined by analysing sections for immunoreactivity 
for Mac-2 (macrophage content) and immunoreactivity for -smooth muscle actin 
(smooth muscle content). Positive controls were used to ensure that technique is working 
and negative controls were used to ensure specificity of primary antibodies used. 
Immunoreactivity for Mac-2 yielded positive staining (brown) in spleen (a), vessel 
sections without primary antibody (b) did not shown any staining and therefore vessel 
sections with primary antibody (c) show specific staining of macrophages.
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2.10.4 Morphometric analysis of lesion composition 
Images of sections stained histologically or immunohistochemically were digitalised (as 
described in section 2.10.3). Quantification of the area of a particular stain was 
performed using semi-automated colour de-convolution process (Figure 2.5) with 
Photoshop CS3 Extended (Adobe Systems Inc, USA) software. This technique has been 
validated in literature [Loughlin et al., 2007] and also in our deprtment (Kirkby et al., 
unpublished data). 
All analysis was carried out under blinded conditions. 
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Figure 2.6: Illustration of colour deconvolution technique for composition analysis 
of immunohistochemical stains 
a b c
 
The colour deconvolution technique using adobe Photoshop allowed composition 
analysis of lesion. Sections stained for collagen, smooth muscle cells or macrophages 
were digitalised and colour range of a particular stain (for example brown staining in 
panel a) were determined from positive control slides. These colour values were then 
applied to sections of interest and then the area for that colour was identified and 
isolated (green area in panel b). Images were then segmented (panel c) according to this 
selected colour range and the area was calculated and expressed as a percentage of the 
plaque or neointimal lesion area. 
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2.11 Statistical analysis 
Data are expressed as mean ± SEM unless stated otherwise. Student‟s t test was used to 
compare two sets of parametric data. One-way ANOVA was used to compare three or 
more sets of parametric data followed by post-hoc (Tukey or Bonferroni) tests, where 
appropriate. Two-way ANOVA was used to evaluate the effects of two factors on 
measurements. Statistical significance was assumed when p<0.05. All statistical testing 
and data analyses were performed using Prism 4.0 (GraphPad software, USA) software. 
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3. Role of 11β-HSD1 in atherosclerosis 
 76 
3.1 Introduction 
Selective inhibitors of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-
HSD1) are currently being developed as a potential therapeutic target for metabolic 
conditions [Rosenstock et al., 2010] and it is suggested that 11β-HSD1 inhibitors, by 
ameliorating cardiovascular risk factors, may have a role in the prevention and treatment 
of atherosclerosis [Hadoke et al., 2009]. In support of this notion, it has been shown that 
mice with transgenic deletion of 11β-HSD1 have a cardio-protective phenotype [Morton 
et al., 2001] 
 However, few studies have directly assessed the impact of these compounds on the 
development of atherosclerotic lesions. Non-selective inhibition of both isozymes (type 
1 and type 2) of 11β-HSD with carbenoxolone reduced lesion size in obese-
hyperlipidaemic LDL receptor knockout (LDLR
-/-
) mice [Nuotio-Antar et al., 2007]. The 
impact of selective inhibitors of 11β-HSD1, however, remains unclear. A selective 11β-
HSD1 inhibitor produced by Merck Laboratories (compound 544, Triazole group) 
produced a dramatic (~85%) reduction in aortic cholesterol content (a surrogate marker 
of atherosclerosis) in apolipoprotein-E deficient (ApoE
-/-
) mice [Hermanowski-Vosatka 
et al., 2005]. In contrast, it has been suggested that another inhibitor produced by Amgen 
(compound 2922, Thiazolone group) does not influence atherosclerosis in LDLR
-/-
 mice 
[Lloyd et al., 2009]. However, size of atherosclerotic lesions or composition of plaques 
were not analysed in these studies. Furthermore, the mechanism for the potential 
atheroprotective effect remains uncertain, though it is suggested that a direct alteration 
of inflammatory signalling in the vessel wall may account for reduced lipid 
incorporation [Hermanowski-Vosatka et al., 2005]. Finally, given the fact that many 
cardiovascular deaths are the result of plaque rupture [Zaman et al., 2000], it remains to 
be established whether 11β-HSD1 inhibition actually alters plaque composition to 
produce a more stable lesion phenotype. 
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The work in this chapter, therefore, addressed the hypothesis that selective inhibition of 
11β-HSD1 reduces the development of atherosclerotic lesions by improvement in 
cardiovascular risk factors. To test this hypothesis, the specific aims of this chapter 
were: 
 To establish whether selective inhibition of 11β-HSD1 reduces the size of 
plaques in atherosclerosis-prone ApoE
-/-
 mice 
 To determine the effect of selective inhibition of 11β-HSD1 on plaque 
composition 
 To assess the effect of selective inhibition of 11β-HSD1 on systemic 
cardiovascular risk factors 
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3.2 Methods 
3.2.1 Animals and materials 
Adult, male ApoE
-/-
 mice used in this study were bred in-house, caged individually and 
maintained under standard conditions of light (lights on 8am-8pm) and temperature (21-
22
o
C). All animal work was carried out under Home Office (UK) Licence. 
All chemicals were purchased from Sigma-Aldrich, unless stated otherwise. Compound 
544 (3-adamantan-1-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-α]azepine), obtained 
from Enamine Ltd. Ukraine (as compound T5293658) was used as a selective inhibitor 
of 11ß-HSD1 [Hermanowski-Vosatka et al., 2005]. 
3.2.2 Measurement of effect of compound 544 on 11-HSD1 activity 
C57Bl/6J mice (n=6) fed on standard chow were randomised to receive either a single 
dose of compound 544 (30mg/kg, in 5% 2-hydroxypropyl-β-cyclodextrin) or vehicle 
alone by oral gavage. Mice were culled 4hr later and livers were snap-frozen. Hepatic 
11-HSD1 kinetics were determined from liver homogenate (by centrifugation, 1000g, 
4°C, 15min). Protein concentration was assessed using the Bradford method. Liver 
homogenates (40-80µg/ml protein) were incubated (1hr, 37
o
C) in duplicate in Krebs-
Ringer buffer containing 0.2% glucose, NADP (2 mM), [
3
H]4-corticosterone (5nM), and 
unlabeled corticosterone (15nM). Steroids were separated by HPLC, using a reverse 
phase C18 Sunfire Symmetry column (Waters, Edinburgh, UK) and quantified by on-line 
liquid scintillation counting (2ml/min, Proflow, Meridian, Surrey, UK), as described in 
section 2.6. 
3.2.3 Effects of compound 544 on vascular lesions and risk profile 
ApoE
-/-
 mice, aged 10 weeks, were fed an atherogenic western diet (D12079B, Research 
Diets, USA) for 6 weeks and then randomised to either control (n=6, western diet only) 
or inhibitor (compound 544,10 mg/kg/day, mixed with western diet; n=6) groups for 
further 8 weeks. Body weight was measured every week and systolic blood pressure 
(BP) was measured at 2-4week intervals. Fasting samples were collected for 
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biochemical analysis and glucose tolerance tests (section 2.5.1) performed one week 
before cull. 
At the end of the treatment period, mice were weighed for a final time and then killed by 
asphyxiation in CO2. Trunk blood was collected into EDTA tubes on wet ice and 
centrifuged to separate plasma which was then snap-frozen on dry ice and stored at -
80ºC. Internal organs including heart, liver, kidneys, adrenal glands and thymus were 
removed, weighed, snap-frozen and stored at -80º C. The arterial tree, from the aortic 
root to the femoral arteries (including all major branches), was removed for analysis of 
plaque distribution. Arteries were fixed in 10% neutral buffered formalin solution for 24 
hours and then stored in 70% ethanol. The brachiocephalic trunk (BCT) was isolated, 
dehydrated though graded alcohols, embedded in paraffin and cut into 4µm thick 
transverse sections along its entire length. 
3.2.4 Analysis of atherosclerotic lesions 
Atherosclerotic lesions in several predisposed sites were assessed semi-quantitatively by 
inspection of fixed vascular trees under the operating microscope and were scored using 
a scale of arbitrary units (AU 0 - 5). For histological analysis, sections taken at 60µm 
intervals were stained with the United States trichrome (section 2.9.2). Images of stained 
sections were analysed using a light microscope coupled to a colour camera and an 
image analysis system (section 2.9.3). Plaque area (µm
2
) and the area inside the internal 
elastic lamina (IEL) were measured. These measurements were then used to calculate 
the percentage cross-sectional narrowing [(area of plaque / area inside IEL) x 100]. The 
section with the largest cross-sectional narrowing was chosen to represent each artery 
when calculating the mean plaque area in a group. All analyses were carried out under 
blinded conditions. 
3.2.5 Analysis of plaque composition 
Plaque composition was determined by serial sections at the site of maximum plaque 
size. Collagen content was assessed by staining sections with Picrosirius red (section 
2.10.1). Macrophage and smooth muscle content were assessed by 
immunohistochemistry using monoclonal rat anti-mouse Mac-2 antibodies for 
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macrophages and mouse anti-mouse α-smooth muscle actin antibodies for smooth 
muscle cells (section 2.10.2 and 2.10.3). Extra-cellular lipids were quantified by 
measuring acellular clefts within plaques (blank areas in plaques in UST stained 
sections) [Moreno et al., 2002]. A measure of plaque stability was generated by 
calculating a Plaque Vulnerability Index (PVI= area of macrophage staining + area of 
lipid staining /area of collagen staining + area of SMC staining) [Davies, 1996;Suzuki et 
al., 2003;Shiomi et al., 2008;Guo et al., 2009]. All analyses were carried out under 
blinded conditions. 
3.2.6 Biochemical Tests 
GTTs were performed in fasting (6hr) mice by intra-peritoneal bolus injection of glucose 
(2mg/g body weight). Blood samples were taken 0, 15, 30, 60 and 90 minutes after 
glucose administration. Serum glucose levels were determined spectrophotometrically 
by the glucose hexokinase reagent and serum insulin levels were measured by ultra-
sensitive mouse insulin ELISA kit (section 2.5.5). Insulin resistance (IR) was assessed 
by HOmeostasis Model Assessment method (HOMA-IR = Fasting insulin (μU/ml) x 
Fasting glucose (mmol/L) / 22.5) and QUantitative Insulin sensitivity ChecK Index 
(QUICKI = 1/[(log Fasting Glucose)+(log Fasting Insulin)] [Cacho et al., 2008]. Serum 
cholesterol levels and triglyceride levels were measured spectrophotometrically using 
Infinity™ reagents (section 2.5.3). Blood collected at the time of cull was used to 
determine plasma renin activity and angiotensinogen by radioimmunoassay and 
aldosterone by ELISA (kindly performed by Dr. Christopher J Kenyon as previously 
described [Morton et al., 2005b;Al-Dujaili et al., 2009]). 
3.2.7 Statistics 
Data are mean ± SEM (with n indicating the number of animals in each experimental 
group) and were analysed using unpaired Student‟s t-test or repeat measure two-way 
ANOVA, as appropriate. Statistical significance was assumed when p<0.05. All 
calculations were performed using GraphPad Prism software. 
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3.3 Results 
3.3.1 Compound 544 inhibits 11β-HSD1 activity 
A single dose of compound 544 inhibited dehydrogenase activity (29.2±6.8pmol/mg/min 
vs. 61.3±17.9pmol/mg/min, p=0.04, Figure 3.1) in hepatic homogenates. 11-HSD1 is a 
predominant reductase in-vivo [Jamieson et al., 2000], however, in tissue preparations 
dehydrogenase activity predominates, which was quantified here and was nearly halved 
by administration of compound 544. 
3.3.2 Systemic effects of 11β-HSD1 inhibition 
3.3.2.1 11β-HSD1 inhibition reduced weight gain 
All mice gained weight on western diet but this was less pronounced in compound 544-
treated mice than in controls (Figure 3.2). There was no significant difference in food 
intake between the two groups (Control 8.0±0.4g/day vs. Inhibitor 7.6±0.2g/day, p=0.3). 
There were no differences in the weights of heart, kidneys, adrenal glands, thymus or 
spleen but the inhibitor-treated group had lower liver weight (Table 3.1). 
3.3.2.2 11β-HSD1 inhibition lowered blood pressure 
Blood pressure in the two groups was similar at baseline. However, at the end of the 
study (8 weeks of treatment), BP was significantly lower in the inhibitor-treated mice 
than in the vehicle-treated controls (Figure 3.3). To explore the possible mechanism for 
this blood pressure reduction, activity of the renin-angiotensin system was assessed. No 
differences were found in plasma renin activity angiotensinogen levels or aldosterone 
levels between the two groups (Table 3.2). 
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Figure 3.1: Compound 544 inhibited dehydrogenase activity in C57Bl/6J mice 
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Single doses of compound 544 (30mg/kg, in 5% 2-hydroxypropyl-β-cyclodextrin) or 
vehicle (5% 2-hydroxypropyl-β-cyclodextrin) were given to C57Bl/6J mice via oral 
gavage. Mice were culled after 4 hours and hepatic dehydrogenase activity was assessed. 
Compound 544 reduced 11β-HSD1 dehydrogenase activity by ~50%. 
Data are mean ± SEM for n=3/group and analysed by unpaired Student‟s t-test. 
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Table 3.1: Effect of 11β-HSD1 inhibition on organ weights 
 
 
 
 
 
 
 
 
 
Organ weights are expressed as mg/g of body weight after 8 weeks of treatment with 
vehicle or 11β-HSD1 inhibitor (compound 544; 10mg/kg/day in western diet). Data are 
mean ± SEM for n=6/group and analysed by unpaired Student‟s t-test. 
Organ Inhibitor Control p 
Liver 48.0±1.7 53.8±1.5 0.03 
Heart 5.9±0.6 6.5±0.5 0.2 
Kidneys 12.4±0.6 12.6±0.7 0.8 
Adrenal glands 0.11 ± 0.01 0.09±0.01 0.06 
Spleen 2.89±0.18 2.88±0.11 0.9 
Thymus 0.97±0.06 0.84±0.03 0.08 
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Figure 3.2: 11β-HSD1 inhibition reduced weight gain in western diet fed ApoE
-/-
 
mice 
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Treatment with selective 11β-HSD1 inhibitor (compound 544; 10mg/kg/day in 
western diet; 8weeks) reduced weight gain in apolipoprotein E deficient (ApoE
-/-
) 
mice. Data are mean ± SEM for n=6/group and analysed by unpaired Student‟s t-test 
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Figure 3.3: 11β-HSD1 inhibition lowered blood pressure in ApoE
-/-
 mice fed a 
western diet 
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BP was similar in two groups at baseline (time 0, start of treatment). However, treatment 
with 11β-HSD1 inhibitor (compound 544, 10mg/kg/day in western diet; 8weeks) 
significantly lowered blood pressure (p<0.001). Bonferroni post-hoc analysis revealed a 
significant BP difference between the two groups after 6 (**p<0.01) and 8 (***p<0.001) 
weeks of treatment. Data are mean ± SEM for n=6/group. 
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3.3.2.3 11β-HSD1 inhibition had little effect on glycaemic and lipid profile 
There were no differences in fasting total cholesterol or triglyceride levels between 
inhibitor and vehicle treated groups (Table 3.2). Similarly, fasting and GTT glucose 
levels (Figure 3.4a and 3.4b) were not influenced by inhibitor treatment and also the area 
under curve (AUC) for glucose on GTT was not different between vehicle and inhibitor 
treated groups (Table 3.2). However, fasting insulin levels were significantly lower in 
the inhibitor treated group (Figure 3.2c) and insulin levels did not rise during the GTT in 
these mice (Figure 3.4d), producing a trend towards improved insulin sensitivity, as 
measured by HOMA-IR or QUICKI (Table 3.2). 
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Figure 3.4: 11β-HSD1 inhibition did not affect glucose levels but reduced insulin 
levels in ApoE
-/-
 mice fed a western diet 
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After 8 weeks of treatment with vehicle or 11β-HSD1 inhibitor (compound 544; 
10mg/kg/day in western diet) there was no significant difference in fasting (a) and GTT 
(b) glucose levels. However, fasting (c) and GTT (d) insulin levels were lower in the 
inhibitor treated groups, suggesting an improvement in insulin sensitivity (Table 3.2). 
Data are mean ± SEM for n=6/group and analysed by unpaired Student‟s t-test. 
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Table 3.2: Effect of 11β-HSD1 inhibition on biochemical profile 
Parameter Units Control Inhibitor p 
Fasting Glucose (FG) mg/dL 341±39.6 302.±26.7 0.4 
AUCGlucose on GTT (mg/dL).min 54630±1504 50100±4448 0.4 
Fasting Insulin (F1) ng/ml 1.33±0.16 0.95±0.024 0.04 
AUCInsulin on GTT (ng/ml).min 108±15 71±14 0.1 
Insulin Resistance (IR) 
HOMA-IR 
QUICKI 
 
 
 
28.8±6.1 
0.36±0.01 
 
17.7±1.6 
0.39±0.01 
 
0.1 
0.05 
Fasting total cholesterol mmol/L 13.2±1.5 12.0±1.6 0.2 
Fasting triglycerides mmol/L 2.0±0.1 2.1±0.1 0.3 
Plasma renin activity ng-AngI/ml/hr 626±68 637±129 0.9 
Angiotensinogen ng/ml 145±9 127±26 0.5 
Aldosterone pmol/L 2193±653 1675±518 0.5 
 
HOMA HOmeostasis Model Assessment, 
QUICKI QUantitative Insulin sensitivity ChecK Index 
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3.3.3 11β-HSD1 inhibition reduced the size of atherosclerotic lesions 
Atherosclerotic lesions developed in all ApoE
-/-
 mice fed on a western diet but were 
smaller in those treated with the 11β-HSD1 inhibitor (Figure 3.5a). Semi-quantitative 
assessment of atherosclerotic burden revealed that the 11β-HSD1 inhibitor reduced the 
size of atherosclerotic lesions in all major vessels (especially in the aortic arch, common 
carotid arteries and brachiocephalic trunk, Table 3.3) and, hence, reduced the global 
atheroma burden (Figure 3.5b). 
This semi-quantitative assessment was confirmed by the histological data from UST-
stained sections of BCT showing that the maximum cross-sectional narrowing (CSN) 
was reduced by 26% following 11β-HSD1 inhibitor administration (Figure 3.6). 
3.3.4 11β-HSD1 inhibition improved markers of plaque stability 
11β-HSD1 inhibition improved markers of stability by changing plaques from a lipid-
rich to a fibrous composition. Compared with vehicle-treated controls, extracellular lipid 
content was significantly lower in lesions from mice exposed to the 11β-HSD1 inhibitor 
(Figure 3.6). Although there were no differences in macrophage (Figure 3.7a) or smooth 
muscle cell (Figure 3.7b) content between groups, collagen content was increased 
(Figure 3.8) in the treated group. The plaque vulnerability index, calculated by 
incorporating these four parameters, was reduced by 52% in the inhibitor treated group 
(Figure 3.9). 
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Figure 3.5: Selective inhibition of 11β-HSD1 reduced lesion development 
throughout the vasculature of ApoE
-/- 
mice 
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Morphological examination indicated reduced lesion size in the aorta and its major 
branches from apolipoprotein E deficient (ApoE
-/-
) mice treated with the selective 11-
HSD1 inhibitor (compound 544; 10mg/kg/day in western diet; 8weeks). An almost 
occlusive lesion is evident (arrow-head) in the BCT of a mouse from the vehicle-treated 
group (a). Semi-quantitative assessment revealed a reduction in global atheroma burden 
(measured in arbitrary units) in inhibitor treated mice as compared with vehicle treated 
group (b). 
Data are mean ± SEM for n=6/group and analysed by unpaired Student‟s t-test. 
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Table 3.3: Effect of 11β-HSD1 inhibition on plaque burden in ApoE
-/-
 mice 
Vascular territory 
Control (AU) 
(n=6) 
Inhibitor (AU) 
(n=6) 
p 
Aortic Arch 3.2±0.2 2.1±0.3 0.01 
Common carotid 3.0±0.3 2.2±0.2 0.02 
BCT 4.7±0.2 3.7±0.3 0.04 
Iliac arteries 2.7±0.2 1.8±0.3 0.04 
Global (average of all 
territories) 
3.6±0.9 3.0±1.0 0.03 
 
Lesion development was scored semi-quantitatively based on the following scale: AU 1, 
0-20% luminal narrowing; AU 2, 21-40% luminal narrowing; AU 3, 41-60% luminal 
narrowing; AU 4, 61-80% luminal narrowing; AU 5, 81-100% luminal narrowing. Data 
are mean±SEM and were analysed by un-paired Student‟s t-test. 
AU, arbitrary units; BCT, brachiocephalic trunk 
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Figure 3.6: Selective inhibition of 11β-HSD1 reduced cross-sectional narrowing and 
lipid content of plaques 
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United States trichrome staining of brachiocephalic trunk (BCT) cross-sections (a) from 
Apolipoprotein E deficient (ApoE
-/-
) mouse allowed measurement of lesion area using 
image analysis. It also revealed acellular clefts (arrow-head) which represent areas of 
washed out extracellular lipid crystals. The analysis confirmed that lesions in inhibitor-
treated (compound 544; 10mg/kg/day in western diet; 8weeks) mice were smaller than 
those in vehicle-treated controls, with a significant reduction in cross-sectional 
narrowing (CSN, (b)). Quantification of extracellular lipid areas confirmed that plaques 
in inhibitor-treated mice had significantly less lipids than those in vehicle-treated 
controls (c). 
Data are mean ± SEM for n=6/group and were analysed using unpaired Student‟s t-test. 
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Figure 3.7: Selective inhibition of 11β-HSD1 did not alter the macrophage or 
smooth muscle content of lesions 
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Plaque composition was assessed by determining immunoreactivity for MAC-2 
(macrophage content) and immunoreactivity for -smooth muscle actin (smooth muscle 
content) which appear brown on developing colour with DAB reagent. 
Immunohistochemistry confirmed that selective inhibition of 11β-HSD1 (compound 
544; 10mg/kg/day in western diet; 8weeks) did not affect macrophage (a) or smooth 
muscle (b) content of plaques (expressed as percentage area of plaque). 
Data are mean ± SEM for n=6/group and analysed using unpaired Student‟s t-test. 
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Figure 3.8: Selective inhibition of 11β-HSD1 was associated with increased collagen 
content of lesions 
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Picrosirius red staining (a) of sections from brachiocephalic trunk (BCT) of 
apolipoprotein E (ApoE
-/-
) allowed analysis of collagen content of plaques. This 
confirmed that plaques in inhibitor-treated (compound 544; 10mg/kg/day in western 
diet; 8weeks) mice had more collagen content than those in vehicle-treated controls (b). 
Data are mean±SEM for n=6/group and analysed by unpaired Student‟s t-test. 
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Figure 3.9: 11β-HSD1 inhibition reduced plaque vulnerability index in ApoE
-/-
 mice 
 
Vehicle Inhibitor
0
1
2
3
p=0.02
P
V
I
 
 
Analysis of plaque composition allowed calculation of a plaque vulnerability index (PVI 
= area of macrophage staining + area of lipid staining / area of collagen staining + area 
of SMC staining). Treatment with a selective 11-HSD1 inhibitor (compound 544; 
10mg/kg/day in western diet; 8weeks) produced a significant reduction in vulnerability 
index of lesions in ApoE
-/-
 mice. 
Data are mean ± SEM for n=6/group and analysed by unpaired Student‟s t-test. 
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3.4 Discussion 
The data in this chapter show that selective 11β-HSD1 inhibition reduces the size of 
atherosclerotic lesions with a corresponding increase in area of patent lumen. 
Furthermore, the reduction in lipid content of plaque, combined with increased collagen 
deposition (but unchanged smooth muscle and macrophage content), gives the lesions a 
more stable appearance. This is associated with a reduction in weight gain and blood 
pressure and a trend towards improved insulin sensitivity but without any effect on 
glucose or cholesterol levels. 
3.4.1 Selective 11β-HSD1 inhibition reduces atherosclerosis 
Semi-quantitative assessment revealed a reduction in atherosclerotic burden at several 
sites throughout the arterial tree indicating that the beneficial effect of 11β-HSD1 
inhibition is not limited to any specific vascular territory. The BCT was chosen for 
detailed analyses as it develops extensive, complex lesions and has been used widely in 
investigations of atherogenesis [Williams et al., 2002]. The demonstration that lesion 
cross-sectional area in the BCT is reduced following 11-HSD1 inhibition is consistent 
with a previous investigation using ApoE
-/-
 mice in which compound 544 substantially 
reduced aortic cholesterol (which was used as a marker for atherosclerosis) content 
[Hermanowski-Vosatka et al., 2005]. In another study non-selective inhibition of 11β-
HSD with carbenoxolone showed an atheroprotective effect in obese LDLR
-/-
 mice 
[Nuotio-Antar et al., 2007]. However, in mice with LDL receptor deficiency combined 
with severe dyslipidaemia and obesity due to ApoB and leptin deficiency, Amgen 
compound 2922 reduced lipid content (by en face staining with Sudan IV) without 
reducing the atherosclerotic burden [Lloyd et al., 2009]. The extent of reduction in 
atherosclerotic burden in the current study was less than the dramatic (~85%) reduction 
reported previously with compound 544 [Hermanowski-Vosatka et al., 2005]. This 
difference could be attributed to the methods employed for assessment of lesion burden. 
Whilst Hermanowski-Vosatka et al. used qualitative gross morphology combined with 
extraction and quantification of lipids from isolated aortas, the current study combined a 
semi-quantitative assessment of lesion burden throughout the vasculature with a detailed 
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histological analysis of lesions in the BCT with direct measurement of lesion and lumen 
sizes.  It is possible that measurement of lipid incorporation could over-estimate the 
impact of treatment on reducing arterial narrowing. Consistent with this argument, 
results obtained using histological analysis in the current study were closer to the direct 
measurement of lesion size in the aortic root after treatment with carbenoxolone 
[Nuotio-Antar et al., 2007]. The lack of effect of Amgen 2922 on atheroma burden in 
LDLR
-/-
 ApoB
-/-
 ob/ob mice [Lloyd et al., 2009] may reflect both the simplicity of the 
assessment (en face Sudan IV staining) and the severity of the metabolic abnormality in 
these mice. 
3.4.2 Selective 11β-HSD1 inhibition improves plaque stability 
11β-HSD1 inhibition lowered the accumulation of extracellular lipids and increased the 
fibrous collagen component of plaques. Plaques which are rich in extracellular lipids and 
macrophages, and poor in fibro-muscular components are unstable and prone to rupture 
[Davies, 1996;Naghavi et al., 2003a;Naghavi et al., 2003]. Therefore, the present 
findings suggest that plaques were changed beneficially to a more stable form of lesion 
by treatment with selective 11β-HSD1 inhibitor. 
The reduction in the lipid content of atherosclerotic plaques seen in this study was 
without any significant effect on serum cholesterol. This is in contrast with data reported 
by Hermanowski-Vosatka et al., which showed that both serum cholesterol and aortic 
cholesterol were reduced by 11-HSD1 inhibition, however, the reduction in aortic 
cholesterol was more pronounced than the improvement in serum lipid profile 
[Hermanowski-Vosatka et al., 2005]. The mechanism responsible for the reduction in 
cholesterol, however, is unclear. It has been shown previously that certain 
pharmacological agents (e.g. captopril, an ACE inhibitors) may reduce arterial 
cholesterol content without any significant effect on serum cholesterol [Aberg and 
Ferrer, 1990]. Therefore, the results presented here suggest that reduced lesion formation 
in response to 11-HSD1 inhibition is not due to a reduction in circulating lipids. 
Given the anti-inflammatory, anti-proliferative [Longenecker et al., 1982;Longenecker 
et al., 1984] and anti-migratory [Goncharova et al., 2003] properties of glucocorticoids, 
it was a concern that 11β-HSD1 inhibition might increase inflammation and reduce 
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smooth muscle proliferation in the atherosclerotic plaques, hence changing plaques to a 
less stable phenotype. However, this study did not show any difference in SMC or 
macrophage content of plaques in two groups. Indeed, the increase in collagen content 
within the plaque, coupled with reduction in extracellular lipids, point towards a more 
stable phenotype. Although atherosclerotic plaques in ApoE
-/-
 mice on a C57Bl/6J 
background are remarkably stable and the mice do not, as a rule, die from plaque rupture 
[Williams et al., 2002], this change in characteristics of plaques, if translated in humans, 
could help in prevention of plaque rupture potentially leading to reduction in acute 
cardiovascular events. 
3.4.3 Mechanism of atheroprotective effect of 11β-HSD1 inhibition 
Reduction in atherosclerosis in this study was associated with a significant reduction in 
blood pressure and modest improvement in insulin resistance and body weight, but 
independent of any change in circulating glucose or cholesterol levels. 
Western diet fed ApoE
-/-
 mice treated with 11β-HSD1 inhibitor gained less weight than 
the control group.  This is consistent with previous data showing that 11β-HSD
-/-
 mice 
do not gain weight on a high fat diet [Morton et al., 2004]. However, in this study, the 
anti-obesity action was not secondary to a change in food intake. Reduction in weight 
gain can attenuate atherogenesis and it has been shown that early atherosclerotic changes 
seen in obese humans can be attenuated by reducing body weight [Mavri et al., 2001]. 
Insulin resistance and diabetes mellitus are independent risk factors for atherosclerosis 
[Despres et al., 1996] and reducing insulin resistance can improve endothelial 
dysfunction leading to reduction in atherosclerosis [Kim et al., 2006]. Excess 
glucocorticoid action in target tissues may contribute to insulin resistance and impaired 
glucose tolerance [Stewart et al., 1995;Masuzaki et al., 2001;Masuzaki et al., 
2003;Paterson et al., 2004]. Detailed metabolic studies have demonstrated that 11-
HSD1 deletion produces hepatic insulin sensitization [Morton et al., 2001] and selective 
inhibition reduced plasma insulin and improved glucose tolerance in genetically-obese 
and fat-fed mice [Hermanowski-Vosatka et al., 2005;Lloyd et al., 2009]. This contrasts 
with the data presented here, which showed little or no improvement in glucose 
tolerance and a modest trend towards improvement in insulin sensitivity. One possible 
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explanation for the lack of effect on glycaemic profile in this study may be the fact that 
inhibitor was administered by mixing in food so that, during the fasting period (6-8 
hours for GTT) mice did not receive any inhibitor. Hermanowski-Vosatka et al. have 
shown that inhibition of 11β-HSD1 activity in the liver had nearly disappeared 6 hours 
after oral administration [Hermanowski-Vosatka et al., 2005]. The demonstration of an 
effect of the inhibitor on fasting biochemical profile would necessitate the design of 
separate experiments, to recapitulate results of Hermanowski-Vosatka et al. (2005). This 
would involve administration of the inhibitor by mixing in drinking water or sub-cut 
implants. It is also notable, however, that in the studies showing improvements in 
metabolic profile mice were either fed on chow or on an obesogenic diet [Hermanowski-
Vosatka et al., 2005;Nuotio-Antar et al., 2007;Lloyd et al., 2009], rather than the 
atherogenic western diet used here. Furthermore, whilst carbenoxolone reduced fasting 
insulin in genetically-obese LDLR
-/-
, no such improvement was observed in non-obese 
LDLR
-/-
 mice fed a western diet [Nuotio-Antar et al., 2007]. This suggests that the effect 
of 11-HSD1 inhibitors on glycaemic profile in rodents may actually depend on diet, 
genotype and the cause of obesity. 
This study has also shown, for the first time, a reduction in BP with administration of 
compound 544 in ApoE
-/-
 mice fed a western diet. Hypertension is a recognised feature 
of glucocorticoid excess, but the mechanisms of glucocorticoid-induced hypertension 
are complex and probably involve both central actions in the CNS and peripheral actions 
on vascular tone and sodium balance [Whitworth et al., 1997]. Neither deletion nor 
selective inhibition of 11β-HSD1 in C57Bl/6J mice, however, have previously been 
shown to lower BP [Kotelevtsev et al., 1997]. BP has only been mentioned in one 
previous study with 11-HSD1 inhibition, which found no effect of Amgen compound 
2922, but data were not shown [Lloyd et al., 2009]. Transgenic over-expression of 11-
HSD1 in the liver or adipose tissue causes hypertension, putatively due to increased 
local angiotensinogen expression and hence activation of the renin-angiotensin system 
[Masuzaki et al., 2003;Paterson et al., 2004]. However, measurement of 
angiotensinogen, aldosterone and plasma renin activity suggested that this did not 
account for the anti-hypertensive effect of compound 544 and the mechanism remains 
uncertain. Whether the atheroprotection associated with 11-HSD1 inhibition is a 
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consequence of reduced blood pressure remains to be established. Clinical studies have 
consistently correlated hypertension and atherosclerotic coronary artery disease 
[Kuulasmaa et al., 2000;Neaton et al., 1984] and hypertension is a recognised target in 
prevention and treatment of atherosclerosis [Weiss and Taylor, 2008;Irace et al., 
2005;Agmon et al., 2000]. However, changes in blood pressure are not invariably linked 
to lesion development; for example, normalising blood pressure (by hydralazine 
administration) in hypertensive atherosclerosis-prone eNOS knockout ApoE
-/-
 mice had 
no effect on atherogenesis [Chen et al., 2001]. Therefore, it is possible that compound 
544 is reducing lesion formation by both blood pressure-dependent and -independent 
mechanisms. 
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3.5 Conclusion 
In conclusion, data in this chapter support the hypothesis that selective inhibition of 11-
HSD1 represents a potential new therapeutic option for prevention of atherosclerosis. 
The novel effect shown on markers of plaque stability is of clinical importance given 
that the acute cardiovascular events occur due to plaque disruption. This has 
implications for the development of novel anti-atherosclerotic agents but also provides 
evidence that use of such compounds in the treatment of diabetes mellitus will also lead 
to a reduction in arterial lesion formation. 
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4. Role of 11β-HSD1 in neointimal proliferation 
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4.1 Introduction 
Inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) improves 
cardiovascular risk profile [Hermanowski-Vosatka et al., 2005] and reduces 
atherosclerosis (chapter 3). Emerging data from clinical trials investigating effects of 
11β-HSD1 inhibition on features of metabolic syndrome look very promising, with the 
demonstration in a recently reported Phase-IIb trial that treatment with a selective 11β-
HSD1 inhibitor significantly improved glycaemic control, insulin sensitivity and total-
cholesterol levels [Rosenstock et al., 2010] Many pharmaceutical companies and 
research organisations are, therefore, actively developing 11β-HSD1 inhibitors as a 
potential treatment for metabolic syndrome and currently there are nearly 100 patents 
filed [Hughes et al., 2008]. 
Morbidity and mortality in metabolic syndrome are largely due to the development of 
atherosclerotic lesions [Wang et al., 2007], which often require treatment with 
percutaneous revascularisation procedures (angioplasty ± stenting). However, post 
angioplasty restenosis due to neointimal hyperplasia, which represents an inflammatory 
and proliferative response to acute vascular injury, remains a significant problem [Al et 
al., 2000]. Glucocorticoids have anti-inflammatory and anti-proliferative properties 
suggesting that they may prevent neointimal proliferation after angioplasty. Studies in 
animals have generally supported this hypothesis. Systemic or local glucocorticoid 
administration inhibited neointimal lesion formation in rats [Villa et al., 1994;Guzman et 
al., 1996], rabbits [Van Put et al., 1995;Poon et al., 2001;Ribichini et al., 2007] and dogs 
[Strecker et al., 1998]. However, not all studies in animals have yielded positive results: 
dexamethasone treatment did not reduce neointimal hyperplasia after angioplasty in 
rabbits [Karim et al., 1997] or pigs [Lincoff et al., 1997]. Similarly clinical trials in 
humans have produced variable results [Liu et al., 2004]. However, there are on-going 
studies to explore the role of systemic and local administration of steroids (e.g. STARS 
Trial, ISRCTN05886349). Given the potential beneficial effect of steroids in reducing 
neointimal proliferation, there is a concern that the use of 11β-HSD1 inhibitors at times 
of revascularisation may increase neointimal proliferation by reducing the availability of 
active glucocorticoids within the cells. This study, therefore, addressed the hypothesis 
that 11β-HSD1 inhibition / deletion increases neointimal proliferation. 
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4.2 Materials and methods 
4.2.1 Animals 
C57Bl/6J mice were purchased from Harlan Laboratories (Oxfordshire, UK) and ApoE
-/- 
mice from Charles River Laboratories (Kent, UK). 11β-HSD1
-/-
 mice, homozygous for a 
disrupted hsd11b1 allele and congenic on a C57Bl/6J background were bred in-house as 
reported previously [Kotelevtsev et al., 1997]. ApoE
-/-
 and 11β-HSD1
-/-
 mice, both lines 
congenic on a C57Bl/6J background, were crossed to produce 11β-HSD1
-/-
, ApoE
-/-
 
double knockout (DKO) mice. All animals were maintained under standard conditions 
of light (lights on 8am-8pm) and temperature (21-22
o
C). 
4.2.2 Materials 
Unless stated otherwise, all chemicals were purchased from Sigma-Aldrich, UK. 
Compound 544 (3-(1-adamantyl)-6,7,8,9-tetrahydro-5 H -[1,2,4] triazolo[4,3-α]azepine), 
a potent and selective inhibitor of 11β-HSD1 [Hermanowski-Vosatka et al., 2005] was 
obtained (as compound T5293658) from Enamine Ltd. (Kiev, Ukraine). Standard chow 
(RM1) was obtained from Special Diet Services (Witham, UK) and western diet 
(OpenSource
TM
 D12079B) was obtained from Research Diets Inc. (Brunswick, USA). 
4.2.3 Experimental protocol 
Adult male C57Bl/6J and ApoE
-/-
 mice were divided into treatment (compound 544, 
30/mg/kg/day; n=6/group) and control (vehicle, n=6/group) groups. All mice underwent 
wire-angioplasty of left femoral arteries (section 2.7) one week later. Body weights were 
recorded at weekly intervals, blood pressure was measured fortnightly (by tail-cuff 
photo-plethysmography, section 2.4) and biochemical tests were performed one week 
before cull. Serum glucose, cholesterol and triglyceride levels were measured 
spectrophotometrically by using commercially available Infinity
TM
 kits (section 2.5). 
Mice were culled three weeks after surgery by terminal anaesthesia with phenobarbitone 
and trans-cardiac perfusion fixation. Left femoral arteries were excised from the 
bifurcation of the iliac artery to the branch point of the popliteal artery and processed for 
3-dimensional optical projection tomography (OPT, section 2.8) to analyse lesion 
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volume and subsequently for standard histology to measure luminal area and area inside 
the internal elastic lamina (IEL) as described (section 2.9). These measurements were 
then used to calculate the neointimal area (area inside IEL - luminal area) and cross-
sectional stenosis (neointimal area/area inside IEL x 100). 
Lesion composition was determined by staining sections at the point of maximum 
neointimal proliferation (section 2.10). Collagen content was indentified by staining 
with Picrosirius red. Macrophage and smooth muscle content were assessed by 
immunohistochemistry using purified monoclonal rat anti-mouse Mac-2 antibody for 
macrophages (1:6000; Cedarlane, UK) and monoclonal mouse anti-mouse α-smooth 
muscle actin antibody for smooth muscle cells (1:400; Sigma-Aldrich, UK). 
Quantification of stained areas was performed using a semi-automated colour 
deconvolution process with Photoshop CS3 Extended software. 
All analyses were carried out under blinded conditions. 
4.2.4 Statistical analysis 
Data are expressed as mean ± SEM (with n indicating the number of animals in each 
experimental group) and were analysed using unpaired Student‟s t test or two-way 
ANOVA, as appropriate. Statistical significance was assumed when p<0.05. All 
calculations were performed using GraphPad prism (GraphPad Software Inc, California, 
USA). 
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4.3 Results 
4.3.1 Effect of 11β-HSD1 inhibition in C57Bl/6J mice 
Pharmacological inhibition of 11β-HSD1 did not have any significant effect on body 
weight of C57Bl/6J mice (Figure 4.1a). There was also no effect of 11β-HSD1 inhibition 
on systolic blood pressure (Figure 4.1b). 
Wire-angioplasty stimulated development of fibro-cellular neointimal lesions in all mice 
(Figure 4.2a). There was no significant effect of 11β-HSD1 inhibition on neointimal 
proliferation and consequent cross-sectional stenosis in angioplastied femoral arteries 
(Figure 4.2b). 
11β-HSD1 inhibition had no effect on macrophage (Figure 4.3a) or smooth muscle cell 
(Figure 4.3b) content of neointimal lesions and a trend to increase collagen content of 
lesions was not statistically significant (Figure 4.3c). 
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Figure 4.1: 11-HSD1 inhibition had no effect on body weight and blood pressure 
in C57Bl/6J mice 
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C57Bl/6J mice (n=6/group) were treated with a selective 11β-HSD1 inhibitor 
(compound 544; 30mg/kg/day in standard chow; 4weeks) or vehicle, starting one week 
before wire-angioplasty. 11β-HSD1 inhibition had no effect on body weight (a). Data 
are mean ± SEM and were analysed by repeat measures two-way ANOVA. 
Systolic blood pressure (SBP) in C57Bl/6J mice was no different after 4 weeks treatment 
with the vehicle or 11β-HSD1 inhibitor (b). Data are mean ± SEM and were analysed by 
unpaired Student‟s t-test. 
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Figure 4.2: 11-HSD1 inhibition had no effect on neointimal proliferation in 
C57Bl/6J mice 
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C57Bl/6J mice (n=6/group) were treated with a selective 11β-HSD1 inhibitor 
(compound 544; 30mg/kg/day in standard chow; 4weeks) or vehicle, starting one week 
before wire-angioplasty. Wire-angioplasty produced fibro-cellular neointimal lesions (a) 
in both groups (x 20 magnification). Administration of the selective 11-HSD1 inhibitor 
produced an apparent reduction in lesion size in C57Bl/6J mice but this did not achieve 
significance (b). 
Data are mean ± SEM for n=6/group and were analysed by unpaired Student‟s t-test. 
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Figure 4.3: 11-HSD1 inhibition had no significant effect on composition of 
neointimal lesions in C57Bl/6J mice 
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Neointimal lesion composition was determined by analysing sections for Picrosirius red 
staining (collagen content), immunoreactivity for Mac-2 (macrophage content) and 
immunoreactivity for -smooth muscle actin (smooth muscle content). Quantification of 
stained areas showed no effect of the selective 11-HSD1 inhibitor (compound 544; 
30mg/kg/day in standard chow; 4weeks) on macrophage or smooth muscle content. An 
apparent increase in collagen content did not achieve significance. 
Data are mean ± SEM for n=6/group and were analysed using unpaired Student‟s t-test. 
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4.3.2 Effect of 11β-HSD1 inhibition in ApoE-/- mice 
ApoE
-/-
 mice were fed a western diet mixed with vehicle (n=6) or 11β-HSD1 inhibitor 
(compound 544, 30/mg/kg/day; n=6) from one week before femoral artery surgery to 
three weeks after the surgery. 
4.3.2.1 Systemic effects of 11-HSD1 inhibition 
Body weights were similar at the start of experiment; however, during the 4 weeks of 
treatment, the inhibitor treated group gained less weight compared with vehicle-treated 
controls (Figure 4.4a). Four weeks treatment with the 11β-HSD1 inhibitor resulted in a 
trend towards reduction in blood pressure; however, it did not achieve statistical 
significance (Figure 4.4b). 
11β-HSD1 inhibition produced modest reduction in fasting glucose levels (Figure 4.5a) 
but had no effect on fasting total cholesterol (Figure 4.5b) or fasting triglyceride levels 
(Figure 5c) as compared with vehicle treated control group. 
4.3.2.2 Effect on neointimal lesions 
Optical projection tomography (OPT) allowed 3-dimensional reconstruction of lesions 
and quantification of lesion volume (Figure 4.6a). Systemic inhibition of 11-HSD1 in 
ApoE
-/-
 mice significantly reduced neointimal lesion volume (Figure 4.6b). Histological 
analysis confirmed the development of extensive neointimal lesions in all mice (Figure 
4.7a). These lesions contained a large number of foam cells and hence looked different 
from lesions seen in C57Bl/6J mice. The maximum cross-sectional stenosis was 
significantly reduced in the inhibitor treated group as compared with the control group 
(Figure 4.7b). 
11-HSD1 inhibition had no effect on smooth muscle content of the plaque; however, it 
reduced the macrophage and increased the collagen content of plaques compared with 
vehicle treated control mice (Figure 4.8). 
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Figure 4.4: 11-HSD1 inhibition reduced body weight and tended to lower blood 
pressure in ApoE
-/-
 mice 
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There was a significant difference in change in weight of ApoE
-/-
 mice treated with a 
selective 11β-HSD1 inhibitor (compound 544; 30mg/kg/day in western diet; 4weeks) 
compared with vehicle treated mice (a). 11β-HSD1 inhibition also produced a non-
significant trend towards reduction in systolic blood pressure in ApoE
-/-
 mice (b). 
Data are mean ± SEM for n=6/group and analysed by unpaired Student‟s t-test. 
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Figure 4.5: 11-HSD1 inhibition tended to lower plasma glucose but had no effect 
on lipid profile in ApoE
-/-
 mice 
 
Apo-E
-/-
-Vehicle Apo-E
-/-
-Inhibitor
0
100
200
300
400
p=0.08
G
lu
c
o
s
e
 (
m
g
/d
l)
Apo-E
-/-
-Vehicle Apo-E
-/-
-Inhibitor
0
2
4
6
8
10
p=0.9
C
h
o
le
s
te
ro
l 
(m
m
o
l/
L
)
Apo-E
-/-
-Vehicle Apo-E
-/-
-Inhibitor
0
1
2
p=0.9
T
ri
g
ly
c
e
ri
d
e
s
 (
m
m
o
l/
L
)
a)
b)
c)
 
 
Selective 11β-HSD1 inhibitor (compound 544; 30mg/kg/day in western diet, 4 weeks) 
produced an apparent reduction in fasting glucose levels, but it did not achieve statistical 
significance (a). 11β-HSD1 also had no effect on fasting cholesterol (b) or triglyceride 
levels (c). 
Data are mean ± SEM for n=6/group and analysed by unpaired Student‟s t-test. 
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Figure 4.6: 11-HSD1 inhibition reduced neointimal lesion volume in ApoE
-/-
 mice 
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Optical Projection Tomography (OPT) allowed acquisition of 3dimensional images (a) 
to calculate neointimal lesion volume after wire angioplasty. Quantification of lesion 
volume revealed a significant reduction in neointimal lesion size in ApoE
-/-
 mice treated 
with the selective 11β-HSD1 inhibitor (compound 544; 30mg/kg/day in western diet; 
4weeks) compared with vehicle-treated ApoE
-/-
 mice (b). 
Data are mean ± SEM for n=6/group and analysed by unpaired Student‟s t-test. 
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Figure 4.7: 11-HSD1 inhibition reduced neointimal proliferation in ApoE
-/-
 mice 
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Wire-angioplasty produced fibro-cellular neointimal lesions (a) in both groups (20 x 
magnifications). ApoE
-/-
 mice treated with selective 11-HSD1 inhibitor (compound 
544; 30mg/kg/day in western diet; 4weeks) had significantly smaller neointimal lesions 
and hence less cross-sectional stenosis (b) than vehicle treated group. 
Data are mean ± SEM for n=6/group and were analysed by unpaired Student‟s t-test. 
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Figure 4.8: 11-HSD1 inhibition altered macrophage and collagen, but not the 
smooth muscle, content of neointimal lesions in ApoE
-/-
 mice 
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Neointimal lesion composition was determined by analysing sections for Picrosirius red 
staining (collagen content), immunoreactivity for Mac-2 (macrophage content) and 
immunoreactivity for -smooth muscle actin (smooth muscle content). Quantification of 
stained areas showed a significant reduction in macrophage content and an increase in 
collagen content of lesions in the 11-HSD1 inhibitor (compound 544; 30mg/kg/day in 
western diet; 4weeks) treated group, compared with vehicle-treated controls. In contrast, 
11-HSD1 inhibition did not alter smooth muscle content of lesions. 
Data are mean ± SEM for n=6/group and analysed using unpaired Student‟s t-test. 
 116 
4.3.3 Effect of 11β-HSD1 deletion in Apo-E-/- mice 
To test whether the results seen with compound 544 represent effects of selective 
11-HSD1 inhibition, post-angioplasty neointimal proliferation was also studied in 
ApoE
-/-
 and ApoE
-/-
,11β-HSD1
-/-
 (DKO) mice (n=8/group) fed on western diet for four 
weeks, starting one week before wire-angioplasty.  
4.3.3.1 Systemic effects of 11-HSD1 deletion 
DKO mice weighed less than age-matched ApoE
-/-
 mice at the start of the study. 
However, mice in both groups gained weight equally during the four weeks‟ exposure to 
western diet (Figure 4.9a). DKO mice had lower blood pressure at baseline and their 
blood pressure remained lower than ApoE
-/-
 mice during four weeks of western diet 
feeding (Figure 4.9b).  
DKO mice had lower fasting glucose levels than ApoE
-/-
 mice (Figure 10a). There was 
no effect of 11β-HSD1 deletion (Figure 10b) on fasting total plasma cholesterol as 
compared with controls. Similarly, fasting plasma triglyceride levels also remain 
unaffected by 11β-HSD1 deletion (Figure 4.10c). 
4.3.3.2 Effects on neointimal lesions 
Transgenic deletion of 11-HSD1 in ApoE
-/-
 mice significantly reduced neointimal 
lesion volume (456±48μm3 vs. 700±96μm3, p=0.04), as assessed by OPT. Histological 
analysis of lesions revealed that the maximum cross-sectional stenosis was significantly 
reduced in DKO mice compared with control group (Figure 4.11). 
11-HSD1 deletion had no effect on smooth muscle content of the plaques (25±1% vs. 
25±3%, p=1); however, it reduced the macrophage (11±1% vs. 16±2%, p=0.02) and 
increased the collagen (40±3% vs. 30±3%, p=0.05) content of plaques compared with 
control mice. 
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Figure 4.9: 11-HSD1 deletion reduced body weight and blood pressure in ApoE
-/-
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Mice with transgenic deletion of ApoE
 
and 11β-HSD1 (double knockout, DKO) had 
significantly lower body weight than ApoE
-/-
 controls (a). DKO mice also had lower 
systolic blood pressure than age-matched ApoE
-/-
 controls (b). Bonferroni post-hoc 
analysis revealed a significant BP difference between the two groups (p<0.05) at day 1 
and day 18 (from start of experiment and angioplasty on day 7) but not at day 14 
(p>0.05). 
Data are mean ± SEM for n=7-8/group and analysed by repeat measures two-way 
ANOVA. 
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Figure 4.10: 11-HSD1 deletion reduced fasting plasma glucose but had no effect 
on lipid profile in ApoE
-/-
 mice 
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Mice with transgenic deletion of ApoE
 
and 11β-HSD1 (double knockout, DKO) had 
significantly lower fasting plasma glucose levels than control ApoE knockout mice (a). 
However, there was no difference in fasting total plasma cholesterol (b) or triglyceride 
(c) levels between the two groups. 
Data are mean ± SEM for n=7-8/group and analysed unpaired Student‟s t-test. 
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Figure 4.11: 11-HSD1 deletion reduced neointimal proliferation in ApoE
-/-
 mice 
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Wire-angioplasty produced fibro-cellular neointimal lesions in both groups (x20 
magnification, a). Mice with transgenic deletion of ApoE and11β-HSD1 (double 
knockout, DKO) had significantly lower neointimal proliferation and consequent cross-
sectional (c-s) stenosis as compared with ApoE
-/-
 mice. Data are mean ± SEM for n=7-
8/group and were analysed by unpaired Student‟s t-test. 
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4.4 Discussion 
This study, contrary to the original hypothesis (endogenous glucocorticoid regeneration 
increases neointimal proliferation) suggests that 11β-HSD1 inhibition does not increase 
neointimal proliferation after wire-angioplasty and, indeed, reduces the size of 
neointimal lesions in western diet fed ApoE
-/-
 mice. The reduction in neointimal lesions 
seen here is associated with improvements in systemic cardiovascular risk factors (body 
weight, blood pressure and glucose levels) and reduction in vascular inflammation, but 
without any effect on plasma lipid profile or VSMC proliferation. 
The experiments described in this chapter evaluated the influence of pharmacological 
inhibition of 11β-HSD1 in chow-fed C57Bl/6J mice and western diet fed ApoE
-/-
 mice. 
There was a concern that the reduction in blood pressure and vascular lesions may be 
due to off-target effects of compound 544. Therefore, the results were confirmed using 
ApoE
-/-
 mice with transgenic deletion of 11β-HSD1 which also produced similar effects 
on blood pressure, lesion volume and lesion areas, suggesting that the effect of 
compound 544, indeed, represents effects of selective 11β-HSD1 inhibition. 
4.4.1 Effect of 11-HSD1 inhibition on metabolic profile 
11β-HSD1 inhibition produced differential metabolic effects in chow-fed C57Bl/6J mice 
and western diet fed ApoE
-/-
 mice. C57Bl/6J mice fed on standard chow are known to 
have metabolically normal phenotype with no obesity, hyperglycaemia or dyslipidaemia 
[Ellis et al., 2008]. ApoE
-/- 
mice fed on western diet, on the other hand, develop adverse 
lipid and glycaemic profile [Zhang et al., 1992]. In this study, administration of a 
selective 11β-HSD1 inhibitor had no effect on body weight and blood pressure in 
C57BL/6J mice but reduced weight gain and blood pressure in ApoE
-/-
 mice. It has been 
shown previously that the effect of 11β-HSD1 inhibition on body weight varies in 
different rodent models (e.g. compound 544 reduced weight gain in a model of diet 
induced obesity but not in a model of streptozotocin induced diabetes [Hermanowski-
Vosatka et al., 2005]). 11β-HSD1 deletion in ApoE
-/-
 mice also reduced fasting plasma 
glucose. Pharmacological inhibition of 11β-HSD1 also produced a similar trend, 
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however, did not achieve statistical significance probably due to methodological 
limitations (as discussed in chapter 3). 
The data presented in this chapter have also shown for the first time that 11β-HSD1 
deletion in ApoE
-/-
 mice lowers systolic blood pressure. These findings are consistent 
with the effect of 11β-HSD1 inhibition described in Chapter 3. However, there was no 
effect of  11β-HSD1 inhibition on blood pressure in C57Bl/6J mice which contrasts with 
the blood pressure lowering effect seen in ApoE
-/-
 mice fed on western diet, but is 
consistent with previous studies where transgenic deletion of 11β-HSD1 in C57Bl/6J 
mice did not affect blood pressure [Kotelevtsev et al., 1997]. One possible explanation 
for this difference may be that the metabolic effects of 11β-HSD1 inhibition are minimal 
when administered to mice without any significant metabolic derangements. 
11β-HSD1 deletion or pharmacological inhibition in ApoE
-/-
 mice had no effect on 
plasma total cholesterol and triglyceride levels. The lack of effect on lipid profile seen 
here is not consistent with previously reported beneficial effects of 11β-HSD1 deletion 
on lipid profile in C57Bl/6J mice [Morton et al., 2001]. Unfortunately, fasting lipid 
levels were not checked in C57Bl/6J mice in the current experiment and, therefore, a 
direct comparison is not possible.  However, lack of effect of 11β-HSD1 deletion in 
ApoE
-/-
 mice on cholesterol and triglyceride levels suggests that these mice have severe 
dyslipidaemia which may not be ameliorated by modest effects of blocking 11β-HSD1 
activity. Finally, various lipid fractions (such as LDL, VLDL, NEFA) were not analysed 
in this study (due to small volume of blood samples) and, therefore, an effect on these 
lipid subtypes can‟t be excluded. 
4.4.2 Effect of 11-HSD1 inhibition/deletion on neointimal lesions 
Since it was hypothesised that endogenous glucocorticoids inhibit neointimal 
proliferation, attenuation of glucocorticoid regeneration by inhibition of 11β-HSD1 
would be expected to increase neointimal proliferation after angioplasty. Experimental 
studies using pharmacological doses of glucocorticoids have been shown to reduce 
neointimal lesions [Villa et al., 1994;Van Put et al., 1995;Poon et al., 2001;Ribichini et 
al., 2007]. The beneficial effect of glucocorticoids on neointimal proliferation probably 
originates from their effect on VSMC proliferation and inflammation [Celik et al., 
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2009]. However, systemic glucocorticoid administration may also exacerbate 
cardiovascular risk factors [Walker, 2007] with potential secondary increase in 
neointimal proliferation. Glucocorticoids can also possibly influence neointimal 
proliferation via activating mineralocorticoid receptors in the vascular wall if these 
receptors are not being protected by 11β-HSD2 (discussed in chapter 5). Therefore, the 
net effect will be determined by the balance between these factors. 
The data presented in this chapter indicate that loss of 11β-HSD1 activity does not 
increase neointimal proliferation and, on the contrary, may reduce neointimal 
proliferation (at least in western diet fed ApoE
-/-
 mice). There was also an apparent 
reduction in neointimal lesion size in C57Bl/6J mice, however, it did not reach statistical 
significance (p=0.13).  Due to a relatively small sample size (n=6/group) and variability 
in lesion size, the statistical power of the experiment (calculated retrospectively) was 
only 33%. If there was more time and resources available, it would have been useful to 
increase the sample size (~n=10/group) to obtain adequate statistical power to ensure 
that the lack of effect observed in C57Bl/6J mice is indeed due to differential effect of 
11β-HSD1 inhibition in the two genotypes. However, in support of the notion that loss 
of 11β-HSD1 activity in C57Bl/6J mice does not influence the vascular response to 
injury, it is worth noting that in a previous experiment transgenic deletion of 11β-HSD1 
in C57Bl/6J mice also did not influence post-angioplasty neointimal lesion formation 
(LJ Macdonald, unpublished data). 
ApoE
-/-
 mice fed on western diet had more pronounced neointimal proliferation than 
chow-fed C57Bl/6J mice. The lesions also appeared different in C57Bl/6J and ApoE
-/-
 
mice with the presence of a large number of foam cells in latter. This may reflect the 
hyperlipidaemic state of western diet fed ApoE
-/-
 mice and consequent accumulation of 
cholesterol in macrophages. Loss of whole-body 11β-HSD1 activity by systemic 
inhibition or transgenic deletion attenuated neointimal lesion development in ApoE
-/-
 
mice. The absolute reduction in the cross-sectional stenosis (~10%), though statistically 
significant, is relatively modest in-terms of clinical outcomes; however the reduction in 
the volume of lesions (~35%) may also be clinically relevant, given that the currently 
used drug eluting stents produce 40-70% reduction in neointimal proliferation [Heldman 
et al., 2001;Weissman et al., 2005]. 
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ApoE
-/-
 mice had significantly higher macrophage content in neointimal lesions than 
C57Bl/6J. Whilst 11β-HSD1 inhibition had no effect on macrophage content of lesions 
in C57Bl/6J mice, it significantly reduced macrophage content in neointimal lesions of 
ApoE
-/-
 mice suggesting that the role of 11β-HSD1 in modulating inflammation may be 
more important in the presence of a continuous inflammatory stimulus like feeding a 
western or high fat diet [Baer et al., 2004;Esposito and Giugliano, 2006]. 11β-HSD1 is 
expressed in macrophages [Thieringer et al., 2001] and may regulate immune and 
inflammatory processes [Chapman et al., 2006]. However, the precise mechanism of 
how 11β-HSD1 interacts with inflammatory cells remains unknown and merits future 
studies (discussed in section 6.2). Furthermore, although glucocorticoids inhibit 
proliferation of VSMC in-vitro; they may also promote VSMC proliferation in-vivo by 
increasing ACE activity in vascular cells [Mendelsohn et al., 1982;Fishel et al., 1995], 
up-regulating endothelin-1 expression [Morin et al., 1998] or decreasing the activity of 
nitric oxide [Mangos et al., 2000]. These opposing effects may have resulted in no net 
effect on VSMC content of neointimal lesions. 
The reduction in neointimal proliferation in ApoE
-/-
 mice was associated with a reduction 
in plasma glucose, systolic blood pressure and macrophage content of neointimal lesions 
but without any effect on plasma cholesterol or VSMC proliferation. Glucocorticoids 
have been shown to promote foam cell formation by increasing the accumulation of 
cholesterol esters, by enhancing acyl coenzyme A cholesterol acyltransferase 1 (ACAT-
1) expression [Yang et al., 2004]. Loss of 11β-HSD1 activity reduced the number of 
foam cells in lesions without affecting systemic cholesterol levels, suggesting a direct 
effect on cholesterol uptake or efflux in macrophages. Diabetes mellitus is also a well 
recognised risk factor for development of restenosis [Stein et al., 1995;Hong et al., 2006] 
due to increased neointimal proliferation [Kornowski et al., 1997] as well as constrictive 
remodelling [Van et al., 1997]. Optimum glycaemic control has been shown to reduce 
the incidence of post angioplasty restenosis [Mazeika et al., 2003;Corpus et al., 2004]. 
Hypertension has also been linked to the development of restenosis [Klugherz et al., 
2000;G.Tocci et al., 2010] and lowering blood pressure along with improvements in 
glycaemic profile may have contributed towards beneficial effect of 11β-HSD1 
inhibition on neointimal proliferation. The data presented here, therefore, suggest that 
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regulating intra-cellular pre-receptor metabolism of physiological concentrations of 
endogenous glucocorticoids in metabolically normal mice does not affect metabolic 
profile or VSMC proliferation and, hence, has no influence on neointimal lesion 
formation. However, in ApoE
-/-
 mice, it seems plausible that 11β-HSD1 inhibition may 
have reduced neointimal proliferation by improving systemic risk factors and reducing 
vascular inflammation, but without affecting VSMC proliferation. 
4.4.3 Potential of OPT in assessment of vascular lesions 
Finally, these experiments also highlight the potential of OPT in vascular lesion 
analysis. OPT is a relatively new technique for vascular lesion assessment and has been 
validated by NS Kirkby et al. (unpublished data). It has been shown to correlate well 
with standard histology and additionally provides a three dimensional volumetric 
assessment of the lesions. OPT is a non-destructive technique and tissues can be 
processed for standard histology and immunohistochemistry afterwards. Therefore, OPT 
can complement histological analysis in pre-clinical work. Both the extent (volume 
determined by OPT) and severity (maximum cross-sectional stenosis determined by 
OPT/histology) are important in clinical practice to determine the management and 
prognosis of vascular lesions in humans. 
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4.5 Conclusion 
In conclusion, work presented in this chapter has shown that selective inhibition of 11β-
HSD1 does not increase post-angioplasty neointimal proliferation in mice and may 
indeed reduce neointimal lesions in western diet fed ApoE
-/-
 mice. These results suggest 
that 11β-HSD1 inhibition may reduce neointimal proliferation in the presence of 
metabolic syndrome or cardiovascular risk factors but may have no effect in 
metabolically normal individuals. These data also suggest that 11β-HSD1 inhibitors can 
be initiated or continued for treatment of diabetes mellitus or metabolic syndrome in 
patients undergoing angioplasty procedures. This may also have implications for the 
development of novel anti-restenotic agents, though the magnitude of reduction in lesion 
size (and hence likelihood of any clinical benefit in the era of stents) needs to be 
assessed in future studies. 
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5. Role of 11-HSD2 and MR in neointimal 
proliferation 
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5.1 Introduction 
Investigations into the effect of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) 
inhibition on neointimal proliferation (Chapter 4) suggested that regulating pre-receptor 
metabolism of endogenous glucocorticoids alters arterial remodelling by modulating 
systemic risk factors and local inflammatory response.  It is logical, therefore, that the 
activity of the type 2 isozyme of 11β-HSD (which converts glucocorticoids into their 
inactive form and protects MR from glucocorticoid-mediated activation) may also 
influence vascular remodelling and neointimal proliferation. 
MR activation has been suggested to play a key role in cardiovascular remodelling (in 
humans and in experimental animals) by influencing inflammation and VSMC 
proliferation [Ishizawa et al., 2005b;Suzuki et al., 2006c]. MR antagonism improves 
cardiovascular outcome in patients with heart failure [Pitt et al., 1999d;Pitt et al., 2001d] 
and also attenuates post-angioplasty neointimal proliferation in rabbits [Van et al., 
1995d] and pigs [Ward et al., 2001i]. MR bind mineralocorticoids and glucocorticoids 
with equal affinity but the circulating levels of glucocorticoids are 100-1000 fold greater 
than those of aldosterone [Arriza et al., 1987;Funder et al., 1988]. Mineralocorticoid 
selectivity of MR in aldosterone target tissues is conferred by 11β-HSD2. 11β-HSD2 
converts cortisol (corticosterone in rodents) to its inert 11-keto metabolite, cortisone, 
(11-dehydrocorticosterone) which has negligible affinity for MR. Thus the presence of 
11β-HSD2 effectively excludes cortisol from MR and allows aldosterone to occupy and 
activate MR [Edwards et al., 1988;Funder et al., 1988]. Pharmacological inhibition or 
genetic deletion of 11β-HSD2, therefore, can lead to activation of MR by 
glucocorticoids, producing the glucocorticoid-mediated „syndrome of apparent 
mineralocorticoid excess‟ [Stewart et al., 1988]. 
Whilst 11β-HSD2 is expressed predominantly in mineralocorticoid target tissues (e.g., 
kidneys, colon) it is also present in the cells of the vascular wall; especially in 
endothelial cells [Walker et al., 1991;Christy et al., 2003]. However, any role for 
vascular 11β-HSD2 in modulating neointimal lesion development remains unknown. 
The intriguing findings that MR blockade improves cardiovascular outcome in the face 
of normal circulating aldosterone levels [Pitt et al., 1999;Pitt et al., 2001] and reduces 
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neointimal proliferation even though aldosterone administration itself has a limited 
effect [Ward et al., 2001] led to the hypothesis that glucocorticoids may modulate 
vascular remodelling by acting as MR ligands. If this hypothesis is correct, it predicts 
that the effects of MR on neointimal proliferation are not influenced by 11-HSD2. This 
was addressed by studying vascular remodelling in mice with targeted deletion of 
hsd11b2 and further exploring the effect of MR blockade in the presence and absence of 
11β-HSD2. The specific objectives of studies in this chapter, therefore, included: 
 To determine the effect of 11β-HSD2 deletion on vascular remodelling 
 To determine the effect of MR blockade in the presence or absence of 11β-HSD2 
 129 
5.2 Materials and methods 
5.2.1 Animals 
C57Bl/6J mice (Harlan Laboratories, UK) and 11β-HSD2
-/-
 mice, homozygous for a 
disrupted hsd11b2 allele and congenic on a C57Bl/6J background [Kotelevtsev et al., 
1999;Bailey et al., 2008], were used in this study (genotype confirmed at weaning by Dr. 
Bailey). Animals were maintained under standard conditions of light (lights on 8am-
8pm) and temperature (21-22
o
C).  
5.2.2 Experimental protocol 
Adult (12 week old) male C57Bl/6J and 11β-HSD2
-/-
 mice (n=6/group) underwent wire-
angioplasty of left femoral arteries, as described (section 2.7). Three weeks later 
vascular remodelling was studied in uninjured right femoral arteries and angioplastied 
left femoral arteries. In a further experiment, groups of mice (n=6) of each genotype 
received vehicle or the MR antagonist eplerenone (Merck & Co., New Jersey, USA) 
mixed with chow (1.7mg/g) to achieve a daily dose of eplerenone ~ 200mg/kg body 
weight, for one week before and three weeks after wire-angioplasty. Mice were housed 
singly and their body weights measured weekly. Systolic blood pressure (sBP) was 
measured weekly in conscious, warmed, restrained mice using tail-cuff photo-
plethysmography (section 2.4). 
Three weeks after the femoral angioplasty mice were killed by either asphyxiation (non-
drug experiment) or terminal anaesthesia with phenobarbitone and trans-cardiac 
perfusion fixation (eplerenone experiment). Left femoral arteries were excised from the 
bifurcation of the iliac artery to the branch point of the popliteal artery. Arteries were 
fixed in 10% formalin for 24hr, and then stored in 70% ethanol. Arteries were then 
processed for histology and embedded in paraffin. Transverse sections (4 µm) were cut 
along the length of the vessel. 
5.2.3 Lesion analysis 
Sections of femoral artery (taken at 60m intervals) were stained with United States 
trichrome (section 2.9.2). Images of stained sections were digitised and used for analysis 
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of sections as described (section 2.9.3). Mean areas (µm
2
) were measured inside the 
external elastic lamina (EEL, for vessel area), internal elastic lamina (IEL) and lumen. 
Medial area was calculated as (area inside EEL - area inside IEL) and neointimal area as 
(area inside IEL - luminal area). 
Lesion composition was determined by staining sections at the point of maximum 
neointimal proliferation. Collagen content was quantified by staining with Picrosirius 
red (section 2.10.1). Macrophage and smooth muscle content were assessed by 
immunohistochemistry (section 2.10.2) using purified monoclonal rat anti-mouse Mac2 
antibodies for macrophages (1:6000) and monoclonal mouse anti-mouse α-smooth 
muscle actin antibodies for smooth muscle cells (1:400). Photomicrographs of stained 
sections were acquired and quantification of the stained areas performed using a semi-
automated colour deconvolution process with Adobe Photoshop CS3 Extended software 
(chapter 2.10.4). All lesion analyses were carried out under blinded conditions. 
5.2.4 Statistical analysis 
Data are expressed as mean ± SEM, with n indicating the number of different animals in 
each group. Student‟s unpaired t-test was used to compare variables from two groups. 
Two-way ANOVA was used to investigate effects of genotype and drug treatment for 
the four groups. Statistical analyses were performed using GraphPad prism software. 
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5.3 Results 
5.3.1 Influence of 11β-HSD2 deletion on arterial remodelling 
5.3.1.1  Systemic effects of 11-HSD2 deletion 
11β-HSD2 deletion did not have any effect on body weight. There was no difference in 
body weights between 11β-HSD2
-/-
 and C57Bl/6J mice, either pre-operatively (baseline) 
or 3 weeks after angioplasty (Table 5.1). All mice lost some weight after surgery, but 
this was regained over the next 3 weeks of the study. There were no obvious differences 
in wound healing and fur re-growth. The weights of most organs retrieved at cull were 
similar in 11-HSD2
-/-
 and C57Bl/6J (Table 5.1). However, the thymus was significantly 
heavier in 11β-HSD2
-/-
 mice and a trend towards higher spleen weight in these mice did 
not reach significance (Table 5.1) 
5.3.1.2 Influence on blood pressure and arterial structure 
11β-HSD2
-/-
 mice had substantially higher systolic blood pressure (129±3mmHg vs. 
112±2mmHg, p<0.001) than age-matched C57Bl/6J mice. 
Uninjured right femoral arteries in 11β-HSD2
-/-
 mice had 31% larger vessel calibre due 
to bigger luminal and medial area compared with C57Bl/6J controls (Figure 5.1) 
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Table 5.1: Effect of 11-HSD2 deletion on body/organ weights 
 
Organ 11-HSD2
-/-
 C57Bl/6J p 
Body wt (baseline) 27.0±0.7 28.2±0.8 0.3 
Body wt (final) 27.5±0.7 28.6±0.3 0.2 
Liver (mg/g of body wt) 45.5±1.1 47.5±0.6 0.1 
Heart (mg/g of body wt) 5.5±0.3 5.0±0.1 0.1 
Kidneys (mg/g of body wt) 13.2±0.3 12.8±0.2 0.3 
Spleen (mg/g of body wt) 2.64±0.1 2.26±0.2 0.07 
Thymus (mg/g of body wt) 1.69±0.06 1.28±0.06 0.001 
Adrenal glands (mg/g of body wt) 0.12±0.01 0.13 ± 0.01 0.3 
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Figure 5.1: 11-HSD2 deletion produces an outward remodelling in mouse femoral 
artery 
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Sections of uninjured vessels stained with United States trichrome (20x magnification) 
illustrate the difference in size of vascular layers (a). 11-HSD2
-/-
 mice (grey columns) 
had larger calibre arteries than C57Bl/6J controls (white columns) with significantly 
bigger medial and luminal cross-sectional areas (b). 
Data are mean ± SEM for n=6/group and were analysed by un-paired Student‟s t-test. 
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5.3.1.3 Vascular remodelling after wire-angioplasty 
Wire-angioplasty produced fibro-cellular neointimal lesions in all mice (Figure 5.2a) and 
resulted in a significant outward remodelling with an approximately three fold increase 
in the total vessel area in the angioplastied arteries compared with uninjured vessels. 
After wire-angioplasty, the size of neointimal lesions was similar in 11β-HSD2
-/-
 mice 
and C57Bl/6J controls. Furthermore, there was no difference in the size of patent lumen, 
although differences in the area of the media and total vessel persisted between the two 
groups (Figure 5.2b). 
Neointimal lesions in the 11β-HSD2
-/-
 group contained more macrophages (13.5±1.2% 
vs. 9.9±0.8%, p=0.02) and tended to contain less collagen (23±3% vs. 32±4%, p=0.08) 
but there was no difference in smooth muscle content (14.0±1.9% vs. 11.7±1.3%, 
p=0.3). 
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Figure 5.2: 11-HSD2 deletion does not influence neointimal proliferation after 
wire angioplasty 
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Wire-angioplasty produced fibro-cellular neointimal lesions and an outward remodelling 
in both groups (x 20 magnification, (a)). 11-HSD2 deletion had no effect on the size of 
lumen or neointimal lesion in angioplastied arteries. However, wire-angioplasty caused 
significantly greater outward remodelling in 11-HSD2
-/-
 mice, mainly due to an 
increase in the medial area (b). 
Data are mean ± SEM for n=6/group and were analysed by unpaired Student‟s t-test. 
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5.3.2 Effect of mineralocorticoid receptor antagonism on neointimal remodelling 
in C57Bl/6J and 11β-HSD2
-/-
 mice 
5.3.2.1 Systemic effects 
Neither eplerenone administration nor 11β-HSD2 deletion altered body weight (Figure 
5.3a). Eplerenone also had no effect on blood pressure in either normotensive C57Bl/6J 
or hypertensive 11β-HSD2
-/-
 mice (Figure 5.3b). 
5.3.2.2 Effect on post-angioplasty vascular remodelling 
Wire-angioplasty resulted in fibro-cellular neointimal lesion formation in all four groups 
(Figure 5.4). Eplerenone administration reduced neointimal lesion area in both C57Bl/6J 
and 11β-HSD2
-/-
 mice but had no effect on lumen, media or vessel area (Figure 5.5). 
There was no significant interaction between eplerenone treatment and 11β-HSD2 
deletion. 
Eplerenone reduced the macrophage content in both C57Bl/6J and 11β-HSD2
-/-
 mice 
(Figure 5.6) but had no effect on collagen and smooth muscle cell content of neointimal 
lesions (Figure 5.7). 
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Figure 5.3: Effect of eplerenone administration and 11-HSD2 deletion on body 
weight and blood pressure 
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Body weights were similar in vehicle or eplerenone (200mg/kg/day, mixed with chow, 4 
weeks) treated C57Bl/6J or 11-HSD2
-/-
 mice throughout the experiment, indicating no 
effect of eplerenone treatment (p=0.12) or 11-HSD2 deletion (p=0.4) (a). 11-HSD2
-/-
 
mice had substantially higher blood pressure (p<0.001) than C57Bl6 controls. 
Eplerenone treatment had no effect on blood pressure in either C57Bl/6J or 11-HSD2
-/-
 
mice (p=0.6) (b). 
Data are mean ± SEM for n=6/group and were analysed by two-way ANOVA. 
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Figure 5.4: Wire-angioplasty produced fibro cellular neointimal proliferation 
Figure 
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All groups developed fibro-proliferative neointimal lesions (indicated by arrows) in 
response to wire-angioplasty (x 20 magnifications). However, it appears that size of 
lesions was smaller in eplerenone treated, as compared with vehicle treated, groups. 
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Figure 5.5: Eplerenone reduced neointimal proliferation in C57Bl/6J and 11-
HSD2
-/-
 mice 
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C57Bl/6J and 11-HSD2
-/-
 mice received vehicle or eplerenone (200mg/kg/day) for four 
weeks, starting one week before wire angioplasty of femoral arteries. (a) Lumen size 
was not influenced by eplerenone treatment (p=0.2) or 11-HSD2 deletion (p=0.3). (b) 
Eplerenone reduced neointimal area in both C57Bl/6J and 11-HSD2
-/-
 mice (p=0.005). 
(c & d) Eplerenone had no effect on medial or vessel area, whereas 11-HSD2 deletion 
tended to increase vessel area (p=0.07). There was no genotype-eplerenone interaction. 
Data are mean ± SEM for n=6/group and were analysed by two-way ANOVA. 
CV, C57Bl/6J mice receiving vehicle (open column); CE, C57Bl6 mice receiving 
eplerenone (hatched column); HV, 11-HSD2
-/-
 mice receiving vehicle (grey column); 
HE, 11-HSD2
-/-
 mice receiving eplerenone (grey hatched column). 
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Figure 5.6: Eplerenone decreases macrophage content of neointimal lesions 
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C57Bl/6J and 11-HSD2
-/-
 mice received vehicle or eplerenone (200mg/kg/day) for four 
weeks, starting one week before wire angioplasty. Macrophage content of neointimal 
lesions was assessed in transverse sections of femoral arteries with 
immunohistochemistry (representative pictures from two groups at x 20 magnification) 
(a). 11-HSD2 deletion increased macrophage content of neointimal lesions (p=0.007). 
Conversely, eplerenone reduced macrophage content of lesions from both C57Bl/6J and 
11-HSD2
-/-
 mice (p=0.002). There was no eplerenone and genotype interaction (p=0.9) 
(b). Data are mean ± SEM for n=6/group and were analysed by two-way ANOVA. 
CV, C57Bl6 mice receiving vehicle (open column); CE, C57Bl/6J mice receiving 
eplerenone (hatched column); HV, 11-HSD2
-/-
 mice receiving vehicle (grey column); 
HE, 11-HSD2
-/-
 mice receiving eplerenone (grey hatched column). 
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Figure 5.7: Effect of eplerenone administration and 11-HSD2 deletion on smooth 
muscle and collagen content of lesions 
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C57Bl/6J and 11-HSD2
-/-
 mice received vehicle or eplerenone (200mg/kg/day) for four 
weeks, starting one week before wire angioplasty. Collagen content of neointimal 
lesions was assessed by picrosirius red staining and smooth muscle content by 
immunohistochemistry (representative pictures from two groups at x 20 magnification). 
Neither eplerenone administration nor 11-HSD2 deletion had a significant effect on 
smooth muscle (a) or collagen (b) content of lesions. Data are mean ± SEM for 
n=6/group and were analysed by two-way ANOVA. 
CV, C57Bl/6J mice receiving vehicle (open column); CE, C57Bl/6J mice receiving 
eplerenone (hatched column); HV, 11-HSD2
-/-
 mice receiving vehicle (grey column); 
HE, 11-HSD2
-/-
 mice receiving eplerenone (grey hatched column). 
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5.4 Discussion 
The data in this chapter highlight that MR, but not 11-HSD2, play a significant role in 
vascular remodelling after wire angioplasty in mice. These results not only indicate a 
potential therapeutic role of selective MR antagonists in preventing neointimal lesion 
formation but also suggest that glucocorticoids act as MR ligands in murine vessel wall. 
5.4.1 Effect of 11β-HSD2 on vascular remodelling 
11-HSD2
-/-
 mice had evidence of outward remodelling in uninjured vessels. This is 
probably due to substantially higher systolic blood pressure in 11-HSD2
-/-
 mice 
(compared with C57Bl/6J mice) which is consistent with previous data from these 
knockout mice on C57Bl/6J and other genetic backgrounds [Kotelevtsev et al., 
1999;Bailey et al., 2008]. 
Neointimal proliferation after wire-angioplasty was similar in C57Bl/6J and 11-HSD2 
knockout mice, suggesting a limited, if any, role of 11β-HSD2 in neointimal lesion 
formation. This contrasts with the role of 11β-HSD2 proposed in the development of 
atherosclerotic lesions, where ApoE/11β-HSD2 double knockout mice developed 
extensive plaques without need for dietary intervention (Deuchar et al., unpublished 
data). This could possibly be explained by mechanistic difference in lesion formation 
during atherogenesis and post-angioplasty neointimal proliferation (section1.2.1). 
11β-HSD2
-/-
 mice had more macrophage content of neointimal lesions compared with 
C57Bl/6J group. This is consistent with literature showing that pharmacological 
inhibition (with carbenoxolone) [Wilson et al., 2009] or transgenic deletion [Armour et 
al., 2009] of 11β-HSD2 can lead to increased monocyte/macrophage infiltration and 
consequent vascular inflammation. In the absence of convincing evidence for 11-HSD2 
expression in the resident or inflammatory macrophages [Schmidt et al., 2005;Lim et al., 
2007;Gilmour et al., 2006], the difference in macrophage count in lesions in 11-HSD2 
knockout mice might represent a paracrine effect of neighbouring (e.g. endothelial) cells 
on macrophage recruitment, differentiation or survival and merits detailed mechanistic 
studies in future. There was no difference in the smooth muscle content of lesions 
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between the two groups. 11-HSD2
-/-
 mice have amplification of glucocorticoid activity 
in target cells leading to not only increased GR activation but these glucocorticoids can 
also mediate MR activation in the absence of 11-HSD2. GR activation is known to 
inhibit proliferation of VSMCs [Longenecker et al., 1984] and MR activation, on the 
other hand, stimulates VSMCs proliferation [Ishizawa et al., 2005].  This could have 
resulted in no net effect on smooth muscle content of neointimal lesion in 11-HSD2
-/-
 
mice. Furthermore, 11-HSD2
-/-
 mice showed a trend towards less collagen formation in 
the lesions (22.91±2.7 vs. 31.9±3.9, p=0.09). This is contrary to the expectation that 
inappropriate MR activation will result in more collagen accumulation [Wilson et al., 
2009]. However, it is consistent with the observation that mice with transgenic over-
expression of 11β-HSD2 have three fold increase in collagen deposition in their heart 
[Qin et al., 2003]. Furthermore, ApoE/11β-HSD2 double knockout mice have also been 
shown to have decreased collagen in the atherosclerotic plaques as compared with ApoE 
knockout mice [Armour et al., 2009]. 
5.4.2 Effect of Eplerenone on vascular remodelling 
The data presented here confirm that eplerenone, a selective MR antagonist, reduces 
neointimal proliferation. These findings, novel in a mouse model, are consistent with 
data from other experimental models. Spironolactone, a mineralocorticoid antagonist, 
has been shown to inhibit neointimal proliferation, both in the iliac artery and in the 
aorta, after balloon angioplasty in rabbits [Van et al., 1995]. Eplerenone administration 
significantly increased luminal area (~60%) with modest reduction in neointimal 
proliferation after balloon angioplasty in pigs [Ward et al., 2001]. Wakabayashi et al. 
have shown that eplerenone treatment reduced the neointimal lesion size with 
consequent increase in lumen area after angioplasty and stent implantation in porcine 
coronary arteries [Wakabayashi et al., 2006]. 
Surprisingly, eplerenone did not have any effect on sBP in this study despite the fact that 
inappropriate MR activation is the underlying mechanism of hypertension in 11-HSD2 
knockout mice [Kotelevtsev et al., 1999]. This may be due to irreversible vascular or 
renal tubular remodelling during development in these mice [Bailey et al., 2008]. 
Furthermore, although eplerenone treatment has been shown to reduce blood pressure in 
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rodents [Bayorh et al., 2006], this effect is not invariable [Nehme et al., 2006;Kuster et 
al., 2005]. Eplerenone has also been shown to significantly reduce atherosclerosis 
[Suzuki et al., 2006] and cerebral ischemia/neurological deficit [Iwanami et al., 2007], 
without any effect on blood pressure. Eplerenone has been shown to reduce 
atherosclerotic lesions in DKO mice without affecting BP (Deuchar et al., Abstract at 
90th Annual Meeting of The Endocrine Society, June 2008, San Francisco, USA). 
However, the substantial hypertension in 11-HSD2
-/-
 mice, though associated with 
vascular remodelling at baseline, did not increase the size of neointimal lesions. This is 
consistent with data from clinical studies in which hypertension, though strongly linked 
to the development of atherosclerosis [Yusuf et al., 2004], has not been shown to 
correlate with post-angioplasty restenosis [Bauters et al., 1998;Rensing et al., 1993]. 
Moreover, blood pressure reduction is not inextricably related to reduction in neointimal 
proliferation: hydralazine had no effect on neointimal proliferation despite lowering 
blood pressure in wild type and hypertensive mice [Kitada et al., 2009;Imai et al., 2002]. 
Finally, in the RALES and EPHESUS trials, the difference in sBP did not account for 
the observed beneficial effect of MR antagonism [Pitt et al., 1999;Pitt et al., 2001]. Thus 
the results presented here suggest that reduced neointimal proliferation in response to 
eplerenone treatment is not due to an effect on systolic blood pressure. 
Restenosis after percutaneous revascularisation procedures develops as a result of 
arterial recoil with constrictive remodelling and neointimal proliferation [Bauters et al., 
1996]. Collagen deposition in the vessel wall is suggested to mediate constrictive 
remodelling. It has been shown previously that eplerenone suppresses constrictive 
remodelling by reducing collagen content in the media [Ward et al., 2001]. The data 
shown in this chapter suggest no effect of eplerenone on collagen deposition in 
neointimal lesions in mice. The effect on collagen content, however, may be of limited 
clinical significance as restenosis in the era of stents mainly involves neointimal 
proliferation rather than the constrictive remodelling [Hoffmann et al., 1996]. 
Neointimal proliferation represents an inflammatory and proliferative response to 
iatrogenic vascular injury [Bennett, 2003]. MR activation is known to be pro-
inflammatory in the vessel wall and MR blockade reduces vascular inflammation 
[Suzuki et al., 2006]. This study indicates that the beneficial effect of eplerenone in 
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reducing the size of neointimal lesions is associated with a reduction in macrophage, but 
not smooth muscle, content of lesions. Eplerenone has also been shown to reduce 
macrophage content of neointimal lesions in previous studies [Wakabayashi et al., 
2006]. 
5.4.3 Glucocorticoids as ligand for vascular MR 
Eplerenone reduced neointimal lesion size after wire-angioplasty in mice. If it is 
aldosterone that is displaced from the relevant MR by eplerenone, then local expression 
of 11-HSD2 would have to protect these MR from corticosterone, so that this 
protection would fail in the absence of 11-HSD2. Therefore, 11-HSD2
-/-
 mice would 
be predicted to have increased neointimal proliferation and, since corticosterone 
provides a higher level of occupancy of unprotected MR than does aldosterone [Edwards 
et al., 1988;Funder et al., 1988], a greater incremental response to eplerenone. The 
results show that deletion of 11β-HSD2 had no effect on neointimal proliferation and the 
effect of MR antagonism was not altered in 11-HSD2
-/-
 mice, so it can be concluded 
that 11β-HSD2 in the vessel wall does not protect the MR involved in modifying 
neointimal proliferation from glucocorticoids. Thus it is likely to be glucocorticoids, 
rather than mineralocorticoids, that occupy and activate the MR directly involved in 
post-angioplasty vascular remodelling. This concept is further supported by the data 
from different experimental models in which MR blockade (with spironolactone or 
eplerenone) significantly reduced neointimal proliferation whereas, in many cases, 
administration of aldosterone does not increase lesion size. For example, although 
aldosterone administration increased neointimal proliferation in rabbit iliac arteries [Van 
et al., 1995], it did not do so in rabbit aorta [Van et al., 1995] or pig coronary arteries 
[Ward et al., 2001]. This was despite MR blockade (with oral spironolactone or 
eplerenone) consistently reducing neointimal proliferation after balloon angioplasty in 
rabbits [Van et al., 1995] and pigs [Wakabayashi et al., 2006]. Finally, if MR is also not 
being protected by 11-HSD2 in the human cardiovascular system, as others have also 
proposed [Funder, 2005], then it may explain the findings of the RALES and EPHESUS 
trials where patients with heart failure greatly benefited from MR antagonists despite 
having unremarkable aldosterone levels and salt status [Pitt et al., 1999;Pitt et al., 2001]. 
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5.5 Conclusion 
In conclusion, results in this chapter indicate that eplerenone substantially reduces the 
size of neointimal lesions associated with a reduction in macrophage, but not the smooth 
muscle or collagen, content of lesions and independent of any effect on systolic blood 
pressure. However, inhibition of 11-HSD2 has no effect on the size of neointimal 
lesions. This suggests that MR blockade is a potential target to prevent post-angioplasty 
restenosis, but that it is glucocorticoids, rather than aldosterone, that activate vascular 
MR. 
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6. General discussion and future directions 
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Cardiovascular disease is the leading cause of death worldwide and, despite recent 
improvements in mortality, it is likely to remain number the one killer in the near future 
[Iqbal and Fox, 2010]. It is, therefore, important to understand the pathophysiology of 
(and to develop newer therapeutic targets for) atherosclerosis (the root cause of 
cardiovascular disease) and neointimal proliferation (cause of post angioplasty and in-
stent restenosis). The main objective of the work described in this thesis was to examine 
the role of enzymes regulating intra-cellular levels of endogenous glucocorticoids in the 
development of atherosclerotic and neointimal lesions. The results suggest that 11-
HSD1 inhibition reduces development of vascular lesions whereas 11-HSD2 does not 
play a significant role in modulation of neointimal proliferation. This chapter will 
discuss the overall results in the context of relevant literature, consider its implications 
and describe some pilot data suggesting further experiments to be performed in the 
future. 
6.1 General discussion 
6.1.1 Novel findings described in this thesis 
The work described in the thesis has produced a number of novel observations, as 
summarised below: 
1. Selective 11-HSD1 inhibition or deletion lowers blood pressure in ApoE
-/-
 mice 
2. Selective 11-HSD1 inhibition reduces the size of atherosclerotic lesions 
3. Selective 11-HSD1 inhibition improves markers of plaque stability 
4. 11-HSD1 inhibition does not alter neointimal proliferation in C57Bl/6J mice 
5. 11-HSD1 inhibition/deletion reduces neointimal proliferation in ApoE
-/-
 mice 
6. 11-HSD1 inhibition reduces neointimal macrophage content in ApoE
-/-
 mice 
7. 11-HSD2 deletion does not alter neointimal proliferation in C57Bl/6J mice 
8. Eplerenone reduced neointimal proliferation in C57Bl/6J mice and 11-HSD2 
knockout mice without measurably altering blood pressure 
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6.1.2 Atheroprotective effect of 11-HSD1 inhibition 
Studies described in this thesis confirmed that selective 11β-HSD1 inhibition reduces the 
size of atherosclerotic lesions and improves markers of plaque stability. This is 
associated with reduced weight gain, lower blood pressure and a trend towards improved 
insulin sensitivity but without any change in circulating lipids. 
The atheroprotective effect of selective 11β-HSD1 inhibition could possible be predicted 
from its ability to reduce cardiovascular risk factors [Hadoke et al., 2009]. But no 
previous study directly measured the effect of selective 11β-HSD1 inhibition on plaque 
size. The few relevant investigations available in the literature assessed lesion 
development indirectly by measuring intra-arterial lipids by aortic cholesterol extraction 
[Hermanowski-Vosatka et al., 2005], oil red O staining [Nuotio-Antar et al., 2007] or en 
face staining with Sudan IV [Lloyd et al., 2009]. These studies yielded variable results 
ranging from a dramatic reduction in aortic cholesterol with compound 544 (a triazole 
type selective 11β-HSD1 inhibitor) [Hermanowski-Vosatka et al., 2005], variable 
improvement in size of lesions with carbenoxolone (a non-selective inhibitor) [Nuotio-
Antar et al., 2007] and no effect with compound 2922 (a thiazolone type selective 11β-
HSD1 inhibitor) [Lloyd et al., 2009]. This study, for the first time, has histologically 
confirmed the atheroprotective and plaque stabilising effect of a selective 11β-HSD1 
inhibitor. The precise mechanism for the atheroprotective effect, however, remains to be 
fully understood. 
It is reassuring that the use of 11-HSD1 inhibitors for the treatment of diabetes mellitus 
[Rosenstock et al., 2010] may have the additional benefit of reducing macro-vascular 
complications which are the main cause of morbidity and mortality in these patients 
[Wang et al., 2007]. This study also has implications for the use of selective 11-HSD1 
inhibitors as anti-atherosclerotic agents. However, it would not be appropriate to 
extrapolate results directly from the mouse model to humans and, therefore (and also 
due to issues of safety and economy), this atheroprotective effect should be further 
confirmed using other animal models (such as fat-fed pigs), before contemplating trial in 
humans. 
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6.1.3 Effect of 11-HSD1 inhibition on neointimal proliferation 
11-HSD1 inhibition reduced neointimal proliferation in western diet fed ApoE
-/-
 mice 
but had no effect on chow-fed C57Bl/6J mice. The effect of glucocorticoids (and 
glucocorticoid regulation by 11-HSD1) on post-angioplasty neointimal proliferation is 
complex and determined by a number of variables including metabolic and 
inflammatory status [Liu et al., 2004]. Systemic or local glucocorticoid administration 
inhibited neointimal lesion formation in rats [Villa et al., 1994;Guzman et al., 1996], 
rabbits [Van Put et al., 1995;Poon et al., 2001;Ribichini et al., 2007] and dogs [Strecker 
et al., 1998]. However, not all studies in animals have yielded positive results, as 
dexamethasone treatment did not reduce neointimal hyperplasia after angioplasty in 
rabbits [Karim et al., 1997] or pigs [Lincoff et al., 1997]. In humans, the IMPRESS and 
STRIDE trials showed a reduction in restenosis with oral glucocorticoid administration 
[Versaci et al., 2002;Ferrero et al., 2007b;Liu et al., 2003]. On the other hand, oral 
methylprednisolone did not inhibit restenosis after coronary angioplasty [Pepine et al., 
1990] or stenting [Reimers et al., 1998] and dexamethasone-drug eluting stents (D-DES) 
did not reduce the incidence of restenosis [Hoffmann et al., 2004;Ribichini et al., 2007]. 
These results probably indicate opposing local (beneficial) and systemic (adverse) 
effects of glucocorticoid administration. In current studies (using a mouse model of 
wire-angioplasty), 11-HSD1 inhibition improved systemic risk factors without having 
any deleterious local effects and therefore, produced a reduction in neointimal 
proliferation. 
The results presented here along with previously published data highlight the potential 
use of 11-HSD1 inhibitors in the treatment of cardiovascular diseases (Figure 6.1). 
These data suggest that initiation or continuation of 11-HSD1 inhibitors for the 
treatment of diabetes mellitus or metabolic syndrome is unlikely to have any detrimental 
effect on post-angioplasty restenosis and may indeed decrease neointimal lesion 
formation in high risk patients undergoing coronary angioplasty. The magnitude of 
reduction in neointimal proliferation is, however, small and its usefulness in clinical 
practice as an anti-restenotic target may be limited but needs to be explored in future 
experiments (section 6.2.2). 
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Figure 6.1: Potential role of 11-HSD1 inhibitors in the treatment of 
cardiovascular diseases 
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There are robust data to suggest that 11-HSD1 inhibition ameliorates cardiovascular 
risk factors. Studies described in this thesis have shown a reduction in the size and 
vulnerability of atherosclerotic plaques and a potential reduction in neointimal 
proliferation after angioplasty. A recent study (McSweeney et al., 2010) has also shown 
a reduction in infarct size and an improvement in heart function in a murine model of 
myocardial infarction. These potential therapeutic effects of 11-HSD1 inhibition are 
highlighted in green (shaded) boxes. 
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6.1.4 Role of 11-HSD2 and MR in neointimal proliferation 
Studies described in chapter 5 have shown minimal, if any, role of 11-HSD2 in 
neointimal lesion formation. Since the physiological role 11-HSD2 is to protect MR 
from glucocorticoids, this could either mean that vascular MR is not playing a role in 
neointimal proliferation or 11-HSD2 is not protecting vascular MR from inappropriate 
(glucocorticoid-mediated) activation. However, eplerenone treatment reduced 
neointimal proliferation to a similar extent in both 11-HSD2
-/-
 mice and C57Bl/6J 
controls and, hence, provided the evidence that MR play a key role in development of 
neointimal lesions but that it is the glucocorticoids rather than aldosterone that occupy 
MR in murine vessel wall. These findings promote a significant shift from the idea that 
aldosterone is the major culprit in cardiovascular pathologies and MR antagonists derive 
their benefit by blocking effects of aldosterone. This is consistent with data from various 
studies showing beneficial effect of MR blockade with spironolactone or eplerenone but 
minimal or no effect with aldosterone itself [Van et al., 1995;Wakabayashi et al., 2006].  
The effect of eplerenone in reducing neointimal proliferation (chapter 5) in the mouse 
wire-angioplasty model is consistent with data from porcine angioplasty [Ward et al., 
2001] and porcine stenting models [Wakabayashi et al., 2006]. The underlying 
mechanism seems to be a reduction in vascular inflammation leading to reduced 
neointimal proliferation  [Keidar et al., 2003;Ward et al., 2001;Wakabayashi et al., 
2006]. These results suggest a possible therapeutic application of eplerenone in 
preventing restenosis in human (discussed in 6.2.3). 
6.1.5 Limitations of work 
The studies described in this thesis have several potential limitations, some of these 
inherent to the nature of this work, and some specific to the experiments. 
One potential limitation is that these studies used a single compound (Compound 544, a 
triazole) as a selective 11-HSD1 inhibitor. However, most of the work presented here 
has been validated by using genetically modified mice to ensure that results indeed 
represent effects of enzyme inhibition, and not any off-target effects of this compound. 
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Moreover, studies were conducted using a single animal model (mouse model of 
atherosclerosis or wire-angioplasty), and therefore it would be unwise to directly 
extrapolate results to humans. However, it was not possible to conduct studies in other 
animal models at the same time due to limitation of time and resources. 
Finally, the effect of systemic administration or whole body deletion of enzymes may be 
due to direct local effects or indirect systemic effects which could not be tested in 
current experiments. To overcome this limitation, experiments could be set-up giving 
locally administered inhibitors or using tissue specific knockout mice. It was not 
possible to carry out these further experiments during the time-scale of the current 
project; however, this and other un-answered questions can be addressed in future 
studies as outlined below. 
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6.2 Future directions 
The work described in this thesis has not only helped to clarify the role of endogenous 
glucocorticoid metabolism by 11-HSD enzymes in vascular lesion development but has 
also provided ideas for future experimental and translational investigations. A few pilot 
studies were undertaken with a view to future development of the field and some 
preliminary data is also presented here to illustrate the future directions. 
6.2.1 Mechanism of vascular lesion reduction with 11-HSD1 inhibition 
Experiments in this thesis have confirmed the atheroprotective effect of 11-HSD1 
inhibition and suggested improvements in systemic risk factors, including a novel blood 
pressure lowering effect, as a possible mechanism for this effect. However, it has also 
been suggested that 11-HSD1 inhibition can also directly influence vascular 
inflammation [Hermanowski-Vosatka et al., 2005] and VSMCs, but this remains to be 
established unequivocally. A better understanding of whether (and how) these enzymes 
interact with inflammatory or smooth muscle cells will provide insight into the cellular 
mechanism by which 11-HSD1 inhibition/deletion reduces vascular lesions and may 
identify novel therapeutic targets. The data presented in chapter 4 suggest that 11-
HSD1 inhibition may be modulating inflammatory, but not the VSMC proliferative, 
responses. Therefore, experiment(s) to investigate the effects of 11-HSD1 inhibition on 
macrophages and T-cells during vascular lesion development is an important next step. 
In current experiments, arteries were collected three weeks after angioplasty when 
lesions would have stabilised and acute inflammation settled, therefore, it may be 
appropriate to evaluate effect of 11-HSD1 inhibition on adhesion and migration of 
inflammatory cells at earlier time points. This could be achieved by designing short term 
experiments where mice lacking 11β-HSD1 activity (pharmacologically or genetically) 
get wire angioplasty and are killed at day 1 and day 7 after the procedure (as opposed to 
21 days in current studies). The role of macrophages in mediating effects of 11-HSD1 
inhibition on lesion formation can also be studied in macrophage-specific knock-outs of 
11-HSD1. Since such knockout models are not available at the moment, another useful 
but relatively complex experiment may be to perform bone marrow transfer from 11β-
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HSD1
-/-
 mice into wild-type animals (and vice versa) which will selectively attenuate 
11β-HSD1 activity in circulating haematic and inflammatory cells (or in whole body 
except these cells). This may help to confirm whether the atheroprotective effect of 11β-
HSD1 is mediated by inflammatory cells. Finally, investigating the effect of 11-HSD1 
inhibition on inflammatory chemokines/cytokines (e.g. MCP-1 or IL-1) during post-
angioplasty vascular remodelling can provide insight into the pathways modulated by 
these enzymes. 
The data presented in chapter 3 and chapter 4 suggests a novel blood pressure lowering 
effect of 11-HSD1 inhibition/deletion. However, the precise underlying mechanism 
remains unknown. Systolic blood pressure was measured using the tail-cuff photo-
plethysmography technique which is a relatively crude method and provides a 
measurement of stressed blood pressure. Since glucocorticoids are stress hormones, it is 
possible that the blood pressure lowering effect of blocking glucocorticoid activation 
may represent blockade of the stress response. This blood pressure effect should first be 
confirmed with invasive blood pressure monitoring (e.g. using indwelling telemetry 
catheter) to get accurate (and non-stressed) measurement of blood pressure. Once the 
blood pressure lowering effect is confirmed, further experiments to elucidate potential 
mechanism (such as central nervous/sympathetic, vascular reactivity or renovascular), 
can be carried out. 
6.2.2 Systemic vs. local effect of 11-HSD1 inhibition on neointimal proliferation 
The studies described in this thesis explored the effect of abolishing whole-body 11-
HSD1 activity by systemic inhibition or transgenic deletion. Glucocorticoids may have 
opposing systemic and local effects on vascular lesion development (Macdonald et al., 
unpublished data) and it has been suggested that the atheroprotective effects of 11β-
HSD1 inhibition may partially be mediated by direct effects on the vessel wall 
[Hermanowski-Vosatka et al., 2005]. Therefore, it would be a logical next step to dissect 
the effects of local versus systemic inhibition of 11-HSDI activity in vessel wall. This 
could be achieved either by local administration of an inhibitor or by development of 
transgenic tissue-specific models of 11β-HSD1 knockout in vascular smooth muscle 
cells or macrophages. The tissue-specific knockout models of 11-HSD1 are not 
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available at the moment and, therefore, local administration of inhibitor via a drug 
eluting stent, implanted pellet or a sub-cutaneous mini-pump may be a more practical 
option. 
Furthermore, it would be important to determine whether the beneficial effect of 11-
HSDI inhibition on lesion formation (seen here using the wire-angioplasty model) can 
be reproduced in a stent model as the mechanism of post-angioplasty stenosis may differ 
in these models. This could be achieved using a recently-described mouse model of 
stenting [Chamberlain et al., 2010] or in a porcine coronary stenting model [Lowe et al., 
2003]. Use of porcine angioplasty models may also help to establish whether the 
magnitude of reduction in neointimal lesions is likely to be of any clinical significance 
in humans. 
6.2.3 Effect of eplerenone on in-stent restenosis in man 
Eplerenone, a selective MR antagonist, reduces neointimal proliferation after wire-
angioplasty. These findings, novel in the mouse model, are consistent with data from 
other experimental models [Ward et al., 2001;Wakabayashi et al., 2006]. 
Spironolactone, a mineralocorticoid receptor antagonist, inhibited neointimal 
proliferation after balloon-angioplasty in rabbits [Van et al., 1995e]. In humans,  there is 
association of elevated baseline plasma aldosterone level with subsequent post 
angioplasty restenosis [Amano et al., 2006]. However,  a  single centre, placebo-
controlled, double-blind, randomised study using spironolactone (50mg twice a day for 
six months) did not reduce the incidence of angiographic in-stent restenosis 
[Kursaklioglu et al., 2004]. It could be argued that eplerenone, where the 17α-thioacetyl 
group of spironolactone has been substituted with a carbomethoxy group, differs 
considerably in terms of selectivity, intensity and action. Certainly, the interest in 
mineralocorticoid blockade with eplerenone as a potential therapeutic target in restenosis 
has been revived with very promising experimental data from different animal models 
Eplerenone administration reduced neointimal proliferation after wire angioplasty in 
mice (current study), balloon angioplasty [Ward et al., 2001] and angioplasty with stent 
implantation in pigs [Wakabayashi et al., 2006], suggesting its potential role as an anti-
restenotic agent.. Currently used drug eluting stents (Sirolimus and Paclitaxel) activate 
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anti-proliferative mechanisms by pathways that are independent of MR [Poon et al., 
1996;Suzuki et al., 2001]. Eplerenone may have a complimentary role in preventing 
neointimal proliferation (and in-stent restenosis) and, hence, merits translational studies 
in man. 
6.2.4 11-HSD in the human cardiovascular system 
The work presented in this thesis examined the role of 11β-HSD enzyme activity in 
regulation of the cardiovascular system, using rodent models. To translate these studies 
to humans, a basic first step is to establish the expression and activity of 11β-HSD in the 
human cardiovascular system. 
Studies in rodents have suggested that the predominant 11β-HSD isozyme in the heart is 
11β-HSD1, with trivial 11β-HSD2 activity (section 1.4). In humans, however, the 
pattern of expression may be different. Lombès et al., obtained myocardial biopsies 
during cardiac surgery or from endocavity catheterization and provided evidence for MR 
and 11β-HSD expression in the human heart [Lombes et al., 1995]. Cardiac 11β-HSD 
activity was detected and was dependent on the presence of the cofactor NAD, but not 
NADP, suggesting indirectly that there is predominant 11β-HSD type 2 activity 
[Lombes et al., 1995]. Other groups have also showed detectable 11β-HSD2 mRNA in 
human heart and also confirmed that 11β-HSD2 activity is distributed evenly between 
atria and ventricles [Slight et al., 1996;Kayes-Wandover and White, 2000].  
Tissues from atrial appendage and vessels (including radial artery, internal mammary 
artery and saphenous vein) were obtained from adult patients undergoing elective 
cardiac surgery (at the Royal Infirmary of Edinburgh) and able to give informed consent. 
During heart surgery, a small sample from the right atrial appendage and trimmings 
from blood vessels were collected for the purpose of this study. Ethical approval was 
obtained from Lothian Research Ethics Committee. Provisional data, using polymerase 
chain reaction (PCR) technique (kindly performed by Ms Eileen Miller) confirmed 
expression of GR, MR, 11β-HSD1 and 11β-HSD2 in human cardiovascular tissues 
(Figure 6.2a). 11β-HSD1 expression was also shown in human vessels using 
immunohistochemistry (Figure 6.2b). 
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 Figure 6.2: Expression of 11-HSD1 in the human cardiovascular system 
 
 
Human samples obtained during coronary artery bypass grafting (CABG) surgery were 
used to detect expression of 11-HSD1 in saphenous vein (SV), internal mammary 
artery (IMA), atrial appendage (AA) and radial artery (RA) using polymerase chain 
reaction (PCR) with specific primers (forward, 5‟-AAA GTG ATT ACW GGG GCC 
AGC AAA-3‟; reverse, 5‟-ATC CAR AGC AAA CTT GCT TGC-3‟) to detect the 
hsd11b1 allele. PCR conditions included an initial denaturing step (95ºC for 15min) 
followed by 34 cycles of annealing (90ºC for 1min, 56ºC for 1min and 72ºC for 2min) 
and final extension (72ºC for 5min). Gel electrophoresis showed expression in 
cardiovascular tissues at 440bp (a). Immunoreactivity for 11-HSD1 antibody was then 
used to detect presence of 11-HSD1 in arterial wall (brown staining, x 10 
magnification, b). 
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However, so far there has been no study to measure the activity of 11β-HSD type 1 and 
type 2 in human heart in-vivo. This is obviously important for determining the effects of 
11β-HSD1 inhibitors in the human cardiovascular system and to establish whether the 
human heart has sufficient 11β-HSD2 activity to exclude cortisol from MR binding sites. 
It has been shown that stable isotope tracers can be used to quantify in-vivo 11β-HSD 
activity in man [Andrew et al., 2002]. Andrew et al. have successfully used D4-cortisol 
tracers to measure the rate of regeneration of cortisol from cortisone by 11β-HSD1. 
More recently, using a D2-cortisone tracer, it has been possible to measure the rate of 
conversion of cortisol to cortisone by 11β-HSD2 (Hughes et al., unpublished data). It is 
possible, using these tracers in combination with tissue-specific sampling, to elucidate 
11β-HSD activities in human heart. A feasibility study was carried out where a patient 
requiring coronary angiography for clinical reasons, received these tracers (D4-cortisol 
3.5mg bolus and then 1.74mg/hr infusion; D2-cortisone 150µg bolus and 210 µg/hr 
infusion) and once steady state was reached then blood samples were collected from 
atrial (ascending aorta) and venous (coronary sinus) sides of heart (Figure 6.3). Mass 
spectrometry analysis confirmed that the tracers and their metabolites can be reliably 
identified and quantified in both venous and arterial samples. 
Therefore, future studies can be conducted in humans to determine the activity of the 
two isozymes of 11β-HSD in human heart in-vivo and explore whether human heart has 
sufficient 11β-HSD2 activity to prevent glucocorticoid-mediated MR activation. Once 
the activity of the two isozymes of 11β-HSD in the human cardiovascular system is 
established, it may be a useful next step to evaluate 11β-HSD1 and 11β-HSD2 activity 
in patients with confirmed coronary artery disease and heart failure against a matched 
population without these conditions. It will provide a useful insight into possible effects 
of manipulating these enzymes, since glucocorticoids (and therefore 11β-HSD enzymes) 
have been linked to coronary atherosclerosis, and heart muscle function [Small et al., 
2005]. 
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Figure 6.3: Schematic illustration of the methodology for evaluating in-vivo activity 
of 11-HSD isozymes in the human heart 
 
 
Stable isotope tracers, D4-cortisol (D4-F) and D2-cortisone (D2-E) are infused via 
peripheral veins. Once steady state is achieved, sampling from the arterial (ascending 
aorta or femoral artery) and venous (coronary venous sinus) sides of the myocardium 
can allow quantification of tracers and their metabolites (as a result of 11-HSD1&2 
activity) using mass spectrometry. 
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6.2.5 Ex-vivo assessment of in-stent restenosis using OPT 
The studies presented in this thesis have identified a possible therapeutic role of 11-
HSD1 inhibition, using a wire angioplasty model (chapter 4) and it may be a desirable 
next step to evaluate the effect of this inhibition in a model of arterial stenting. OPT has 
emerged as a novel tool for assessment of vascular lesions but has not been used to study 
stented arteries. Therefore, it would be useful to establish if OPT can be used to quantify 
lesion area and volume in stented murine or porcine vessels. 
A preliminary feasibility study using porcine coronary artery stenting model, a well 
established and clinically-relevant model of in-stent restenosis, was conducted. 
Circumflex and left anterior descending porcine coronary arteries, stented with bare 
metal stents (BMS, 3.5x15 mm) and excised at various time points, were kindly 
provided by Dr. Julian Gunn (Senior Lecturer, University of Sheffield). 
These vessels were prepared for OPT analysis using the standard technique described in 
section 2.8. The scanning was done initially with white light and then with UV light. 
Pilot data show that OPT can provide optimum images of both the metallic stent (white 
light imaging) and biological tissue (UV light imaging) which can be used to calculate 
3-dimensional lesion volume (Figure 6.4). Comparison with standard histology to 
validate OPT measurements will help to establish this technique for routine use and 
thereby helping to improve analysis and reduce number of animals required to obtain 
statically valid results in this useful experimental model. 
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Figure 6.4: OPT appears to be a promising tool for ex-vivo assessment of in-stent 
restenosis 
a b c
d
 
The left anterior descending (LAD) coronary artery from a juvenile Yorkshire white pig 
(weight~25kg) stented with a bare metal stents (BMS, 3.5x15 mm) was analysed with 
optical projection tomography (OPT). Scanning with white light (a) provided clear 
visualisation of metal stent (b), whereas scanning with UV light (c) enabled optimum 
visualisation of neointimal lesions (d) (indicated by arrow-head). 
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6.2.6 In-vivo assessment of vascular lesions in mice 
In pre-clinical work, histological analysis of the cross-sections of vessels remains the 
gold standard for quantification of lesion size. However, histology has obvious 
limitations. It can only provide cross-sectional 2-dimensional assessment, is time 
consuming, requires culling of large number of animal at each time point and cannot be 
used for temporal assessment of lesion development in same animals. Optical Projection 
Tomography (OPT) can provide useful ex-vivo 3-dimensional analysis of these lesions, 
as demonstrated in chapter 4. However, it remains highly desirable to have a reliable and 
reproducible non-invasive imaging tool for in-vivo assessment of vascular lesions in 
longitudinal studies which can potentially increase the amount of information from each 
animal, increase statistical power and reduce the number of animal killed for each study. 
In-vivo imaging techniques used in pre-clinical work can also allow direct comparison 
with clinical data. 
6.2.6.1 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a commonly used technique in clinical practice 
and increasingly employed in cardiovascular medicine for detailed structural and 
functional analyses [Rehwald et al., 2007]. It has the advantage of being free from 
ionising radiation; however, it is expensive and time consuming. It has been used in pre-
clinical work to study atherosclerotic plaques in the murine aortic arch [Trogan et al., 
2004;Weinreb et al., 2007]. However, there are limited data on feasibility of scanning 
the brachiocephalic trunk and carotid arteries (which are used more commonly for 
studying vascular lesions) particularly without use of contrast agents. A pilot study was, 
therefore, conducted to evaluate feasibility of MRI scan for the assessment of vascular 
lesions in mice using the currently available MRI scanner at the Biomedical Research 
Facility, University of Edinburgh. 
MR imaging was performed with a Varian 7-Tesla scanner with 305mm bore system 
operating at a proton frequency of 300MHz. A gradient insert (internal diameter of 
60mm) was capable of generating a maximum of 100 gauss/cm. Mice were 
anaesthetized with continuous inhaled isoflurane and were placed in a 39mm (inner 
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diameter) transmit/receive birdcage coil. Constant body temperature of 37ºC was 
maintained using a thermocouple/heater system. The aortic arch was identified in an 
approximately coronal section on a localizing sequence. Serial (0.5mm thick) transverse 
slices spanning from aortic arch to carotid bifurcation were acquired (117 x 117μm
2
 in 
plane resolution) using a dark-blood (fat suppressed) fast spin-echo sequence. Repetition 
time (TR) and echo time (TE) for the proton density-weighted (PDW) images were 
2000ms and 9ms, respectively. The total imaging time for this scan was ~20 
minutes/mouse. The same area was then scanned using bright-blood gradient echo 
sequence with TR 30ms and TE 1.86ms. Sequential (0.5mm thick) images were acquired 
with field of view of 30 x 30mm, acquisition matrix 256 x 256 and flip angle 30°. The 
total imaging time for this gradient echo scan was ~30 minutes/mouse. On average, it 
took about 2hr to scan one mouse. 
MRI provided images with a recognisable aortic arch, BCT, common carotid arteries 
and the carotid bifurcation (Figure 6.5a). However, resolution was not adequate to 
provide reliable measurements of vessel wall and lesions (Figure 6.5 b & c). It was 
concluded that MRI scanning using 7-Tesla scanner and the adopted protocol is 
suboptimal for imaging carotid vessels in mice. However, it may be possible to scan 
mice arteries using a scanner with higher magnetic flux density or different protocol 
with longer scanning time and providing higher resolution images. 
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Figure 6.5: MRI scan is of limited value for assessment of atherosclerotic lesions in 
mice 
a
c
b
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Magnetic resonance images were acquired from an adult male apolipoprotein-E deficient 
mouse fed a western diet for 8 weeks (using Varian 7-Tesla scanner). Heart, aortic arch 
and major neck vessels could be distinguished in coronal sections (a). However, 
resolution of scans did not allow reliable measurements of wall thickness or plaques in 
cross-sectional images using either dark-blood (b) or white-blood (c) techniques. 
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6.2.6.2 High frequency ultrasound 
After rather disappointing results from MRI and due to the pressing need for having a 
technique for in-vivo assessment of vascular lesions, high resolution ultrasound using a 
Vevo-770 imaging system was tried. There are no published data to evaluate use of 
ultrasound for post-angioplasty lesion development in femoral arteries of mice, probably 
due to the concern that the lesions in these small calibre vessels may not be visualised 
with ultrasound. However, a small number of studies describe the use of ultrasound for 
evaluating advanced lesions in mouse aortic arch and common carotid arteries [Gan et 
al., 2007;Ni et al., 2008]. Thus, it remains to be established whether neointimal lesions 
in murine femoral arteries and mild to moderate atherosclerotic lesions in carotid arteries 
can be visualised with ultrasound. 
A pilot study was conducted to explore the feasibility of high resolution ultrasound to 
image atherosclerotic and neointimal lesions. The Vevo-770 high resolution imaging 
system (VisualSonics, Canada) was used for ultrasound scanning. Mice were 
anaesthetised using inhaled isoflurane (4-5% for induction, 1-2% for maintenance). 
Hairs were chemically removed from the anterior thorax and neck, using a 
commercially-available depilatory cream (Veet, UK) and a generous amount of 
ultrasound transmission gel was applied. 
For assessment of atherosclerotic lesions, a parasternal long-axis view to visualise the 
aortic arch and the origin of brachiocephalic trunk (BCT) and a right cervical 
longitudinal view to visualise the right common carotid artery, the carotid bifurcation, 
and the external and internal carotid arteries were obtained. For parasternal long-axis 
views, mice were in the left lateral position and the probe was positioned at anterior 
thorax with the notch pointing towards left shoulder of the animal. For right cervical 
longitudinal views, mice were lying supine and the probe was positioned with the notch 
pointing toward the chin of the animal. For assessment of neointimal lesions in femoral 
arteries, mice were lying flat with the left the hind limb pulled towards midline to align 
with vertebral column, and a soft cushion was placed under the left hip. 2D images of 
femoral arteries arising from iliac arteries and Doppler spectral display were obtained 
from the common femoral, superficial femoral and popliteal arteries. 
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The pilot data suggest that susceptible arteries can be imaged (Figure 6.6) and 
ultrasound can provide reproducible measurements of vascular lumen, wall thickness 
and flow velocities (Figure 6.7). However, it remains to be seen how accurately the 
plaque size and associated changes in flow velocity can be determined. Furthermore, the 
Vevo-770 scanner is not equipped with colour Doppler, which could be very helpful to 
distinguish the lumen from the plaque in future studies. This scanner also lacks a linear 
array transducer which could have been useful to overcome the problem of getting a 
suitable angle of insonation for common carotid arteries (CCA) and BCT, as unsuitable 
angles of insonation can cause considerable measurement errors [Huo et al., 2008]. 
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Figure 6.6: High frequency ultrasound can be used to image murine arteries in vivo 
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Ultrasound images of an adult apolipoprotein-E deficient mouse scanned using a Vevo-
770 system shows that arteries of interest can be visualised. It was possible to image 
brachiocephalic trunk (BCT) originating from aortic arch (a), common carotid artery 
(CCA) with its bifurcation (b) and external/internal carotid arteries (ECA/ICA) (c), and 
femoral artery (FA) divining into popliteal artery (PA) and superficial femoral arteries 
(SFA) (d). 
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Figure 6.7: Ultrasound can be used to measure lumen size, wall thickness and flow 
velocities 
a b
 
Ultrasound images of an adult apolipoprotein-E deficient mouse scanned using a Vevo-
770 system. Images illustrate that m-mode (a) can be used to assess lumen and intima-
media thickness (IMT) and Doppler flow velocity (b) to detect hemodynamic 
significance of a vascular lesion. 
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6.3 Conclusion 
The work described in this thesis aimed to investigate the role of intra-cellular 
glucocorticoid regulation (by 11β-HSD type 1 and 2) in vascular lesion (atherosclerosis 
and neointimal proliferation) development. The results presented in this thesis highlight 
the potential therapeutic application of selective 11β-HSD1 inhibition in reducing the 
size and vulnerability of atherosclerotic plaques. 11β-HSD1 inhibition also reduced 
neointimal proliferation in ApoE
-/-
 mice, pointing towards a possible role in preventing 
post-angioplasty restenosis in high risk groups with “metabolic syndrome” phenotype. 
The data in this thesis also indicate that 11β-HSD2 has little, if any, role in modifying 
the development of neointimal lesions; however, eplerenone substantially reduced 
neointimal proliferation. This suggests that mineralocorticoid receptors are another 
potential target to prevent post-angioplasty restenosis, but that it is likely that 
glucocorticoids rather than aldosterone activate vascular mineralocorticoid receptors in 
this setting. These results improve our understanding of how intra-cellular 
glucocorticoid regulation influences vascular lesion development, identify potential 
therapeutic targets and pave the way for further mechanistic and translational studies. 
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